How many companies are developing Prostate Cancer treatments?

12 companies have active or registered Prostate Cancer programs in TheraRadar's competitive landscape (159 classified trials). The most active are Novartis, Johnson & Johnson, and AstraZeneca.

What mechanisms of action are being developed for Prostate Cancer?

23 distinct mechanisms of action appear across the Prostate Cancer pipeline, including KLK2 BiTE, AR antagonist, PSMA, AR-directed, and Undisclosed target.

What is the most crowded mechanism in Prostate Cancer?

KLK2 BiTE is the most contested mechanism in Prostate Cancer, with 7 programs mapped to it.

Are there upcoming Prostate Cancer clinical readouts or FDA decisions?

Near-term Prostate Cancer catalysts include HRS-1738 Injection (data readout, Aug '26); 64Cu-SAR-bisPSMA (data readout, Sep '26); Ifinatamab deruxtecan (FDA decision, Oct '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.

Where does TheraRadar's Prostate Cancer landscape data come from?

Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.

Landscape / Oncology

Page updated Jul 4, 2026 · using data updated on Jun 28, 2026

Prostate Cancer Clinical Trial Landscape

Prostate cancer is a disease in which malignant cells form in the tissues of the prostate, a gland in the male reproductive system. Clinical trials are essential for developing new and improved treatments for this condition.

Since 2008, 2,244 prostate cancer trials have been registered, with 863 currently active, meaning they are recruiting, enrolling, or active but not recruiting. The majority of active trials are in Phase 2, with 541 trials, followed by Phase 1 with 298 trials.

Phase 3 trials account for 154 active trials, while Phase 4 trials represent 24 active trials. Industry sponsorship is led by Novartis, which currently has 22 active trials.

AstraZeneca follows with 17 active trials, and Jiangsu HengRui Medicine Co., Ltd. has 11. Pfizer and Bayer are also notable sponsors, with 8 and 7 active trials, respectively.

The high volume of Phase 2 trials suggests a strong focus on evaluating the efficacy and safety of novel interventions in prostate cancer.

Trial activity

879 active / 2,287 total since 2008

Active by phase 162 Ph3 / 351 522 Ph2 / 1345 169 Ph1 / 514 26 Ph4 / 77

Competitive Intelligence

This Prostate Cancer competitive landscape maps 11 companies against 16 mechanisms of action (MOA) across 26 active drug-development programs, including 1 with a confirmed FDA PDUFA date. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in Prostate Cancer, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.

Beta 11 companies of 12 16 mechanisms of 23 26 programs mapped 5 lowTrust (19%) 1 ⚖ PDUFA-dated ⏰ 6 due ≤6 mo click any cell → asset tearsheet

At a glance

Prostate Cancer shows 26 programs across 11 companies and 16 mechanisms. The most contested mechanism is KLK2 BiTE (7 programs).

Key findings

53% of AR antagonist programs (9 of 17) are combos with novel agents — class-extension work, not class-validation.
Top 3 mechanisms (AR antagonist, PSMA, PSMA radioligand) account for ~27% of programs — class concentration is low.
Novartis runs 15 programs — the deepest pipeline in this view.
Johnson & Johnson has the highest composite score (100) — most-imminent / most-advanced asset weighted higher than program count.
28 hot readouts in next 6 months — most imminent: Orion Corporation, Orion Pharma (CYP11A1, CYPIDES).
33 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
40 single-program mechanisms in the long tail — 6 are Ph2+ first-in-class first-mover bets.
29 NME candidates in the long tail.
Most-novel-of-novel: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair CYP17 inhibitor (Ph2+Ph3) — first-in-class within scope + NME candidate.

Forward catalysts next 18 months⏰ 6 due ≤6 mo⚖ 1 PDUFA-dated

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Company × Mechanism

Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet. · showing top 11 of 12 companies × top 16 of 23 mechanisms by program count — long tail omitted for width, not a data cap.

⏰ Due soon Hide 🇨🇳 Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →

	KLK2 BiTE	AR antagonist	PSMA	AR-directed	Undisclosed target	AR degrader (PROTAC)	225Ac-PSMA	PARP	Glucocorticoid receptor agonist	B7-H3 ADC	GMCI / gene therapy	PSMA radioligand (imaging)	PSMA × CD28/CD3 bispecific	PSMA radioligand	Radioligand (isotope-labeled)	PSMA radioligand (next-gen)
Novartis
AstraZeneca
Johnson & Johnson
🇨🇳Jiangsu HengRui Medicine
Merck & Co.
Amgen
Bayer
Candel
Clarity
Regeneron
Roche / Genentech

Phase 3 leaders · most advanced

recruiting Merck Sharp & Dohme LLC NCT06136650
recruiting Jiangsu HengRui Medicine Co., Ltd. NCT07241416
active Aragon Pharmaceuticals, Inc. NCT02489318
recruiting Amgen NCT07213674
recruiting Pfizer NCT06629779

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

Single-company mechanisms — BD white space 15 found

Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 61 mapped landscapes — scope-limited, not a global claim.

⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 61 mapped landscapes

Single-program mechanisms (40) — one program each — earliest-stage, sorted by phase

Phase	Mechanism	Company	Modality	Readout	Trial
Ph3	AR degrader (LDD) 🌱	Bristol-Myers Squibb	IV	3Q27	NCT06764485
Ph3	Corticosteroid 🌱	BioNTech	IV	1Q31	NCT07365995
Ph2+Ph3	CYP17 inhibitor ⚡ 🌱 🆕	Han Xu, M.D., Ph.D., FAPC…	Oral	⏰ 4Q26	NCT03348670
Ph2+Ph3	EGFR / HER3 bispecific ADC 🌱	Sichuan Baili	IV	4Q28	NCT07641855
Ph3	PARP inhibitor 🌱 🆕	Jiangsu HengRui Medicine	Oral	⏰ 4Q26	NCT04691804
Ph3	PSMA radioligand (Telix) 🌱 🆕	Telix Pharmaceuticals (In…	Radioligand	4Q27	NCT06520345
Ph1+Ph2	177Lu-PSMA-617 (Pluvicto) 🌱 🆕	OncoC4		⏰ 4Q26	NCT05682443
Ph1+Ph2	Aromatase inhibitor 🌱	Novartis	Oral	2Q31	NCT07288359
Ph2	CD19 × CD3 T-cell engager 🌱 🆕	MediLink Therapeutics (Su…		1Q27	NCT06241846
Ph2	CD46 ADC 🌱 🆕 ⚙️	Kyntra Bio		1Q28	NCT06842498
Ph2	CXCR1/2 🌱 🆕	Syntrix Biosystems	Oral	2Q27	NCT06228053
Ph1+Ph2	CYP11A1 🌱 🆕	Orion Corporation, Orion …		⏰ 3Q26	NCT03436485
Ph1+Ph2	DLL3 🌱 🆕	Phanes	IV	4Q27	NCT05652686
Ph2	DLL3 × CD3 trispecific 🌱 🆕	Suzhou Zelgen Biopharmace…		4Q27	NCT07024277
Ph1+Ph2	GPRC5D bispecific ⚡ 🌱 🆕 ⚙️	GSK		4Q27	NCT06990880
Ph2	HER2 ADC 🌱 🆕	RemeGen	IV	4Q25	NCT06227156
Ph1+Ph2	Hypoxia-activated prodrug 🌱 🆕 ⚙️	AbbVie		4Q27	NCT06782555
Ph1+Ph2	IL-2 🌱	CuraCell TX AB	IV	2Q27	NCT07255664
Ph2	In situ tumor vaccine 🌱 🆕 ⚙️	Syncromune		2Q28	NCT06533644
Ph2	Microtubule stabilizer 🌱 ⚙️	Jina	Oral	⏰ 4Q26	NCT06890832
Ph1+Ph2	PARP1-selective 🌱	AstraZeneca	IV	4Q27	NCT05417594
Ph2	Phosphodiesterase 5A inhibitor ⚡ 🌱	Biozeus Biopharmaceutical	Oral	4Q24	NCT05558007
Ph1+Ph2	Photosensitizer ⚡ 🌱 ⚙️	SpectraCure AB		1Q28	NCT06807359
Ph2	PI3K-α (mutant-selective) 🌱	Roche / Genentech	IV	1Q28	NCT07287150
Ph1+Ph2	PSMA logic-gated CAR-T 🌱 🆕	Arsenal	Cell therapy	2Q29	NCT07285694
Ph1+Ph2	PSMA-targeted MRI contrast agent ⚡ 🌱 🆕 ⚙️	Songqi Gao		⏰ 4Q26	NCT06262139
Ph1+Ph2	RIPTAC degrader 🌱 🆕 ⚙️	Halda Therapeutics OpCo	Oral	2Q28	NCT06800313
Ph1+Ph2	STEAP2 ⚡ 🌱 🆕	AstraZeneca		4Q27	NCT07529717
Ph2	Wnt pathway inhibitor 🌱 🆕 ⚙️	Debiopharm International		⏰ 2Q26	NCT06395753
Ph1	ACK1 🌱 🆕	TechnoGenesys		4Q27	NCT06705686
Ph1	AR degrader 🌱 🆕	Bristol-Myers Squibb		3Q29	NCT06067841
Ph1	BET ⚡ 🌱 🆕	Epigenetix		2Q25	NCT05488548
Ph1	CDK4/6 inhibitor 🌱	Jiangsu HengRui Medicine	Oral	4Q28	NCT06099990
Ph1	EZH1/2 inhibitor 🌱 🆕 ⚙️	Daiichi Sankyo		1Q28	NCT07189403
Ph1	GCN2 activator 🌱 🆕	Deciphera		1Q29	NCT06966024
Ph1	GPRC6A antagonist 🌱 🆕 ⚙️	Haisco Pharmaceutical Gro…		⏰ 4Q26	NCT07007910
Ph1	KAT6 inhibitor 🌱 🆕	Olema		2Q27	NCT06784193
Ph1	Local drug delivery hydrogel ⚡ 🌱 🆕 ⚙️	SURGE		⏰ 3Q26	NCT06450106
Ph1	PSMA × CD3 T-cell engager 🌱 🆕	Janux		2Q28	NCT07545811
Ph1	PSMA × STEAP1 ADC 🌱 🆕	AbbVie	IV	2Q27	NCT06318273

Emerging & small-cap sponsors (45) — few programs here — partnering / M&A radar

Phase	Mechanism	Company	Modality	Readout	Trial
Ph1	AR antagonist	Alessa	Oral	2Q27	NCT04943536
Ph1	AR antagonist	Alessa	Oral	2Q28	NCT06257693
Ph1	Glucocorticoid receptor agonist	Astellas Pharma Global De…		4Q28	NCT07339267
Ph1	Glucocorticoid receptor agonist	Astellas Pharma Global De…	Oral	2Q29	NCT04729114
Ph1	PSMA	Cellbion	IV	2Q29	NCT07244393
Ph1+Ph2	PSMA radioligand	Cellbion		4Q24	NCT05547061
Ph3	PSMA	Curium US		⏰ 3Q26	NCT06235151
Ph3	PSMA radioligand	Curium US	Radioligand	3Q24	NCT05204927
Ph1	AR antagonist	Daiichi Sankyo	Oral	1Q28	NCT07244341
Ph1+Ph2	Undisclosed target	GSK		1Q28	NCT07332455
Ph1	🇨🇳 DLL3 ADC	Hansoh BioMedical R&D Com…		4Q27	NCT07115446
Ph2	🇨🇳 DLL3 ADC	Hansoh BioMedical R&D Com…		4Q24	NCT06001255
Ph1+Ph2	AR degrader (PROTAC)	Hinova	Oral	1Q26	NCT06155084
Ph3	AR-directed	Hinova		3Q25	NCT03851640
Ph1	PSMA	Janux	Oral	3Q27	NCT05519449
Ph3	PSMA	ABX advanced biochemical …		1Q27	NCT06122584
Ph1	🇨🇳 AR antagonist	Acerand Therapeutics (Hon…		1Q28	NCT06801236
Ph1+Ph2	PSMA radioligand	AdvanCell		1Q29	NCT05720130
Ph1	PSMA-targeted alpha radioligand	Aktis Oncology		4Q27	NCT07581184
Ph1+Ph2	PSMA	Antelope Surgical Solutio…		⏰ 3Q26	NCT06906471
Ph2	GNRHR	Antev		3Q27	NCT07457164
Ph3	AR antagonist	Aragon	Oral	⏰ 2Q26	NCT02531516
Ph1	PSMA radioligand	ARTBIO	Radioligand	4Q27	NCT07214961
Ph1	AR antagonist	Atridia		⏰ 4Q26	NCT06830850
Ph1+Ph2	PSMA radioligand	Bivision		⏰ 2Q26	NCT06139575
Ph1+Ph2	PSMA	Blue Earth		⏰ 3Q26	NCT05413850
Ph2	Autologous DC vaccine	Cellvax		1Q27	NCT06636682
Ph2	PSMA	Convergent		4Q25	NCT06549465
Ph2	Radioligand (isotope-labeled)	Curasight		1Q27	NCT06474806
Ph2	Autologous DC vaccine	Dendreon		4Q31	NCT06134232
Ph3	AR antagonist	Dongkook		2Q25	NCT06490328
Ph1	PSMA radioligand	Eli Lilly		3Q27	NCT06229366
Ph1	Radioligand (isotope-labeled)	Full-Life Technologies		⏰ 4Q26	NCT06492122
Ph3	PSMA radioligand	FutureChem		2Q25	NCT05936658
Ph1	PSMA radioligand	Gan & Lee Pharmaceuticals.		4Q31	NCT07468396
Ph1	AR degrader (PROTAC)	Geode	Oral	4Q25	NCT06866795
Ph1	🇨🇳 B7-H3 ADC	Hangzhou DAC		2Q30	NCT06926283
Ph3	PSMA radioligand	HTA	Radioligand	1Q26	NCT06754085
Ph1+Ph2	Radioligand (isotope-labeled)	Norroy Bioscience	Radioligand	2Q25	NCT06383052
Ph1	PSMA	Nova	Cell therapy	4Q25	NCT05656573
Ph1	AR antagonist	ORIC	Oral	4Q25	NCT05413421
Ph1+Ph2	AR antagonist	Pathos AI	Oral	2Q28	NCT06785636
Ph3	PARP	Pfizer	Oral	1Q26	NCT04821622
Ph1	Radioligand (isotope-labeled)	Philogen S.p.A.	Radioligand	4Q27	NCT07600554
Ph3	🇨🇳 AR antagonist	Qilu		⏰ 4Q26	NCT06837896
Ph1	🇨🇳 PSMA × CD3 bispecific	Shanghai Henlius		2Q27	NCT07533708
Ph1+Ph2	🇨🇳 AR degrader (PROTAC)	Shenzhen Ionova Life Scie…		1Q28	NCT06609005
Ph1+Ph2	Radioligand (isotope-labeled)	Sinotau Pharmaceutical Gr…		4Q25	NCT06081686
Ph2	AR antagonist	Sun Pharmaceutical Indust…	Oral	4Q27	NCT05422911
Ph1+Ph2	PSMA	T.O.A.D. Oncology		1Q28	NCT07258407
Ph1	PSMA radioligand	VitsGen	Radioligand	2Q27	NCT07660211

Unclassified programs (64) — mechanism not captured yet

Phase	Mechanism	Company	Trial
Ph3	Rezvilutamide Tablets, Enzalutamide Soft Capsulesunclassified	Jiangsu HengRui Medicine …	NCT07241416
Ph3	Xaluritamig, Abiraterone acetate, Docetaxelunclassified	Amgen	NCT07213674
Ph3	PF-06821497, Placebo, Enzalutamideunclassified	Pfizer	NCT06629779
Ph3	Niraparib, Abiraterone acetate (AA), Prednisoneunclassified	Janssen Research & Develo…	NCT04497844
Ph3	Mevrometostat, Placebo, Enzalutamideunclassified	Pfizer	NCT07028853
Ph3	PF-06821497, Docetaxel, Enzalutamideunclassified	Pfizer	NCT06551324
Ph3	Xaluritamig, Abiraterone, Enzalutamideunclassified	Amgen	NCT06691984
Ph3	[F-18]Florastaminunclassified	FutureChem	NCT05004285
Ph2+Ph3	PSMA-PET to Guide Prostatectomyunclassified	Five Eleven Pharma, Inc.	NCT05381103
Ph3	68-Ga-NYM032unclassified	Norroy Bioscience Co., LTD	NCT07615101
Ph3	AZD2265, Cabazitaxel, Abirateroneunclassified	AstraZeneca	NCT07611110
Ph3	This Study Evaluates the Diagnostic Performance and Safety of 6…unclassified	Norroy Bioscience Co., LTD	NCT07649122
Ph3	QLC5508, Docetaxelunclassified	Qilu Pharmaceutical Co., …	NCT07632690
Ph2	Darolutamide, ADTunclassified	Bayer	NCT07450599
Ph1+Ph2	Tulmimetostat, Darolutamide, Abirateroneunclassified	Novartis Pharmaceuticals	NCT07190300
Ph1+Ph2	AMO959, Enzalutamide, Abirateroneunclassified	Novartis Pharmaceuticals	NCT07226986
Ph1+Ph2	ZEN003694, Enzalutamideunclassified	Zenith Epigenetics	NCT04145375
Ph2	ZEN003694, Enzalutamideunclassified	Zenith Epigenetics	NCT04986423
Ph1+Ph2	Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QDunclassified	Novartis Pharmaceuticals	NCT07206056
Ph2	FPI-2265, Olaparibunclassified	Fusion Pharmaceuticals In…	NCT06909825
Ph1+Ph2	Radiopharmaceuticalsunclassified	C Ray Therapeutics	NCT07567521
Ph2	ASP5541, Prednisone, Prednisoloneunclassified	Astellas Pharma Global De…	NCT07005154
Ph1+Ph2	Verteporfinunclassified	SpectraCure AB	NCT03067051
Ph2	RS-113, 160 mg, RS-113, 240 mg, RS-113, 320 mgunclassified	R-Pharm International, LLC	NCT07553988
Ph1+Ph2	SHR-4394, Rezvilutamide, HRS-5041 Tabletsunclassified	Jiangsu HengRui Medicine …	NCT07407283
Ph1+Ph2	Opevesostat, Olaparib, Docetaxelunclassified	Merck Sharp & Dohme LLC	NCT06353386
Ph2	PF-07248144, Fulvestrant, Letrozoleunclassified	Pfizer	NCT04606446
Ph1+Ph2	Autologous dual-target CAR-T cells selected from the predefined…unclassified	Beijing Biotech	NCT07523529
Ph1+Ph2	Gedatolisib, Darolutamideunclassified	Celcuity Inc	NCT06190899
Ph2	enzalutamide, abiraterone acetate, prednisoneunclassified	Astellas Pharma Global De…	NCT02960022
Ph1+Ph2	MHB048C for Injectionunclassified	Minghui Pharmaceutical (H…	NCT07192120
Ph1+Ph2	161Tb RAD402unclassified	Radiopharm Theranostics, …	NCT07259213
Ph2	AAA617, 68Ga-PSMA-11unclassified	Novartis Pharmaceuticals	NCT06004661
Ph1+Ph2	Pembrolizumab 200 mg, Olaparib 400 mg, Docetaxel 75 mg/m^2unclassified	Merck Sharp & Dohme LLC	NCT02861573
Ph1+Ph2	HRS-5041 tablets, Abiraterone Acetate tablets（II）, Prednisone A…unclassified	Jiangsu HengRui Medicine …	NCT06568094
Ph1+Ph2	68Ga-PSMA-0057, 177Lu-PSMA-0057unclassified	Chengdu StarRay Therapeut…	NCT07310355
Ph1+Ph2	QLC5508, abiraterone acetate, enzalutamideunclassified	Qilu Pharmaceutical Co., …	NCT07198633
Ph1+Ph2	TQB3201 tabletsunclassified	Chia Tai Tianqing Pharmac…	NCT07172126
Ph1+Ph2	TY-302, Abiraptorunclassified	TYK Medicines, Inc	NCT07104617
Ph1+Ph2	QLH12016, abiraterone acetate, enzalutamideunclassified	Qilu Pharmaceutical Co., …	NCT07104110
Ph1+Ph2	TYK-00540, Enzalutamideunclassified	TYK Medicines, Inc	NCT07104643
Ph1+Ph2	XNW5004, enzalutamideunclassified	Evopoint Biosciences Inc.	NCT06702995
Ph2	Placebo, MCS®unclassified	Health Ever Bio-Tech Co.,…	NCT02042807
Ph1+Ph2	dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Fol…unclassified	Mochida Medical USA, Inc.	NCT07564102
Ph1+Ph2	AZD2265 (FPI-2265), AZD9574, Docetaxelunclassified	AstraZeneca	NCT07590934
Ph1	[68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoBunclassified	Novartis Pharmaceuticals	NCT06379217
Ph1	ARX517, Apalutamide, Abiraterone acetateunclassified	Janssen Research & Develo…	NCT04662580
Ph1	AMG 509, Abiraterone, Enzalutamideunclassified	Amgen	NCT04221542
Ph1	Mervometostat (PF-06821497), Enzalutamide, Itraconazoleunclassified	Pfizer	NCT03460977
Ph1	Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Canc…unclassified	Endocyte	NCT04597411
Ph1	A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Particip…unclassified	Regeneron Pharmaceuticals	NCT07543055
Ph1	VIR-5500unclassified	Vir Biotechnology, Inc.	NCT05997615
Ph1	BAY3546828unclassified	Bayer	NCT06052306
Ph1	Intravenous (IV) single doseunclassified	C Ray Therapeutics	NCT07236112
Ph1	Treatment arm: TSL2109 capsules。Oral administration。unclassified	Tasly Pharmaceutical Grou…	NCT07514065
Ph1	KTX-2001, KTX-2001 + Darolutamide (NUBEQA®)unclassified	K36 Therapeutics, Inc.	NCT07103018
Ph1	Saruparib (AZD5305), Darolutamideunclassified	AstraZeneca	NCT05938270
Ph1	DSB2455unclassified	Duke Street Bio Ltd	NCT06458712
Ph1	dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Inject…unclassified	Shanghai AbelZeta Ltd.	NCT07344311
Ph1	AAA617, Gonadotropin-releasing hormone (GnRH) analogues, Gonado…unclassified	Novartis Pharmaceuticals	NCT06531499
Ph1	Flotufolastat F-18 Injectionunclassified	Sinotau Pharmaceutical Gr…	NCT07149831
Ph1	ETB-DualNK-01, Fludarabine, Cyclophosphamideunclassified	Beijing Biotech	NCT07641049
Ph1	QLF4113 for injectionunclassified	Qilu Pharmaceutical Co., …	NCT07636707
Ph1	DEC003Munclassified	Hangzhou DAC Biotechnolog…	NCT07657806

Drugs in this landscape: Apalutamide · Prednisone Acetate tablets · Hydrocortisone · Darolutamide · Darolutamide (BAY1841788

Beta 26 mechanisms of 60 5 lines of therapy 40 programs mapped 2 lowTrust (5%) 1 ⚖ PDUFA-dated ⏰ 10 due ≤6 mo click any cell → asset tearsheet

At a glance

Prostate Cancer: 40 programs mapped across 26 mechanisms and 5 lines of therapy. The most contested line of therapy is 1L metastatic (91 programs).

Forward catalysts next 18 months⏰ 10 due ≤6 mo⚖ 1 PDUFA-dated

Mechanism × Line of Therapy

Each cell = the most-advanced program for that mechanism in that line/setting. Click for details. · showing top 26 of 60 mechanisms by program count — long tail omitted for width, not a data cap.

⏰ Due soon Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →

	1L metastatic	2L+ metastatic	Neoadjuvant	Locally advanced	Adjuvant
AR antagonist
PSMA
PSMA radioligand
KLK2 BiTE
Radioligand (isotope-labeled)
AR degrader (PROTAC)
AR-directed
Undisclosed target
Glucocorticoid receptor agoni…
PARP
B7-H3 ADC
225Ac-PSMA
PSMA-targeted alpha radioliga…
DLL3 ADC
GMCI / gene therapy
PSMA radioligand (imaging)
PSMA × CD28/CD3 bispecific
PSMA radioligand (next-gen)
AKT inhibitor
GNRHR
STEAP1 × CD3 bispecific
PSMA × CD3 bispecific
Autologous DC vaccine
AR degrader (LDD)
Corticosteroid
EGFR / HER3 bispecific ADC

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 1 mapped landscape

Unclassified programs (13) — mechanism not captured yet

Phase	Mechanism	Company	Trial
Ph3	An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetra…unclassified	Novartis	NCT05939414
Ph1+Ph2	Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Pros…unclassified	Jiangsu HengRui Medicine	NCT07056439
Ph3	PSMA PET Combined With MRI for the Detection of PCaunclassified	Telix Pharmaceuticals (In…	NCT07052214
Ph3	68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chine…unclassified	Telix Pharmaceuticals (In…	NCT05847348
Ph2+Ph3	Pharmacogenomics IND Commercial SNP Clinical Study - Abirateron…unclassified	Han Xu, M.D., Ph.D., FAPC…	NCT03348670
Ph2	A Phase II Study to Evaluate the Safety, Efficacy, and Pharmaco…unclassified	MediLink Therapeutics (Su…	NCT06241846
Ph1+Ph2	A Study of Evofosfamide in Combination with Zalifrelimab and Ba…unclassified	AbbVie	NCT06782555
Ph1+Ph2	A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of…unclassified	Antelope Surgical Solutio…	NCT06906471
Ph1+Ph2	Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injectionunclassified	Blue Earth	NCT05413850
Ph3	Study of 18F-Florastamin PET/CT Imaging in Patients With Suspec…unclassified	HTA	NCT06754085
Ph1+Ph2	A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combin…unclassified	Pathos AI	NCT06785636
Ph1	A Phase I Study to Evaluate the Safety and Dosimetry of Imaging…unclassified	Philogen S.p.A.	NCT07600554
Ph2	Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive…unclassified	Sun Pharmaceutical Indust…	NCT05422911

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed

Novartis 21 12 5

AstraZeneca 19 12 2

Jiangsu HengRui Medicine Co., Ltd. 11 6 3

Pfizer 8 13 1

Bayer 7 10 0

Amgen 7 7 3

Astellas 5 20 4

Exelixis 5 2 3

Merck 4 9 2

Eli Lilly 4 7 0

Johnson & Johnson 4 7 0

Regeneron 4 0 1

Qilu Pharmaceutical Co., Ltd. 4 0 0

Roche 3 5 0

Telix Pharmaceuticals (Innovations) Pty Limited 3 2 0

All 15 active Prostate Cancer sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2024 (186 registered); 2025 saw 159. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (222 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016

105

2017

116

2018

137

2019

126

2020

135

2021

150

2022

2023

139

2024

186

2025

159

2026

145

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (19)

200

2017 (16)

367

2018 (17)

450

2019 (9)

186

2020 (29)

356

2021 (26)

188

2022 (13)

300

2023 (29)

240

2024 (21)

439

2025 (24)

572

2026 (19)

365

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT07574489 NOT YET RECRUITING

Whole Versus Partial Gland Boost During Prostate SBRT

University of Nebraska n=186

NCT06136650 RECRUITING

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Merck Sharp & Dohme LLC n=1,314

NCT07241416 RECRUITING

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd. n=206

NCT02489318 ACTIVE NOT RECRUITING

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Aragon Pharmaceuticals, Inc. n=1,052

NCT07213674 RECRUITING

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Amgen n=750

NCT06629779 RECRUITING

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Pfizer n=900

NCT04497844 ACTIVE NOT RECRUITING

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Janssen Research & Development, LLC n=696

NCT06931340 RECRUITING

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Alliance for Clinical Trials in Oncology n=1,260

NCT06925737 RECRUITING

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Merck Sharp & Dohme LLC n=1,440

NCT07548164 RECRUITING

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

Memorial Sloan Kettering Cancer Center n=224

NCT01368588 ACTIVE NOT RECRUITING

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Radiation Therapy Oncology Group n=2,590

NCT05946213 RECRUITING

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

NRG Oncology n=1,209

NCT02319837 ACTIVE NOT RECRUITING

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Pfizer n=1,068

NCT04134260 ACTIVE NOT RECRUITING

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

NRG Oncology n=586

NCT03819101 RECRUITING

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Gustave Roussy, Cancer Campus, Grand Paris n=1,210

NCT06056830 RECRUITING

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Clarity Pharmaceuticals Ltd n=383

NCT06764485 RECRUITING

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Celgene n=960

NCT04136353 ACTIVE NOT RECRUITING

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

University of Sydney n=1,100

NCT06136624 RECRUITING

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Merck Sharp & Dohme LLC n=1,310

NCT07028853 RECRUITING

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Pfizer n=1,000

NCT04423211 RECRUITING

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

ECOG-ACRIN Cancer Research Group n=804

NCT06520345 RECRUITING

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Telix Pharmaceuticals (Innovations) Pty Limited n=520

NCT07365995 RECRUITING

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

BioNTech SE n=736

NCT04493853 ACTIVE NOT RECRUITING

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

AstraZeneca n=1,012

NCT06551324 ACTIVE NOT RECRUITING

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Pfizer n=600

NCT05050084 ACTIVE NOT RECRUITING

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology n=2,050

NCT04513717 ACTIVE NOT RECRUITING

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology n=2,753

NCT06780670 RECRUITING

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Novartis Pharmaceuticals n=443

NCT05939414 RECRUITING

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Novartis Pharmaceuticals n=450

NCT04916613 RECRUITING

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

UNICANCER n=300

NCT03706365 ACTIVE NOT RECRUITING

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Eli Lilly and Company n=393

NCT06274047 RECRUITING

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

M.D. Anderson Cancer Center n=120

NCT06952803 RECRUITING

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

AstraZeneca n=700

NCT05794906 ACTIVE NOT RECRUITING

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

Bayer n=985

NCT04076059 ACTIVE NOT RECRUITING

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Astellas Pharma China, Inc. n=180

NCT06439225 RECRUITING

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Canadian Cancer Trials Group n=236

NCT06592924 RECRUITING

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Canadian Cancer Trials Group n=830

NCT06235697 RECRUITING

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Canadian Cancer Trials Group n=710

NCT06122584 RECRUITING

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

ABX advanced biochemical compounds GmbH n=380

NCT06970847 ACTIVE NOT RECRUITING

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Clarity Pharmaceuticals Ltd n=220

NCT04787744 RECRUITING

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

VA Office of Research and Development n=464

NCT06235151 RECRUITING

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

Curium US LLC n=439

NCT04821622 ACTIVE NOT RECRUITING

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Pfizer n=599

NCT06626022 RECRUITING

Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.

University of Alberta n=1,284

NCT06120491 ACTIVE NOT RECRUITING

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

AstraZeneca n=1,889

NCT02064673 RECRUITING

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

yair lotan n=650

NCT07500701 RECRUITING

Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer

Samsung Medical Center n=270

NCT05678322 ACTIVE NOT RECRUITING

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

NYU Langone Health n=26

NCT07426055 RECRUITING

PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer

Affidea Nu-med Center of Oncological DIagnostics and Therapy n=1,200

NCT07426094 RECRUITING

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

Affidea Nu-med Center of Oncological DIagnostics and Therapy n=1,600

NCT03594760 RECRUITING

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

Centre hospitalier de l'Université de Montréal (CHUM) n=1,000

NCT06282588 RECRUITING

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Cancer Research Antwerp n=493

NCT07477626 RECRUITING

Radiotherapy After Prostatectomy for Node Positive Prostate Cancer

Sun Yat-sen University n=372

NCT05884398 ACTIVE NOT RECRUITING

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

Janssen Research & Development, LLC n=420

NCT05171816 ACTIVE NOT RECRUITING

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

AstraZeneca n=110

NCT06691984 ACTIVE NOT RECRUITING

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Amgen n=707

NCT05154162 ACTIVE NOT RECRUITING

PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI

Peter MacCallum Cancer Centre, Australia n=660

NCT03495427 RECRUITING

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

H. Lee Moffitt Cancer Center and Research Institute n=60

NCT03574571 ACTIVE NOT RECRUITING

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center n=732

NCT06650579 RECRUITING

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Emory University n=72

NCT06855277 RECRUITING

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Novartis Pharmaceuticals n=940

NCT07427043 RECRUITING

Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)

Brigham and Women's Hospital n=300

NCT04455750 ACTIVE NOT RECRUITING

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

Alliance for Clinical Trials in Oncology n=61

NCT06563388 RECRUITING

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Roswell Park Cancer Institute n=800

NCT07311694 RECRUITING

A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd. n=370

NCT03732820 ACTIVE NOT RECRUITING

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

AstraZeneca n=895

NCT06825091 RECRUITING

Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)

University Health Network, Toronto n=320

NCT06470243 RECRUITING

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

SWOG Cancer Research Network n=528

NCT06205316 RECRUITING

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Mayo Clinic n=118

NCT03367702 ACTIVE NOT RECRUITING

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

NRG Oncology n=692

NCT05838716 RECRUITING

Vitamin D for Prostate Endocrine Therapy

University of Rochester n=240

NCT04647526 ACTIVE NOT RECRUITING

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company n=455

NCT07333066 RECRUITING

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD n=320

NCT03258320 RECRUITING

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

Shanghai Jiao Tong University School of Medicine n=300

NCT02051218 ACTIVE NOT RECRUITING

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Swiss Cancer Institute n=1,380

NCT07293585 RECRUITING

Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment

Jonsson Comprehensive Cancer Center n=200

NCT04446117 ACTIVE NOT RECRUITING

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Exelixis n=575

NCT03701581 RECRUITING

4-aminopyridine Treatment for Nerve Injury

John Elfar n=70

NCT06851663 RECRUITING

Trop2-targeted immunoPET Imaging of Solid Tumors

RenJi Hospital n=400

NCT07260435 RECRUITING

Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer

Nick Beije n=400

NCT05786716 RECRUITING

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Cancer Research UK n=30

NCT03987386 ACTIVE NOT RECRUITING

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

M.D. Anderson Cancer Center n=186

NCT04263025 ACTIVE NOT RECRUITING

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

Hackensack Meridian Health n=100

NCT07209878 RECRUITING

68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

First Affiliated Hospital of Fujian Medical University n=100

NCT07200830 RECRUITING

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Alliance for Clinical Trials in Oncology n=1,524

NCT06320067 RECRUITING

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

University College, London n=3,360

NCT05520255 RECRUITING

18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

University of Alberta n=2,800

NCT02194842 ACTIVE NOT RECRUITING

Phase III Radium 223 mCRPC-PEACE III

European Organisation for Research and Treatment of Cancer - EORTC n=446

NCT05974774 RECRUITING

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

European Organisation for Research and Treatment of Cancer - EORTC n=1,600

NCT03678025 RECRUITING

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

SWOG Cancer Research Network n=1,273

NCT07052214 RECRUITING

PSMA PET Combined With MRI for the Detection of PCa

Telix Pharmaceuticals (Innovations) Pty Limited n=204

NCT01230866 ACTIVE NOT RECRUITING

Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer

Proton Collaborative Group n=150

NCT01492972 RECRUITING

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Proton Collaborative Group n=192

NCT03348670 ACTIVE NOT RECRUITING

Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair n=600

NCT01407263 ACTIVE NOT RECRUITING

Trial of Modifications to Radical Prostatectomy

Memorial Sloan Kettering Cancer Center n=3,204

NCT06986083 RECRUITING

A Study of Changes to Prostate Procedures

Memorial Sloan Kettering Cancer Center n=800

NCT01436968 ACTIVE NOT RECRUITING

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

Candel Therapeutics, Inc. n=711

NCT01952223 ACTIVE NOT RECRUITING

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

UNICANCER n=761

NCT04181203 ACTIVE NOT RECRUITING

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

UNICANCER n=490

NCT05448547 RECRUITING

Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer

Sven Löffeler n=980

NCT05796973 RECRUITING

Measuring Oncological Value of Exercise and Statin

Tampere University Hospital n=240

NCT06625970 RECRUITING

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

UNICANCER n=700

NCT04115007 ACTIVE NOT RECRUITING

Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

UNICANCER n=550

NCT03531099 ACTIVE NOT RECRUITING

Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer

Hospices Civils de Lyon n=108

NCT03769766 RECRUITING

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

University of Texas Southwestern Medical Center n=291

NCT02804815 ACTIVE NOT RECRUITING

Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

University College, London n=11,000

NCT06972511 RECRUITING

Maximal Tumor Eradication for Oligometastatic Prostate Cancer

RenJi Hospital n=120

NCT00567580 ACTIVE NOT RECRUITING

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Radiation Therapy Oncology Group n=1,792

NCT06945315 RECRUITING

SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)

Icahn School of Medicine at Mount Sinai n=196

NCT06112990 RECRUITING

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

University of Utah n=200

NCT06922903 NOT YET RECRUITING

Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

Yunhe Pharmaceutical (Tianjin) Co., Ltd n=240

NCT06922929 NOT YET RECRUITING

A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

Yunhe Pharmaceutical (Tianjin) Co., Ltd n=110

NCT03903835 RECRUITING

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Karolinska Institutet n=750

NCT04302454 ACTIVE NOT RECRUITING

Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

University Medical Center Groningen n=280

NCT05169112 RECRUITING

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Ottawa Hospital Research Institute n=72

NCT04794777 RECRUITING

Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer

Stefan Carlsson n=450

NCT04557501 ACTIVE NOT RECRUITING

PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer

Centre hospitalier de l'Université de Montréal (CHUM) n=800

NCT02692105 ACTIVE NOT RECRUITING

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

British Columbia Cancer Agency n=60

NCT03525288 ACTIVE NOT RECRUITING

PSMA-PET Guided Radiotherapy

Centre hospitalier de l'Université de Montréal (CHUM) n=130

NCT06855589 NOT YET RECRUITING

Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.

Charles LeMoyne Hospital n=400

NCT06565247 RECRUITING

Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation

Region Västerbotten n=60

NCT06837896 NOT YET RECRUITING

Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd. n=110

NCT05676203 ACTIVE NOT RECRUITING

A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Jena University Hospital n=250

NCT05381103 RECRUITING

PSMA-PET to Guide Prostatectomy

Five Eleven Pharma, Inc. n=288

NCT05348577 ACTIVE NOT RECRUITING

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

AstraZeneca n=1,035

NCT06768255 NOT YET RECRUITING

Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC

Ding-Wei Ye n=400

NCT06754085 RECRUITING

Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

HTA Co., Ltd. n=131

NCT04691804 ACTIVE NOT RECRUITING

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd. n=496

NCT06496581 RECRUITING

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER n=500

NCT02303327 ACTIVE NOT RECRUITING

Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

Sir Mortimer B. Davis - Jewish General Hospital n=307

NCT01444820 ACTIVE NOT RECRUITING

Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

Sir Mortimer B. Davis - Jewish General Hospital n=329

NCT02685397 ACTIVE NOT RECRUITING

Management of Castration-Resistant Prostate Cancer with Oligometastases

Sir Mortimer B. Davis - Jewish General Hospital n=102

NCT01957436 ACTIVE NOT RECRUITING

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

UNICANCER n=1,173

NCT02799706 ACTIVE NOT RECRUITING

Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC n=885

NCT05613023 RECRUITING

A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT

Institute of Cancer Research, United Kingdom n=1,128

NCT06585007 RECRUITING

Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

Universitaire Ziekenhuizen KU Leuven n=246

NCT06490328 RECRUITING

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Dongkook Pharmaceutical Co., Ltd. n=154

NCT05352178 RECRUITING

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Universitaire Ziekenhuizen KU Leuven n=873

NCT05847348 RECRUITING

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Telix Pharmaceuticals (Innovations) Pty Limited n=110

NCT05799248 RECRUITING

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

MidLantic Urology n=113

NCT05622162 ACTIVE NOT RECRUITING

Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7

ITEL Telecomunicazioni Srl n=106

NCT06350825 RECRUITING

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

The First Affiliated Hospital with Nanjing Medical University n=200

NCT05116475 RECRUITING

Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie n=152

NCT04642027 RECRUITING

PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy

University Medical Center Groningen n=538

NCT01584258 ACTIVE NOT RECRUITING

Prostate Advances in Comparative Evidence

Royal Marsden NHS Foundation Trust n=2,205

NCT06177015 RECRUITING

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

The First Affiliated Hospital with Nanjing Medical University n=200

NCT04242017 RECRUITING

Long-term Better Than Short-term ADT With Salvage RT

Universitaire Ziekenhuizen KU Leuven n=394

NCT03459820 ENROLLING BY INVITATION

Prostate Cancer Patient Management With 18F-DCFPyL PET/CT

Sir Mortimer B. Davis - Jewish General Hospital n=1,500

NCT05781217 RECRUITING

Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic n=534

NCT05983783 RECRUITING

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

The First Affiliated Hospital with Nanjing Medical University n=200

NCT05956639 RECRUITING

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

The First Affiliated Hospital with Nanjing Medical University n=100

NCT04654338 RECRUITING

2 Ablative RadioTherapy Treatments for Prostate Cancer

Sunnybrook Health Sciences Centre n=30

NCT05019846 RECRUITING

SRT Versus SRT+ADT in Prostate Cancer

Marco Lorenzo Bonu n=310

NCT05232578 NOT YET RECRUITING

Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness

General University Hospital, Prague n=380

NCT07598032 NOT YET RECRUITING

Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate Cancer: Elucidating Differential Effects on Immune Function Between Patients With Localized Disease and Those With Metastatic Progression

University of Ilorin Teaching Hospital n=200

NCT07591467 NOT YET RECRUITING

Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer

Gustave Roussy, Cancer Campus, Grand Paris n=330

NCT07615101 NOT YET RECRUITING

Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.

Norroy Bioscience Co., LTD n=365

NCT07611110 RECRUITING

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

AstraZeneca n=670

NCT07620574 NOT YET RECRUITING

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis n=5,000

NCT07649122 NOT YET RECRUITING

This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.

Norroy Bioscience Co., LTD n=232

NCT07641855 NOT YET RECRUITING

A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer

Sichuan Baili Pharmaceutical Co., Ltd. n=180

NCT07632690 NOT YET RECRUITING

QLC5508 in Participants With Metastatic Prostate Cancer

Qilu Pharmaceutical Co., Ltd. n=700

NCT03070886 COMPLETED

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NRG Oncology n=612

NCT04191096 COMPLETED

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Merck Sharp & Dohme LLC n=1,251

NCT04261777 TERMINATED

Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

Saving Patients' Lives Medical B.V. n=172

NCT05009290 TERMINATED

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Jiangsu HengRui Medicine Co., Ltd. n=391

NCT02044354 COMPLETED

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer

Gustave Roussy, Cancer Campus, Grand Paris n=195

NCT03274687 COMPLETED

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NRG Oncology n=296

NCT01546987 COMPLETED

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Radiation Therapy Oncology Group n=239

NCT00936390 COMPLETED

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Radiation Therapy Oncology Group n=1,538

NCT05597878 TERMINATED

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Wake Forest University Health Sciences n=58

NCT00699751 COMPLETED

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Bayer n=921

NCT04876651 TERMINATED

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Telix Pharmaceuticals (Innovations) Pty Ltd n=16

NCT06235099 COMPLETED

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

Curium US LLC n=235

NCT07413120 COMPLETED

Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery

Incheon St.Mary's Hospital n=40

NCT02003924 COMPLETED

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Pfizer n=1,401

NCT01809691 COMPLETED

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

SWOG Cancer Research Network n=1,313

NCT03009981 COMPLETED

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Alliance Foundation Trials, LLC. n=504

NCT02799602 COMPLETED

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Bayer n=1,306

NCT02294461 COMPLETED

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Astellas Pharma Inc n=395

NCT02677896 COMPLETED

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Astellas Pharma Global Development, Inc. n=1,150

NCT04838613 COMPLETED

Study of Diagnostic Performance of [18F]CTT1057 in BCR

Novartis Pharmaceuticals n=190

NCT04838626 COMPLETED

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Novartis Pharmaceuticals n=195

NCT04934722 COMPLETED

Merck Sharp & Dohme LLC n=186

NCT04186845 COMPLETED

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

Blue Earth Diagnostics n=391

NCT05590793 COMPLETED

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

Ipsen n=195

NCT05605964 COMPLETED

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Sumitomo Pharma America, Inc. n=387

NCT05137561 COMPLETED

Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)

Post Graduate Institute of Medical Education and Research, Chandigarh n=217

NCT05458856 COMPLETED

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

Ipsen n=147

NCT02975934 COMPLETED

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

pharmaand GmbH n=405

NCT05547386 COMPLETED

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer

Mayo Clinic n=163

NCT04742361 COMPLETED

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

ABX advanced biochemical compounds GmbH n=136

NCT04100018 COMPLETED

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Bristol-Myers Squibb n=1,030

NCT03072238 COMPLETED

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

Hoffmann-La Roche n=1,101

NCT00667069 COMPLETED

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

UNICANCER n=424

NCT06984159 COMPLETED

The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.

Changchun GeneScience Pharmaceutical Co., Ltd. n=137

NCT06795178 WITHDRAWN

Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer

Foresee Pharmaceuticals Co., Ltd.

NCT06795191 WITHDRAWN

Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer

Foresee Pharmaceuticals Co., Ltd.

NCT03936218 COMPLETED

Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

Eurofarma Laboratorios S.A. n=94

NCT01220869 COMPLETED

A Study of Degarelix in Taiwanese Patients With Prostate Cancer

Ferring Pharmaceuticals n=110

NCT02288247 COMPLETED

A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone

Astellas Pharma Europe Ltd. n=688

NCT04186819 COMPLETED

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

Blue Earth Diagnostics n=356

NCT03862170 TERMINATED

Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer

CR-CSSS Champlain-Charles-Le Moyne n=158

NCT00887198 COMPLETED

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Janssen Research & Development, LLC n=1,088

NCT03103321 COMPLETED

Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer

Alliance for Clinical Trials in Oncology n=158

NCT03511664 COMPLETED

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Endocyte n=861

NCT02220829 COMPLETED

Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy

Sir Mortimer B. Davis - Jewish General Hospital n=148

NCT01964170 COMPLETED

A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

Astellas Pharma Inc n=234

NCT03031821 TERMINATED

Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome

Canadian Urologic Oncology Group n=168

NCT03777982 TERMINATED

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Dana-Farber Cancer Institute n=12

NCT01272050 COMPLETED

Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery

Swiss Cancer Institute n=350

NCT03056638 TERMINATED

Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

Memorial Sloan Kettering Cancer Center n=56

NCT03850795 TERMINATED

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hinova Pharmaceuticals USA, Inc. n=104

NCT03389451 COMPLETED

68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer

Michael Graham PhD, MD n=30

NCT04676334 COMPLETED

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

pharmaand GmbH n=34

NCT04684628 SUSPENDED

68Ga-PSMA PET/CT in Prostate Cancer

University of Saskatchewan n=500

NCT03388346 COMPLETED

68Ga PSMA in Preprostatectomy Patients

Michael Graham PhD, MD n=22

NCT04644822 COMPLETED

Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.

Centre for Probe Development and Commercialization n=100

NCT04844749 TERMINATED

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Veru Inc. n=105

NCT04887506 COMPLETED

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Tavanta Therapeutics n=107

NCT04409288 TERMINATED

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Chinese University of Hong Kong n=74

NCT03001869 COMPLETED

68Ga-PSMA PET/CT in Prostate Cancer

Sir Mortimer B. Davis - Jewish General Hospital n=540

NCT05197257 COMPLETED

68Ga-PSMA-11 PET in Patients With Prostate Cancer

University of Colorado, Denver n=39

NCT00942331 COMPLETED

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

National Cancer Institute (NCI) n=506

NCT02987543 COMPLETED

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

AstraZeneca n=387

NCT03761225 COMPLETED

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

AB Science n=714

NCT05771896 WITHDRAWN

Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC

GenesisCare USA

NCT05098327 WITHDRAWN

Pioglitazone and Insulin Resistance in ADT

State University of New York at Buffalo

NCT00651326 TERMINATED

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

NCIC Clinical Trials Group n=48

NCT01666808 COMPLETED

FACBC Outcomes for Post Prostatectomy

Emory University n=165

NCT04914195 COMPLETED

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Bharat Serums and Vaccines Limited n=155

NCT00664456 COMPLETED

Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan n=421

NCT05363644 WITHDRAWN

BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy

AdventHealth

NCT02015871 COMPLETED

An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer

Ferring Pharmaceuticals n=206

NCT02659527 COMPLETED

PET/MRI in Patients With Suspected Prostate Cancer

Medical University of Vienna n=220

NCT01907009 TERMINATED

A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)

Barts & The London NHS Trust n=29

NCT02624518 COMPLETED

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

Andrei Iagaru n=122

NCT03103152 COMPLETED

A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression

Queen Mary University of London n=104

NCT01238172 COMPLETED

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Alliance for Clinical Trials in Oncology n=478

NCT02438007 TERMINATED

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

LTN PHARMACEUTICALS, INC. n=953

NCT03921996 TERMINATED

Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer

Swiss Cancer Institute n=57

NCT05744115 TERMINATED

Ga-68-PSMA-11 in Men With Prostate Cancer

Timothy Hoffman n=38

NCT04627896 COMPLETED

Targeted Microwave Focal Therapy

A.O.U. Città della Salute e della Scienza n=11

NCT04854993 COMPLETED

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=34

NCT04457245 TERMINATED

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

Jonsson Comprehensive Cancer Center n=54

NCT02745587 TERMINATED

Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.

University Hospital, Ghent n=69

NCT04237584 TERMINATED

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

MANA RBM n=23

NCT02663908 TERMINATED

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

Ferring Pharmaceuticals n=545

NCT02200614 COMPLETED

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Bayer n=1,509

NCT02961257 COMPLETED

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie n=196

NCT01517802 COMPLETED

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Janssen Research & Development, LLC n=32

NCT03295565 COMPLETED

Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel

The Netherlands Cancer Institute n=100

NCT02678351 COMPLETED

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

Andrei Iagaru n=74

NCT03085095 COMPLETED

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

Myovant Sciences GmbH n=1,134

NCT02673151 COMPLETED

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

Andrei Iagaru n=61

NCT03800784 WITHDRAWN

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03353740 COMPLETED

Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence

Thomas Hope n=346

NCT04563936 COMPLETED

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Luye Pharma Group Ltd. n=290

NCT03803475 COMPLETED

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

Thomas Hope n=485

NCT02981368 COMPLETED

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Progenics Pharmaceuticals, Inc. n=385

NCT02940262 COMPLETED

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Jonsson Comprehensive Cancer Center n=1,138

NCT04102553 COMPLETED

F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence

ABX advanced biochemical compounds GmbH n=200

NCT03739684 COMPLETED

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Progenics Pharmaceuticals, Inc. n=208

NCT03532308 TERMINATED

Nutrition and Prostate Cancer

Yale University n=19

NCT02834416 COMPLETED

ADT Exercise Trial and Economic Analysis

University Health Network, Toronto n=38

NCT02111577 COMPLETED

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

SOTIO a.s. n=1,182

NCT01538628 COMPLETED

SpaceOAR System Pivotal Study

Boston Scientific Corporation n=222

NCT03404648 COMPLETED

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

Mayo Clinic n=19

NCT03911310 COMPLETED

[18F]PSMA-11 PET/CT Phase 3 Clinical Study

University Hospital, Ghent n=96

NCT02919111 COMPLETED

Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients

University of California, San Francisco n=299

NCT04225299 WITHDRAWN

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Steba Biotech S.A.

NCT03488810 WITHDRAWN

Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC

NCT02887976 COMPLETED

Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201

GU Research Network, LLC n=2

NCT01168479 COMPLETED

FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer

UMC Utrecht n=571

NCT01212991 COMPLETED

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Pfizer n=1,717

NCT01591122 COMPLETED

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Janssen Research & Development, LLC n=313

NCT02260817 COMPLETED

Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

Global Isotopes, LLC d/b/a Zevacor Molecular n=109

NCT01902823 TERMINATED

Effect of Cancer Nurse Navigators on Patient Outcomes

University of Wisconsin, Madison n=16

NCT01715129 COMPLETED

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Ipsen n=126

NCT02918357 COMPLETED

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

University of California, San Francisco n=385

NCT01313273 TERMINATED

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

Ipsen n=3

NCT01419717 COMPLETED

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Amgen n=129

NCT01322490 COMPLETED

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Bavarian Nordic n=1,297

NCT04056754 COMPLETED

Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=268

NCT01310894 COMPLETED

Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.

Steba Biotech S.A. n=413

NCT01006395 COMPLETED

Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

Austin Health n=64

NCT02085252 COMPLETED

A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

Takeda n=116

NCT01308567 COMPLETED

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Sanofi n=1,168

NCT01707966 COMPLETED

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Swiss Cancer Institute n=47

NCT01930812 COMPLETED

18F-NaF PET Imaging for Bone Scintigraphy

British Columbia Cancer Agency n=286

NCT02615067 COMPLETED

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer

Molecular Insight Pharmaceuticals, Inc. n=531

NCT01020448 COMPLETED

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

Ipsen n=339

NCT02680041 COMPLETED

18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

Blue Earth Diagnostics n=221

NCT01193257 COMPLETED

Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

Millennium Pharmaceuticals, Inc. n=1,099

NCT00974311 COMPLETED

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

Pfizer n=1,199

NCT02551341 COMPLETED

Lung Protective Ventilation During Robotic Assisted Prostatectomy

Jørgen Bjerggaard Jensen n=24

NCT00838201 COMPLETED

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Amgen n=384

NCT02840552 COMPLETED

The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer

Sir Mortimer B. Davis - Jewish General Hospital n=60

NCT02053311 WITHDRAWN

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Swiss Cancer Institute

NCT01522443 TERMINATED

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Exelixis n=119

NCT00988208 COMPLETED

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Celgene n=1,059

NCT01605227 COMPLETED

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Exelixis n=1,028

NCT00931528 COMPLETED

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Radiation Therapy Oncology Group n=242

NCT01105338 COMPLETED

Lycopene or Green Tea for Men at Risk of Prostate Cancer

University of Bristol n=126

NCT01613651 COMPLETED

Robotic Assisted Laparoscopic Prostatectomy With or Without Pelvic Drain Placement in Reducing Adverse Events After Surgery in Patients With Prostate Cancer

City of Hope Medical Center n=191

NCT02526784 COMPLETED

A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer

Ferring Pharmaceuticals n=120

NCT00925600 COMPLETED

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Amgen n=769

NCT01193244 COMPLETED

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Millennium Pharmaceuticals, Inc. n=1,560

NCT01308580 COMPLETED

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sanofi n=1,200

NCT01415960 COMPLETED

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

GP-Pharm n=163

NCT00928434 COMPLETED

A Study of Degarelix in Patients With Prostate Cancer

Ferring Pharmaceuticals n=409

NCT01188187 COMPLETED

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Achieve Life Sciences n=1,022

NCT01578655 COMPLETED

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Achieve Life Sciences n=630

NCT01083615 TERMINATED

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Achieve Life Sciences n=14

NCT00861614 COMPLETED

Study of Immunotherapy to Treat Advanced Prostate Cancer

Bristol-Myers Squibb n=988

NCT01057810 COMPLETED

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Bristol-Myers Squibb n=837

NCT00691899 WITHDRAWN

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Merck Sharp & Dohme LLC

NCT01981707 TERMINATED

F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer

University Hospital, Grenoble n=12

NCT01875393 COMPLETED

Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer

Steba Biotech S.A. n=81

NCT01603420 TERMINATED

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

Proton Collaborative Group n=2

NCT01234311 COMPLETED

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Active Biotech AB n=1,245

NCT00685646 COMPLETED

Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan n=227

NCT01656161 COMPLETED

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Debiopharm International SA n=120

NCT01546623 COMPLETED

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Takeda n=160

NCT00809458 TERMINATED

Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer

New Mexico Cancer Research Alliance n=15

NCT01744366 COMPLETED

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Ferring Pharmaceuticals n=285

NCT01242748 TERMINATED

A Degarelix Trial in Patients With Prostate Cancer

Ferring Pharmaceuticals n=288

NCT01824342 COMPLETED

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

Amgen n=18

NCT01254279 COMPLETED

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Sanofi n=984

NCT02257827 COMPLETED

Trial Comparing Intensity Modulated Radiotherapy Versus Conformal Radiotherapy to Treat Prostate Cancer With Hypofractionated Schedule

Gustavo Viani Arruda n=220

NCT00801242 COMPLETED

Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer

Ferring Pharmaceuticals n=220

NCT00949962 TERMINATED

Post-operative or Early Salvage XRT and ADT for High Risk PCa

European Organisation for Research and Treatment of Cancer - EORTC n=87

NCT00946920 COMPLETED

A Trial of Degarelix in Patients With Prostate Cancer

Ferring Pharmaceuticals n=859

NCT00950911 COMPLETED

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Amgen n=35

NCT01715064 COMPLETED

Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients

University of Guelph-Humber n=36

NCT00922129 WITHDRAWN

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

NCT00884273 COMPLETED

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Ferring Pharmaceuticals n=182

NCT00831233 TERMINATED

Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Ferring Pharmaceuticals n=42

NCT01901042 COMPLETED

Efficacy of Symbiotic in the Reduction of Acute Radiation Proctitis Symptoms

Federal University of Mato Grosso n=20

NCT01215513 COMPLETED

Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients

Ferring Pharmaceuticals n=127

NCT01071915 COMPLETED

Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer

Ferring Pharmaceuticals n=157

NCT01174017 COMPLETED

Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the Prostate

British Columbia Cancer Agency n=41

NCT00967018 COMPLETED

A Long Term Safety Study of Degarelix in Patients With Prostate Cancer

Ferring Pharmaceuticals n=77

NCT00658229 COMPLETED

The Physical Exercise and Prostate Cancer Study

Oslo University Hospital n=60

NCT00833248 COMPLETED

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Ferring Pharmaceuticals n=246

NCT00617669 COMPLETED

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

AstraZeneca n=1,494

NCT00626548 TERMINATED

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

AstraZeneca n=2,577

NCT00911027 TERMINATED

SonoVue Guided Prostate Biopsy

Bracco Diagnostics, Inc n=282

NCT01367418 COMPLETED

Effects of Anesthetic Technique on Immune and Inflammatory Systems Following Radical Prostatectomy

Örebro University, Sweden n=26

NCT00626431 COMPLETED

A Study of Leuprolide to Treat Prostate Cancer

Abbott n=310

NCT00630799 TERMINATED

Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients

GP-Pharm n=20

NCT05828082 ACTIVE NOT RECRUITING

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

National Cancer Institute (NCI)

NCT07455903 RECRUITING

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Baptist Health South Florida

NCT05169970 RECRUITING

A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT03866382 RECRUITING

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

NCT05036226 RECRUITING

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

Medical University of South Carolina

NCT05691465 RECRUITING

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

National Cancer Institute (NCI)

NCT04550494 RECRUITING

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

NCT07574541 NOT YET RECRUITING

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

National Cancer Institute (NCI)

NCT07450599 RECRUITING

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

Bayer

NCT06022822 RECRUITING

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

National Cancer Institute (NCI)

NCT07285694 RECRUITING

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Arsenal Biosciences, Inc.

NCT05413850 RECRUITING

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

NCT05919264 RECRUITING

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

NCT07190300 RECRUITING

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis Pharmaceuticals

NCT07288359 RECRUITING

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis Pharmaceuticals

NCT07578519 NOT YET RECRUITING

Radiation Treatment of the Prostate That is Specially Adjusted for Each Person

AHS Cancer Control Alberta

NCT07226986 RECRUITING

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Novartis Pharmaceuticals

NCT06111781 RECRUITING

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

Yale University

NCT05751434 ACTIVE NOT RECRUITING

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

City of Hope Medical Center

NCT04848337 ACTIVE NOT RECRUITING

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

University of Michigan Rogel Cancer Center

NCT05689021 ACTIVE NOT RECRUITING

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Mayo Clinic

NCT04262154 ACTIVE NOT RECRUITING

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT07414940 RECRUITING

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

University College, London

NCT06632977 RECRUITING

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Alliance for Clinical Trials in Oncology

NCT04986423 RECRUITING

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Zenith Epigenetics

NCT07206056 RECRUITING

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Novartis Pharmaceuticals

NCT07181161 RECRUITING

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

AstraZeneca

NCT05826509 ACTIVE NOT RECRUITING

SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer

Institut Claudius Regaud

NCT03637543 ACTIVE NOT RECRUITING

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

Beth Israel Deaconess Medical Center

NCT07576335 NOT YET RECRUITING

Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy

Surgical Outcomes Research Centre (SOuRCe)

NCT07192614 RECRUITING

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

AstraZeneca

NCT03824652 RECRUITING

WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

Stephen Freedland

NCT06909825 ACTIVE NOT RECRUITING

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Fusion Pharmaceuticals Inc.

NCT06212583 ACTIVE NOT RECRUITING

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

University of Maryland, Baltimore

NCT06239194 RECRUITING

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

ModeX Therapeutics, An OPKO Health Company

NCT05832086 RECRUITING

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Stephen Freedland

NCT07287150 RECRUITING

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

Hoffmann-La Roche

NCT07568756 NOT YET RECRUITING

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

University of California, Irvine

NCT03217747 ACTIVE NOT RECRUITING

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

M.D. Anderson Cancer Center

NCT07568236 NOT YET RECRUITING

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

Chinese University of Hong Kong

NCT06085664 RECRUITING

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

M.D. Anderson Cancer Center

NCT03317392 ACTIVE NOT RECRUITING

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

National Cancer Institute (NCI)

NCT05873192 RECRUITING

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

M.D. Anderson Cancer Center

NCT07567521 RECRUITING

A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

C Ray Therapeutics

NCT07567846 RECRUITING

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

Genentech, Inc.

NCT07552168 RECRUITING

INSPIRE: INnovative SABR for Prostate Cancer All IREland

Cancer Trials Ireland

NCT05125016 RECRUITING

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

Regeneron Pharmaceuticals

NCT03899987 ACTIVE NOT RECRUITING

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Roswell Park Cancer Institute

NCT06616155 RECRUITING

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

University of Michigan Rogel Cancer Center

NCT05067140 ACTIVE NOT RECRUITING

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Novartis Pharmaceuticals

NCT06849544 RECRUITING

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

Clinton Bahler

NCT07354919 RECRUITING

Axelopran for Advanced Cancer in Patients Receiving Opioids

HealthPartners Institute

NCT07226713 NOT YET RECRUITING

Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

Medical College of Wisconsin

NCT05053152 ACTIVE NOT RECRUITING

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NRG Oncology

NCT07223385 NOT YET RECRUITING

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

Cedars-Sinai Medical Center

NCT07005154 RECRUITING

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Astellas Pharma Global Development, Inc.

NCT03067051 RECRUITING

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

SpectraCure AB

NCT07336446 RECRUITING

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

AstraZeneca

NCT05059236 ACTIVE NOT RECRUITING

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Bayer

NCT07562438 RECRUITING

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

First Affiliated Hospital of Fujian Medical University

NCT06894511 ACTIVE NOT RECRUITING

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Novartis Pharmaceuticals

NCT06991556 RECRUITING

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis Pharmaceuticals

NCT06807359 RECRUITING

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

SpectraCure AB

NCT04194554 ACTIVE NOT RECRUITING

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

University of Michigan Rogel Cancer Center

NCT07451795 RECRUITING

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

Fudan University

NCT05616650 RECRUITING

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

National Cancer Institute (NCI)

NCT07117760 ACTIVE NOT RECRUITING

Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

First Affiliated Hospital of Fujian Medical University

NCT05983198 ACTIVE NOT RECRUITING

Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

Novartis Pharmaceuticals

NCT05682443 ACTIVE NOT RECRUITING

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

OncoC4, Inc.

NCT06395753 ACTIVE NOT RECRUITING

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

Debiopharm International SA

NCT07553988 ACTIVE NOT RECRUITING

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

R-Pharm International, LLC

NCT04465500 ACTIVE NOT RECRUITING

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

University of Virginia

NCT03436654 ACTIVE NOT RECRUITING

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Memorial Sloan Kettering Cancer Center

NCT07224009 NOT YET RECRUITING

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

University of Arkansas

NCT06844383 RECRUITING

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Prostate Cancer Clinical Trials Consortium

NCT07549256 NOT YET RECRUITING

Cannabidiol for Pain Relief of Patients With End-stage mCRPC

Regionshospital Nordjylland

NCT06594926 RECRUITING

Working Out M0 Bipolar Androgen Therapy

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

NCT06785636 RECRUITING

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Pathos AI, Inc.

NCT03976843 ACTIVE NOT RECRUITING

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

National Cancer Institute (NCI)

NCT07550517 NOT YET RECRUITING

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03682289 ACTIVE NOT RECRUITING

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Rahul Aggarwal

NCT03517969 ACTIVE NOT RECRUITING

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

National Cancer Institute (NCI)

NCT06600698 RECRUITING

Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

Milton S. Hershey Medical Center

NCT03522064 RECRUITING

Bipolar Androgen Therapy + Carboplatin in mCRPC

St Vincent's Hospital, Sydney

NCT03181867 ACTIVE NOT RECRUITING

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

National Cancer Institute (NCI)

NCT07407283 RECRUITING

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

NCT04946370 RECRUITING

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Weill Medical College of Cornell University

NCT06378866 RECRUITING

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Mayo Clinic

NCT07234981 RECRUITING

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

University of Nebraska

NCT00951535 ACTIVE NOT RECRUITING

A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17

Cancer Trials Ireland

NCT07535905 NOT YET RECRUITING

Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients

University Health Network, Toronto

NCT05766371 RECRUITING

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

University of California, San Francisco

NCT06347705 RECRUITING

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT04606446 RECRUITING

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Pfizer

NCT07237269 RECRUITING

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

University of Nebraska

NCT03821792 ACTIVE NOT RECRUITING

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

M.D. Anderson Cancer Center

NCT06615752 RECRUITING

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Charles Drew University of Medicine and Science

NCT07111507 RECRUITING

A Study of Tarlatamab for People With Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT05155046 RECRUITING

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

National Cancer Institute (NCI)

NCT07002320 RECRUITING

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Institute of Cancer Research, United Kingdom

NCT07529717 RECRUITING

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

AstraZeneca

NCT05960578 ACTIVE NOT RECRUITING

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

University of Washington

NCT06610825 RECRUITING

Castrate Resistant Prostate Cancer Enhertu Therapy

Washington D.C. Veterans Affairs Medical Center

NCT05849298 ACTIVE NOT RECRUITING

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Novartis Pharmaceuticals

NCT02893917 ACTIVE NOT RECRUITING

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

National Cancer Institute (NCI)

NCT04842890 ACTIVE NOT RECRUITING

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

The New York Proton Center

NCT06190899 RECRUITING

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

NCT02960022 RECRUITING

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Astellas Pharma Global Development, Inc.

NCT04337580 RECRUITING

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

Wake Forest University Health Sciences

NCT05113537 RECRUITING

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Vadim S Koshkin

NCT03361735 ACTIVE NOT RECRUITING

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

City of Hope Medical Center

NCT07192120 RECRUITING

A Study of MHB048C in Patients With Advanced Solid Tumors

Minghui Pharmaceutical (Hangzhou) Ltd

NCT00859781 ACTIVE NOT RECRUITING

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Weill Medical College of Cornell University

NCT07354594 NOT YET RECRUITING

External Beam and Radioligand Radiotherapy for mCRPC

Centre hospitalier de l'Université de Montréal (CHUM)

NCT06402331 ACTIVE NOT RECRUITING

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Fusion Pharmaceuticals Inc.

NCT05457699 RECRUITING

Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)

Centre hospitalier de l'Université de Montréal (CHUM)

NCT07516210 NOT YET RECRUITING

Adaptive Radiotherapy for Safe Hypofractionation

Centre hospitalier de l'Université de Montréal (CHUM)

NCT07515651 NOT YET RECRUITING

Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy Using SBRT for Prostate Cancer to Reduce Treatment Toxicity

University Health Network, Toronto

NCT07512076 NOT YET RECRUITING

A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer

Sunnybrook Health Sciences Centre

NCT04709276 ACTIVE NOT RECRUITING

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Andrew J. Armstrong, MD

NCT03173924 ACTIVE NOT RECRUITING

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

National Cancer Institute (NCI)

NCT04363164 RECRUITING

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05219500 ACTIVE NOT RECRUITING

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Fusion Pharmaceuticals Inc.

NCT07365423 RECRUITING

Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

Swiss Cancer Institute

NCT06085729 RECRUITING

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

M.D. Anderson Cancer Center

NCT06305390 RECRUITING

Fully Hybrid 18F-PSMA PET/MRI as One-stop Approach for the Diagnosis of Clinically Significant Prostate Cancer.

IRCCS San Raffaele

NCT03543189 ACTIVE NOT RECRUITING

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

H. Lee Moffitt Cancer Center and Research Institute

NCT04300855 ACTIVE NOT RECRUITING

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

H. Lee Moffitt Cancer Center and Research Institute

NCT06734130 ACTIVE NOT RECRUITING

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT03419234 ACTIVE NOT RECRUITING

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

ECOG-ACRIN Cancer Research Group

NCT07259213 RECRUITING

A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC

Radiopharm Theranostics, Ltd

NCT03795207 ACTIVE NOT RECRUITING

Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)

Institut Cancerologie de l'Ouest

NCT06401980 RECRUITING

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Swiss Cancer Institute

NCT03471650 ACTIVE NOT RECRUITING

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06244004 RECRUITING

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

Northwestern University

NCT04663997 ACTIVE NOT RECRUITING

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Canadian Cancer Trials Group

NCT05593497 RECRUITING

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

VA Office of Research and Development

NCT06395519 RECRUITING

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

858 Therapeutics, Inc.

NCT07189871 RECRUITING

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Radiopharm Theranostics, Ltd

NCT07073794 RECRUITING

Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer

Mayo Clinic

NCT06832774 RECRUITING

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

NCT06096870 RECRUITING

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

National Cancer Institute (NCI)

NCT06526299 RECRUITING

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

University of Washington

NCT07490210 NOT YET RECRUITING

Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer

Fudan University

NCT06457919 RECRUITING

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT06409910 RECRUITING

Comparing Moderately Ultra Hypofractionated Radiation Treatments for Prostate Cancer

University Health Network, Toronto

NCT06798558 RECRUITING

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Hackensack Meridian Health

NCT03787680 ACTIVE NOT RECRUITING

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

University of Michigan Rogel Cancer Center

NCT05658003 ACTIVE NOT RECRUITING

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Novartis Pharmaceuticals

NCT07332000 RECRUITING

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

NCT06842498 RECRUITING

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Kyntra Bio

NCT07048314 NOT YET RECRUITING

Stem Cells for Erectile Dysfunction Post RALP

The Methodist Hospital Research Institute

NCT05489211 RECRUITING

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

NCT07027124 RECRUITING

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Icahn School of Medicine at Mount Sinai

NCT03412396 ACTIVE NOT RECRUITING

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

M.D. Anderson Cancer Center

NCT07476001 RECRUITING

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

H. Lee Moffitt Cancer Center and Research Institute

NCT05888532 RECRUITING

64Cu-GRIP B in Patients With Advanced Malignancies

Rahul Aggarwal

NCT07476677 NOT YET RECRUITING

Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NCT05751941 ACTIVE NOT RECRUITING

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT04190446 ACTIVE NOT RECRUITING

A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer

Mayo Clinic

NCT04206319 ACTIVE NOT RECRUITING

Radium-223 in Biochemically Recurrent Prostate Cancer

National Cancer Institute (NCI)

NCT07335796 RECRUITING

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT07025369 RECRUITING

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Mayo Clinic

NCT06288113 RECRUITING

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Jonsson Comprehensive Cancer Center

NCT06173362 RECRUITING

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

University of California, Davis

NCT06654336 RECRUITING

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Ontario Clinical Oncology Group (OCOG)

NCT07457164 NOT YET RECRUITING

A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

Antev Ltd.

NCT07466498 NOT YET RECRUITING

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

University of Washington

NCT04585750 RECRUITING

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PMV Pharmaceuticals, Inc

NCT03424850 RECRUITING

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Washington University School of Medicine

NCT06437574 RECRUITING

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

Cedars-Sinai Medical Center

NCT07441837 NOT YET RECRUITING

Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients

Ankara University

NCT07142551 RECRUITING

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06216249 RECRUITING

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Jonsson Comprehensive Cancer Center

NCT06330805 RECRUITING

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

Ohio State University Comprehensive Cancer Center

NCT02905318 ACTIVE NOT RECRUITING

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Canadian Cancer Trials Group

NCT06957691 RECRUITING

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Shehzad Basaria, M.D.

NCT06463457 ACTIVE NOT RECRUITING

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Atish Choudhury, MD

NCT07182279 RECRUITING

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

The Methodist Hospital Research Institute

NCT03808077 ACTIVE NOT RECRUITING

The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT06004661 ACTIVE NOT RECRUITING

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Novartis Pharmaceuticals

NCT02703623 ACTIVE NOT RECRUITING

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

M.D. Anderson Cancer Center

NCT04748042 ACTIVE NOT RECRUITING

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

University of Michigan Rogel Cancer Center

NCT06066437 ACTIVE NOT RECRUITING

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

M.D. Anderson Cancer Center

NCT05726292 RECRUITING

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

University of Chicago

NCT05586360 RECRUITING

T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer

Medical University of South Carolina

NCT06675357 RECRUITING

Using FAPI PET/MRI to Evaluate Prostate Cancer

University of Wisconsin, Madison

NCT03938649 ACTIVE NOT RECRUITING

SRAM study_Postate Cancer

CCTU

NCT07230106 RECRUITING

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

NCT05546268 ACTIVE NOT RECRUITING

Study of Oral MRT-2359 in Selected Cancer Patients

Monte Rosa Therapeutics, Inc

NCT07441889 RECRUITING

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

University of Virginia

NCT06237179 RECRUITING

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

Virginia Commonwealth University

NCT03344211 ACTIVE NOT RECRUITING

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

University of Southern California

NCT04104893 ACTIVE NOT RECRUITING

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

VA Office of Research and Development

NCT06533644 RECRUITING

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

Syncromune, Inc.

NCT04422132 ACTIVE NOT RECRUITING

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

Weill Medical College of Cornell University

NCT07247175 RECRUITING

The Impact of Force Feedback in the dV5 Robotic Surgical System on Learning Curve and Safety in Robot-Assisted Radical Prostatectomy - A Prospective, Single-Center, Investigator-Initiated Clinical Trial

Seong Soo Jeon

NCT02522715 ACTIVE NOT RECRUITING

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

OHSU Knight Cancer Institute

NCT06267729 RECRUITING

Study of AZD0754 in Participants With Metastatic Prostate Cancer

AstraZeneca

NCT06378346 RECRUITING

GU-01: Glycyrrhizin in Prostate Cancer

University of Illinois at Chicago

NCT07285057 RECRUITING

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

Icahn School of Medicine at Mount Sinai

NCT05720130 RECRUITING

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

AdvanCell Pty Limited

NCT01410942 ACTIVE NOT RECRUITING

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

M.D. Anderson Cancer Center

NCT01786265 ACTIVE NOT RECRUITING

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

M.D. Anderson Cancer Center

NCT04947254 RECRUITING

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

NCT06616597 RECRUITING

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04644068 ACTIVE NOT RECRUITING

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

AstraZeneca

NCT05000294 RECRUITING

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

NCT03933670 RECRUITING

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

University of California, San Francisco

NCT07410494 RECRUITING

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Essen Biotech

NCT06111313 RECRUITING

The University of Miami Adapt (UAdapt) Trial

University of Miami

NCT07145255 RECRUITING

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

MBrace Therapeutics

NCT07415135 NOT YET RECRUITING

Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

Zhu Yinjie

NCT06990542 RECRUITING

Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer

University of California, San Diego

NCT06236139 RECRUITING

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Fred Hutchinson Cancer Center

NCT04506567 ACTIVE NOT RECRUITING

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Weill Medical College of Cornell University

NCT02861573 ACTIVE NOT RECRUITING

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Merck Sharp & Dohme LLC

NCT05320406 ACTIVE NOT RECRUITING

RElugolix VErsus LeUprolide Cardiac Trial

Emory University

NCT04754191 ACTIVE NOT RECRUITING

Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

University of Utah

NCT04558866 ACTIVE NOT RECRUITING

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)

Latin American Cooperative Oncology Group

NCT04478279 ACTIVE NOT RECRUITING

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Sapience Therapeutics

NCT04704505 RECRUITING

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT07393867 RECRUITING

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

Martin T. King, MD, PhD

NCT07325721 RECRUITING

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

Medical University of South Carolina

NCT05478239 ACTIVE NOT RECRUITING

ArtemiCoffee in Patients With Rising PSA

Zin W Myint

NCT03902951 ACTIVE NOT RECRUITING

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Jonsson Comprehensive Cancer Center

NCT06591819 RECRUITING

Hypofractionated WPPT With HDR Boost

Abramson Cancer Center at Penn Medicine

NCT07001241 RECRUITING

Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors

University of Colorado, Denver

NCT02955082 ACTIVE NOT RECRUITING

The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment

Institute of Cancer Research, United Kingdom

NCT07387510 NOT YET RECRUITING

PSMA-Targeted Intraoperative Fluorescent Imaging Agents (DGPR1008): Validation Across Different Time Windows

Haitao Niu, MD

NCT05534646 RECRUITING

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Edwin Posadas, MD

NCT05568550 RECRUITING

Pembro With Radiation With or Without Olaparib

Zin W Myint

NCT04997018 ACTIVE NOT RECRUITING

A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT02312401 ACTIVE NOT RECRUITING

Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy

Memorial Sloan Kettering Cancer Center

NCT05806515 RECRUITING

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

SWOG Cancer Research Network

NCT06836726 NOT YET RECRUITING

Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

University Health Network, Toronto

NCT03796767 ACTIVE NOT RECRUITING

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

University of Utah

NCT06397703 RECRUITING

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

NYU Langone Health

NCT06145633 RECRUITING

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Fred Hutchinson Cancer Center

NCT06172478 RECRUITING

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

NCT07210086 RECRUITING

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

City of Hope Medical Center

NCT04734730 RECRUITING

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

City of Hope Medical Center

NCT04989946 RECRUITING

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

University of Wisconsin, Madison

NCT05968144 ACTIVE NOT RECRUITING

Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness

University of Maryland, Baltimore

NCT07364071 NOT YET RECRUITING

Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer

University of California, San Diego

NCT04402151 RECRUITING

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

Weill Medical College of Cornell University

NCT07363382 RECRUITING

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

First Affiliated Hospital of Fujian Medical University

NCT05498272 RECRUITING

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Rana McKay, MD

NCT07363486 RECRUITING

Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

First Affiliated Hospital of Fujian Medical University

NCT05502315 RECRUITING

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Rana McKay, MD

NCT03246347 ACTIVE NOT RECRUITING

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Wake Forest University Health Sciences

NCT06906471 NOT YET RECRUITING

A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS

Antelope Surgical Solutions, Inc

NCT04126070 ACTIVE NOT RECRUITING

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Xiao X. Wei, MD

NCT03333616 ACTIVE NOT RECRUITING

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

NCT07292168 RECRUITING

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Kidney Cancer Research Bureau

NCT03456843 ACTIVE NOT RECRUITING

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Yale University

NCT04267887 ACTIVE NOT RECRUITING

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

OHSU Knight Cancer Institute

NCT05038332 RECRUITING

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

University of Michigan Rogel Cancer Center

NCT07341737 NOT YET RECRUITING

SL-28 for Advanced Solid Tumours

Second Life Therapeutics

NCT06059118 RECRUITING

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03371719 ACTIVE NOT RECRUITING

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

NRG Oncology

NCT05924672 ACTIVE NOT RECRUITING

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

University of California, San Francisco

NCT06334432 ACTIVE NOT RECRUITING

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Nuvation Bio Inc.

NCT06039371 RECRUITING

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

University of Washington

NCT06854250 RECRUITING

Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer

Sun Yat-sen University

NCT04686682 RECRUITING

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Jacobio Pharmaceuticals Co., Ltd.

NCT04777071 ACTIVE NOT RECRUITING

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

University of Washington

NCT05570994 ENROLLING BY INVITATION

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

British Columbia Cancer Agency

NCT06391034 RECRUITING

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

Robert Bok, MD, PhD

NCT02949284 ACTIVE NOT RECRUITING

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Rutgers, The State University of New Jersey

NCT06970119 RECRUITING

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

Yunhe Pharmaceutical (Tianjin) Co., Ltd

NCT06399757 RECRUITING

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Apollo Therapeutics Ltd

NCT07302451 ACTIVE NOT RECRUITING

REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)

National Cancer Institute, Naples

NCT06866938 RECRUITING

Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer

Hospices Civils de Lyon

NCT06084338 RECRUITING

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

VA Office of Research and Development

NCT07313241 RECRUITING

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

University of Texas Southwestern Medical Center

NCT06568094 RECRUITING

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

NCT07310433 NOT YET RECRUITING

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

Yung NA

NCT07310355 NOT YET RECRUITING

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Chengdu StarRay Therapeutics Co., Ltd

NCT06384222 RECRUITING

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

Ivan de Kouchkovsky, MD

NCT03809000 ACTIVE NOT RECRUITING

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

RTOG Foundation, Inc.

NCT06380660 RECRUITING

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Acerand Therapeutics (Shanghai) Limited

NCT07300566 NOT YET RECRUITING

Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial

Joelle Helou

NCT04592237 ACTIVE NOT RECRUITING

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

M.D. Anderson Cancer Center

NCT04655365 ACTIVE NOT RECRUITING

Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

CHU de Quebec-Universite Laval

NCT07299292 RECRUITING

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

SMED Clinical Research

NCT01950351 ACTIVE NOT RECRUITING

Hypofractionated Proton Beam Therapy for Localized Prostate Cancer

M.D. Anderson Cancer Center

NCT06155084 RECRUITING

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

Hinova Pharmaceuticals Inc.

NCT05241860 ACTIVE NOT RECRUITING

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Alliance for Clinical Trials in Oncology

NCT06228053 RECRUITING

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Syntrix Biosystems, Inc.

NCT02452008 ACTIVE NOT RECRUITING

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03753334 ACTIVE NOT RECRUITING

Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.

CHU de Quebec-Universite Laval

NCT07291557 NOT YET RECRUITING

PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer

AHS Cancer Control Alberta

NCT04175431 RECRUITING

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Washington

NCT07150715 RECRUITING

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

Jonsson Comprehensive Cancer Center

NCT06609005 RECRUITING

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Shenzhen Ionova Life Sciences Co., Ltd.

NCT07282197 NOT YET RECRUITING

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

Peking University First Hospital

NCT04025372 ACTIVE NOT RECRUITING

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Brigham and Women's Hospital

NCT03833921 RECRUITING

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

Martha Mims

NCT06943521 RECRUITING

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Tanabe Pharma America, Inc.

NCT06568562 RECRUITING

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

University of Utah

NCT07255664 RECRUITING

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

CuraCell TX AB

NCT04536805 ACTIVE NOT RECRUITING

Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin

Institut Cancerologie de l'Ouest

NCT05367440 ACTIVE NOT RECRUITING

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

AstraZeneca

NCT07268794 NOT YET RECRUITING

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

Fudan University

NCT04090528 ACTIVE NOT RECRUITING

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

University of Wisconsin, Madison

NCT05189457 ACTIVE NOT RECRUITING

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT05893381 RECRUITING

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

NCT02312557 ACTIVE NOT RECRUITING

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

OHSU Knight Cancer Institute

NCT06029998 RECRUITING

Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion

University of Utah

NCT07251829 NOT YET RECRUITING

Neoadjuvant Embolization and Cytoreduction in Prostate Cancer

Srinivas Raman

NCT07250542 RECRUITING

A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer

baotai Liang

NCT06400160 NOT YET RECRUITING

Clinical Trial of TB511 in Advanced Solid Tumors

Twinpig Biolab, Inc.

NCT06126731 RECRUITING

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

NCT06574880 RECRUITING

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

Angela Y. Jia, MD PhD

NCT02333435 ACTIVE NOT RECRUITING

Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life

CHU de Quebec-Universite Laval

NCT07164794 NOT YET RECRUITING

Memantine Hydrochloride in Prostate Cancer Patients

Bin Xu

NCT07163910 RECRUITING

Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study

baotai Liang

NCT06369610 RECRUITING

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Mayo Clinic

NCT05454488 RECRUITING

An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer

M.D. Anderson Cancer Center

NCT06150417 RECRUITING

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

Case Comprehensive Cancer Center

NCT06536374 NOT YET RECRUITING

Folate Study in Men With Advanced Prostate Cancer

University of California, San Diego

NCT05223803 RECRUITING

TERPS Trial for de Novo Oligometastic Prostate Cancer

University of Maryland, Baltimore

NCT03541850 ACTIVE NOT RECRUITING

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

Jonsson Comprehensive Cancer Center

NCT03972657 RECRUITING

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Regeneron Pharmaceuticals

NCT05100472 ACTIVE NOT RECRUITING

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT06100705 RECRUITING

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

Yale University

NCT07216248 RECRUITING

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

University of Utah

NCT06014255 RECRUITING

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05779943 ACTIVE NOT RECRUITING

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

Emory University

NCT03012321 ACTIVE NOT RECRUITING

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Northwestern University

NCT06499870 RECRUITING

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Sean Sachdev

NCT06800313 RECRUITING

Study of HLD-0915 in Patients With Metastatic Prostate Cancer

Halda Therapeutics OpCo, Inc.

NCT05540392 ACTIVE NOT RECRUITING

An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues

Memorial Sloan Kettering Cancer Center

NCT07209865 RECRUITING

68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

First Affiliated Hospital of Fujian Medical University

NCT05869682 RECRUITING

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy

City of Hope Medical Center

NCT07208240 RECRUITING

Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.

Rabin Medical Center

NCT05346848 RECRUITING

Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer

Institut Bergonié

NCT04557449 ACTIVE NOT RECRUITING

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Pfizer

NCT07198633 RECRUITING

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

NCT05652686 RECRUITING

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phanes Therapeutics

NCT02972060 ACTIVE NOT RECRUITING

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC

NCT07179783 RECRUITING

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Tianjin Medical University Second Hospital

NCT03042468 ACTIVE NOT RECRUITING

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Weill Medical College of Cornell University

NCT06922318 RECRUITING

The COSMYC Trial (COmbined Suppression of MYC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04253483 ACTIVE NOT RECRUITING

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

Rutgers, The State University of New Jersey

NCT07172126 NOT YET RECRUITING

Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT06200103 RECRUITING

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Mayo Clinic

NCT06927635 RECRUITING

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

University Health Network, Toronto

NCT06689163 RECRUITING

A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

Jiangsu HengRui Medicine Co., Ltd.

NCT05722288 ACTIVE NOT RECRUITING

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers

City of Hope Medical Center

NCT06134232 RECRUITING

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Dendreon

NCT06738303 RECRUITING

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Case Comprehensive Cancer Center

NCT05011188 ACTIVE NOT RECRUITING

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Rahul Aggarwal

NCT06241846 RECRUITING

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

MediLink Therapeutics (Suzhou) Co., Ltd.

NCT06549465 RECRUITING

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

Convergent Therapeutics

NCT04319783 ACTIVE NOT RECRUITING

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Trans Tasman Radiation Oncology Group

NCT03385655 ACTIVE NOT RECRUITING

Prostate Cancer Biomarker Enrichment and Treatment Selection

Canadian Cancer Trials Group

NCT04038502 RECRUITING

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

VA Office of Research and Development

NCT04015622 ACTIVE NOT RECRUITING

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

British Columbia Cancer Agency

NCT02020070 ACTIVE NOT RECRUITING

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Memorial Sloan Kettering Cancer Center

NCT01990196 ACTIVE NOT RECRUITING

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Jonsson Comprehensive Cancer Center

NCT05864144 ACTIVE NOT RECRUITING

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

NCT01688492 ACTIVE NOT RECRUITING

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT05765500 RECRUITING

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Dana-Farber Cancer Institute

NCT05057013 ACTIVE NOT RECRUITING

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Cancer Research UK

NCT07104617 NOT YET RECRUITING

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

TYK Medicines, Inc

NCT02768363 ACTIVE NOT RECRUITING

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Candel Therapeutics, Inc.

NCT04698564 RECRUITING

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

University of Maryland, Baltimore

NCT02923180 ACTIVE NOT RECRUITING

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05842057 ACTIVE NOT RECRUITING

Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy

University of Miami

NCT04471974 ACTIVE NOT RECRUITING

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Rahul Aggarwal

NCT03436485 ACTIVE NOT RECRUITING

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Orion Corporation, Orion Pharma

NCT07068555 RECRUITING

Prostate Cancer Vaccines

Shenzhen Geno-Immune Medical Institute

NCT06067269 RECRUITING

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

Jonsson Comprehensive Cancer Center

NCT05560659 RECRUITING

Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy

Peter MacCallum Cancer Centre, Australia

NCT04343885 ACTIVE NOT RECRUITING

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

Peter MacCallum Cancer Centre, Australia

NCT05011383 RECRUITING

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

VA Office of Research and Development

NCT03204123 ACTIVE NOT RECRUITING

PSMA PET Imaging of Recurrent Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT07056439 NOT YET RECRUITING

Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

NCT06003556 RECRUITING

PSMA-Guided Ablation of the Prostate

University of Alberta

NCT07038304 RECRUITING

The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)

University Medical Center Groningen

NCT04249154 RECRUITING

Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

McGill University Health Centre/Research Institute of the McGill University Health Centre

NCT04915508 RECRUITING

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

Jonsson Comprehensive Cancer Center

NCT05191680 RECRUITING

TherApeutics in Early ProState Cancer (TAPS02)

Cambridge University Hospitals NHS Foundation Trust

NCT07024277 NOT YET RECRUITING

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

NCT06392295 RECRUITING

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

University of Miami

NCT06402357 RECRUITING

High Intensity Focused Ultrasound in Prostate Cancer

University of Florida

NCT05790213 RECRUITING

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

University of Chicago

NCT02717156 ACTIVE NOT RECRUITING

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

University of Southern California

NCT03525262 ACTIVE NOT RECRUITING

Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)

University of Texas Southwestern Medical Center

NCT06992232 RECRUITING

Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT04140526 ACTIVE NOT RECRUITING

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

OncoC4, Inc.

NCT06383052 ACTIVE NOT RECRUITING

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

Norroy Bioscience Co., LTD

NCT05915442 RECRUITING

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Catherine Spina

NCT04007770 ACTIVE NOT RECRUITING

Acupuncture Pilot Study for Cancer-related Cognitive Function

Memorial Sloan Kettering Cancer Center

NCT03821246 RECRUITING

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

David Oh

NCT06972628 RECRUITING

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

Ebrahim S Delpassand

NCT04104776 RECRUITING

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis Pharmaceuticals

NCT03673787 ACTIVE NOT RECRUITING

A Trial of Ipatasertib in Combination With Atezolizumab

Institute of Cancer Research, United Kingdom

NCT06971211 RECRUITING

Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC

Jianbin Bi

NCT06139575 RECRUITING

Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

Bivision Pharmaceuticals, Inc.

NCT05496959 ACTIVE NOT RECRUITING

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

Jonsson Comprehensive Cancer Center

NCT03725761 ACTIVE NOT RECRUITING

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

University of Wisconsin, Madison

NCT03600350 ACTIVE NOT RECRUITING

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

University of Wisconsin, Madison

NCT05168618 RECRUITING

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

University of Utah

NCT04253262 ACTIVE NOT RECRUITING

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Brown University

NCT04743934 ACTIVE NOT RECRUITING

Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

Andrew McDonald

NCT04503265 RECRUITING

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AtlasMedx, Incorporated

NCT03689699 ACTIVE NOT RECRUITING

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Mark Stein

NCT03951831 ACTIVE NOT RECRUITING

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Mark Stein

NCT06702995 RECRUITING

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evopoint Biosciences Inc.

NCT04619069 ACTIVE NOT RECRUITING

Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

Sunnybrook Health Sciences Centre

NCT06480110 RECRUITING

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

Rigshospitalet, Denmark

NCT05340374 ACTIVE NOT RECRUITING

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Peter MacCallum Cancer Centre, Australia

NCT05521412 RECRUITING

EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T

Peter MacCallum Cancer Centre, Australia

NCT06907641 RECRUITING

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

St Vincent's Hospital, Sydney

NCT04969315 RECRUITING

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Portage Biotech

NCT05896371 NOT YET RECRUITING

A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy

CHU de Quebec-Universite Laval

NCT06890832 NOT YET RECRUITING

A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer

Jina Pharmaceuticals Inc.

NCT04802876 ACTIVE NOT RECRUITING

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

SOLTI Breast Cancer Research Group

NCT04100174 RECRUITING

Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy

Centre hospitalier de l'Université de Montréal (CHUM)

NCT04053842 ACTIVE NOT RECRUITING

Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy

Glenn Bauman

NCT06582446 RECRUITING

Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)

German Oncology Center, Cyprus

NCT06827080 NOT YET RECRUITING

Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

Zhengguo Chen

NCT06449781 RECRUITING

177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

Maria Sklodowska-Curie National Research Institute of Oncology

NCT05383079 ACTIVE NOT RECRUITING

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Peter MacCallum Cancer Centre, Australia

NCT05032040 ACTIVE NOT RECRUITING

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Xencor, Inc.

NCT03763253 ACTIVE NOT RECRUITING

Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms

Imperial College London

NCT06782555 RECRUITING

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

ImmunoGenesis

NCT06783153 NOT YET RECRUITING

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Mansoura University

NCT04009967 ACTIVE NOT RECRUITING

Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning

CHU de Quebec-Universite Laval

NCT06772441 RECRUITING

Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)

German Oncology Center, Cyprus

NCT06758882 RECRUITING

Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET

Marco Oderda

NCT03315754 ACTIVE NOT RECRUITING

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Steba Biotech S.A.

NCT02807805 ACTIVE NOT RECRUITING

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Mamta Parikh

NCT06738745 NOT YET RECRUITING

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

Fudan University

NCT04812366 RECRUITING

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

University of British Columbia

NCT05547061 ACTIVE NOT RECRUITING

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Cellbion Co., Ltd.

NCT03569241 ACTIVE NOT RECRUITING

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases

University Hospital, Ghent

NCT04070209 ACTIVE NOT RECRUITING

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Sir Mortimer B. Davis - Jewish General Hospital

NCT06582628 RECRUITING

Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)

Fundacion Oncosur

NCT05404139 RECRUITING

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

University Health Network, Toronto

NCT06474806 RECRUITING

Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer

Curasight

NCT04879563 ACTIVE NOT RECRUITING

Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project

Region Örebro County

NCT06678126 NOT YET RECRUITING

Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients with Intermediate or High Risk Localized Prostate Cancer (ARP)

Scott Tyldesley

NCT06663007 RECRUITING

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

Tianjin Medical University Second Hospital

NCT06617481 RECRUITING

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

AdventHealth

NCT06655259 RECRUITING

Combination of TURP and Standard Systemic Therapy for MPCa

Fudan University

NCT05558007 RECRUITING

Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

Biozeus Biopharmaceutical S.A.

NCT06636682 RECRUITING

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

Cellvax Therapeutics Inc

NCT05946824 RECRUITING

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

University of Rochester

NCT03230734 ACTIVE NOT RECRUITING

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

NCT06575257 RECRUITING

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

Xijing Hospital

NCT06001255 RECRUITING

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

Hansoh BioMedical R&D Company

NCT06505278 NOT YET RECRUITING

The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy

Sun Yat-sen University

NCT06500247 NOT YET RECRUITING

Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.

Qilu Hospital of Shandong University

NCT03079323 RECRUITING

Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer

Universitaire Ziekenhuizen KU Leuven

NCT03080116 ACTIVE NOT RECRUITING

Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy

Universitaire Ziekenhuizen KU Leuven

NCT06484361 RECRUITING

PET/MRI to Stage Prostate Cancer Patients

IRCCS San Raffaele

NCT05762536 RECRUITING

Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

Erasmus Medical Center

NCT02042807 ACTIVE NOT RECRUITING

To Evaluate the Effect of MCS® in Prostate Cancer Prevention

Health Ever Bio-Tech Co., Ltd.

NCT05563558 RECRUITING

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

Fundacion Oncosur

NCT06227156 RECRUITING

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

RemeGen Co., Ltd.

NCT03762759 ACTIVE NOT RECRUITING

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

Emory University

NCT03141671 ACTIVE NOT RECRUITING

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Dana-Farber Cancer Institute

NCT06081686 RECRUITING

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer

Sinotau Pharmaceutical Group

NCT06387056 RECRUITING

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

The First Affiliated Hospital of Xiamen University

NCT06343077 RECRUITING

Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

Ashutosh Kumar Tewari

NCT06305832 RECRUITING

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT06022757 RECRUITING

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Evopoint Biosciences Inc.

NCT06271551 NOT YET RECRUITING

Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy

Central Finland Hospital District

NCT06259123 RECRUITING

Neoadjuvant PSMA-RLT in Oligometastatic PCa

Medical University of Vienna

NCT06220188 RECRUITING

PSMA-RLT in Biochemically Recurrent PCa

Medical University of Vienna

NCT06249750 RECRUITING

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

Pengyuan Liu

NCT04176081 NOT YET RECRUITING

Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer

University Health Network, Toronto

NCT04889742 NOT YET RECRUITING

Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors

Charite University, Berlin, Germany

NCT06029036 RECRUITING

A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer

Peking University First Hospital

NCT04045717 ACTIVE NOT RECRUITING

Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0

Universitaire Ziekenhuizen KU Leuven

NCT06129851 NOT YET RECRUITING

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

University of Kansas Medical Center

NCT04197141 ACTIVE NOT RECRUITING

Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT02881242 ACTIVE NOT RECRUITING

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Jonsson Comprehensive Cancer Center

NCT05054296 RECRUITING

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

M.D. Anderson Cancer Center

NCT05778097 NOT YET RECRUITING

Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT05003752 ACTIVE NOT RECRUITING

Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer

German Oncology Center, Cyprus

NCT05753566 RECRUITING

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT05717582 NOT YET RECRUITING

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

Fudan University

NCT05373316 NOT YET RECRUITING

Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR-guided Radiotherapy

Radboud University Medical Center

NCT05557604 RECRUITING

Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer

Regina Elena Cancer Institute

NCT03061539 ACTIVE NOT RECRUITING

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

University College, London

NCT05406999 RECRUITING

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT05422911 RECRUITING

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Sun Pharmaceutical Industries Limited

NCT03585114 ACTIVE NOT RECRUITING

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

Columbia University

NCT03444844 ACTIVE NOT RECRUITING

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

Five Eleven Pharma, Inc.

NCT03753243 RECRUITING

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Mark Garzotto, MD

NCT05010343 RECRUITING

Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer

Shanghai Proton and Heavy Ion Center

NCT04114825 ACTIVE NOT RECRUITING

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

RhoVac APS

NCT04700332 RECRUITING

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Hoag Memorial Hospital Presbyterian

NCT04925063 NOT YET RECRUITING

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

Sun Yat-sen University

NCT03294889 RECRUITING

ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer

University Hospital, Geneva

NCT04086290 RECRUITING

National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients

Peter Busch Østergren

NCT04212715 RECRUITING

Prostate SABR With Intra-Prostatic SABR Boost

King Saud University

NCT03392233 RECRUITING

Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors

RenJi Hospital

NCT02391051 RECRUITING

Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial

University of Erlangen-Nürnberg Medical School

NCT07593079 NOT YET RECRUITING

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Washington University School of Medicine

NCT07592910 NOT YET RECRUITING

A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

Prostate Cancer Clinical Trials Consortium

NCT07594106 NOT YET RECRUITING

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Regeneron Pharmaceuticals

NCT07564102 NOT YET RECRUITING

dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy

Mochida Medical USA, Inc.

NCT07590934 NOT YET RECRUITING

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

AstraZeneca

NCT07608718 NOT YET RECRUITING

Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

Pedro Barata, MD, MSc

NCT07623460 NOT YET RECRUITING

Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer

Stuthi Perimbeti

NCT07617272 RECRUITING

Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore

Region Stockholm

NCT07649421 NOT YET RECRUITING

PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC

West China Hospital

NCT07650240 NOT YET RECRUITING

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

Mayo Clinic

NCT07644598 NOT YET RECRUITING

MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer

Georgetown University

NCT07645326 NOT YET RECRUITING

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Georgetown University

NCT07639086 NOT YET RECRUITING

Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

Virginia Commonwealth University

NCT07635524 NOT YET RECRUITING

A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.

Hoag Memorial Hospital Presbyterian

NCT07635238 RECRUITING

A Study of Lower Dose Radiation Therapy for People With Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT07667400 NOT YET RECRUITING

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

National Cancer Institute (NCI)

NCT07668284 NOT YET RECRUITING

COQ10 and Vitamin E for Off-Target Radiation Toxicity

University of Nebraska

NCT04419402 ACTIVE NOT RECRUITING

Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

NCT04071236 SUSPENDED

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

NCT04731844 COMPLETED

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

University of Rochester

NCT01171898 COMPLETED

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Aragon Pharmaceuticals, Inc.

NCT07025512 WITHDRAWN

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

M.D. Anderson Cancer Center

NCT05114746 COMPLETED

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Novartis Pharmaceuticals

NCT07568444 COMPLETED

Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)

University of Southern California

NCT07570966 WITHDRAWN

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis Pharmaceuticals

NCT06765954 WITHDRAWN

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

ImmunityBio, Inc.

NCT05005728 COMPLETED

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Xencor, Inc.

NCT06765902 WITHDRAWN

Immunotherapy Before and After Surgery

ImmunityBio, Inc.

NCT04631744 TERMINATED

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Weill Medical College of Cornell University

NCT03860987 COMPLETED

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Cancer Institute (NCI)

NCT01251861 COMPLETED

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

National Cancer Institute (NCI)

NCT02649855 COMPLETED

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

National Cancer Institute (NCI)

NCT06630325 TERMINATED

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

NCT05133440 COMPLETED

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

Memorial Sloan Kettering Cancer Center

NCT05588609 TERMINATED

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Partner Therapeutics, Inc.

NCT04530552 COMPLETED

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

National Cancer Institute (NCI)

NCT04984343 TERMINATED

Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

Weill Medical College of Cornell University

NCT04925648 COMPLETED

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

St Vincent's Hospital, Sydney

NCT02555189 TERMINATED

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT05848011 COMPLETED

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

MacroGenics

NCT01902680 COMPLETED

Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.

Institut Claudius Regaud

NCT03869762 TERMINATED

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

Cancer Trials Ireland

NCT02225704 COMPLETED

Radium-223 in Combination With Enzalutamide

Cancer Trials Ireland

NCT02772588 COMPLETED

AASUR in High Risk Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT06392841 WITHDRAWN

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Qian Qin

NCT04037254 COMPLETED

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

NRG Oncology

NCT03496805 COMPLETED

Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy

Wake Forest University Health Sciences

NCT03088124 COMPLETED

Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer

Institut Paoli-Calmettes

NCT03360721 TERMINATED

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

M.D. Anderson Cancer Center

NCT03652298 TERMINATED

Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners

Centre Oscar Lambret

NCT05526248 COMPLETED

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide

Bayer

NCT04179864 TERMINATED

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Epizyme, Inc.

NCT02946996 TERMINATED

Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Medical University of South Carolina

NCT05008900 COMPLETED

Timing of Post-prostatectomy PSMA Imaging

University Health Network, Toronto

NCT04288687 COMPLETED

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Abramson Cancer Center at Penn Medicine

NCT05676463 TERMINATED

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

Thomas Jefferson University

NCT01409200 COMPLETED

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

M.D. Anderson Cancer Center

NCT06056791 COMPLETED

Study of INKmune in Patients With mCRPC (CaRe Prostate)

Inmune Bio, Inc.

NCT04443062 COMPLETED

Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

Radboud University Medical Center

NCT01885949 TERMINATED

Tivozanib + Enzalutamide in Adv Prostate Cancer

Massachusetts General Hospital

NCT01314118 COMPLETED

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Janssen Biotech, Inc.

NCT03568188 COMPLETED

Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer

Hospices Civils de Lyon

NCT04751929 COMPLETED

Abemaciclib With or Without Atezolizumab for mCRPC

Dana-Farber Cancer Institute

NCT00809991 COMPLETED

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03421782 COMPLETED

Fatigue Interventions in Cancer (Exercise Intervention)

University of Utah

NCT06661902 COMPLETED

Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial

University of Washington

NCT03263650 COMPLETED

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

M.D. Anderson Cancer Center

NCT01543659 COMPLETED

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT02274779 COMPLETED

Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer

Institut Cancerologie de l'Ouest

NCT05670106 COMPLETED

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Novartis Pharmaceuticals

NCT05730712 COMPLETED

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Mayo Clinic

NCT04754425 TERMINATED

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

M.D. Anderson Cancer Center

NCT05366842 TERMINATED

Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care

Johns Hopkins University

NCT03553602 TERMINATED

HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

Loyola University

NCT04252625 TERMINATED

Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis

University of Utah

NCT03338790 COMPLETED

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

NCT03503344 COMPLETED

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

University of California, San Francisco

NCT03556904 COMPLETED

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

University of Michigan Rogel Cancer Center

NCT07333976 COMPLETED

o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

Tri-Service General Hospital

NCT01995058 TERMINATED

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Exelixis

NCT06881823 WITHDRAWN

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

Novartis Pharmaceuticals

NCT02985957 COMPLETED

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Bristol-Myers Squibb

NCT04037358 COMPLETED

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04019327 COMPLETED

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT04176497 TERMINATED

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

UNC Lineberger Comprehensive Cancer Center

NCT01089387 COMPLETED

Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction

Institut National de la Santé Et de la Recherche Médicale, France

NCT01147965 COMPLETED

QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

NantCell, Inc.

NCT04635059 TERMINATED

Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

Medical College of Wisconsin

NCT05256381 TERMINATED

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

SOTIO Biotech AG

NCT05617040 TERMINATED

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Barinthus Biotherapeutics

NCT04335682 COMPLETED

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Alliance Foundation Trials, LLC.

NCT03480646 COMPLETED

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Constellation Pharmaceuticals

NCT04519879 SUSPENDED

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

City of Hope Medical Center

NCT04019964 COMPLETED

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06060587 WITHDRAWN

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Northwestern University

NCT06434909 COMPLETED

CYTALUX™for the Intraoperative Imaging of Prostate Cancer

Indiana University

NCT03910660 COMPLETED

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

NCT03069937 COMPLETED

Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.

Medical University of South Carolina

NCT03939689 COMPLETED

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

Progenics Pharmaceuticals, Inc.

NCT04631601 TERMINATED

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Amgen

NCT03652493 COMPLETED

Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway

Centre Francois Baclesse

NCT04616547 TERMINATED

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

National Cancer Institute (NCI)

NCT05046782 WITHDRAWN

Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology

M.D. Anderson Cancer Center

NCT03493945 COMPLETED

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

National Cancer Institute (NCI)

NCT06527690 WITHDRAWN

Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

Latin American Cooperative Oncology Group

NCT03516812 COMPLETED

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

University of Washington

NCT03716739 COMPLETED

Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency

Dana-Farber Cancer Institute

NCT06528210 WITHDRAWN

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

OHSU Knight Cancer Institute

NCT04158245 COMPLETED

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Tulane University

NCT05081193 COMPLETED

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05445609 SUSPENDED

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Emory University

NCT03098836 COMPLETED

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

Daniel George, MD

NCT05230251 COMPLETED

Radioligand fOr locAl raDiorecurrent proStaTe cancER

Glenn Bauman

NCT03843918 TERMINATED

A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

Laekna Limited

NCT07161778 COMPLETED

A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer

Barts & The London NHS Trust

NCT00924027 COMPLETED

A Study of Patients Receiving High-Dose Rate Brachytherapy

National Cancer Institute (NCI)

NCT03458247 COMPLETED

Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer

Assistance Publique - Hôpitaux de Paris

NCT05946603 COMPLETED

IS-002 Phase 2 Prostate Cancer Study

Intuitive Surgical

NCT03570827 COMPLETED

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

Mayo Clinic

NCT02874014 COMPLETED

Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer

Mayo Clinic

NCT04391556 COMPLETED

Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma

Centre Leon Berard

NCT04336943 TERMINATED

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

University of Washington

NCT03568656 COMPLETED

Study to Evaluate CCS1477 in Advanced Tumours

CellCentric Ltd.

NCT03298087 COMPLETED

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

VA Office of Research and Development

NCT03729596 TERMINATED

MGC018 With or Without MGA012 in Advanced Solid Tumors

MacroGenics

NCT02769962 COMPLETED

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Cancer Institute (NCI)

NCT03606837 TERMINATED

68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging

University Hospital, Bordeaux

NCT03448458 COMPLETED

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

Emory University

NCT02430480 COMPLETED

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

National Cancer Institute (NCI)

NCT03432897 TERMINATED

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes

Brown University

NCT04621500 COMPLETED

Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans

Medical University of South Carolina

NCT04569461 WITHDRAWN

Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)

Duke University

NCT03815942 TERMINATED

VAccination in Early and ADvanced Prostate caNCEr

University of Oxford

NCT04102124 TERMINATED

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Jiangsu HengRui Medicine Co., Ltd.

NCT05171387 COMPLETED

Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer

Bayer

NCT03315871 COMPLETED

Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

National Cancer Institute (NCI)

NCT07024030 COMPLETED

Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer

Haitao Niu, MD

NCT02903368 COMPLETED

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Dana-Farber Cancer Institute

NCT05253053 COMPLETED

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

TransThera Sciences (Nanjing), Inc.

NCT03442556 TERMINATED

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

University of Washington

NCT05712174 TERMINATED

A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer

AHS Cancer Control Alberta

NCT03712371 TERMINATED

Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients

Medical University of South Carolina

NCT06312670 COMPLETED

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Pedro Barata, MD, MSc

NCT04068896 COMPLETED

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NGM Biopharmaceuticals, Inc

NCT06389695 COMPLETED

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients

Norroy Bioscience Co., LTD

NCT04390880 COMPLETED

18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

VA Greater Los Angeles Healthcare System

NCT04926181 TERMINATED

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Rahul Aggarwal

NCT02788773 COMPLETED

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Canadian Cancer Trials Group

NCT02278185 COMPLETED

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

University of Colorado, Denver

NCT04332744 COMPLETED

Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)

MedSIR

NCT03570619 COMPLETED

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

University of Michigan Rogel Cancer Center

NCT05177770 TERMINATED

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Coherus Oncology, Inc.

NCT01848067 COMPLETED

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT01162135 COMPLETED

Digoxin for Recurrent Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT03304418 COMPLETED

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

University of Utah

NCT01313559 TERMINATED

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT02967458 COMPLETED

Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study

Thomas Jefferson University

NCT03581500 WITHDRAWN

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

M.D. Anderson Cancer Center

NCT02025010 COMPLETED

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

NCT05815316 WITHDRAWN

18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer

IRCCS San Raffaele

NCT03764540 TERMINATED

Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide

Centre hospitalier de l'Université de Montréal (CHUM)

NCT04011410 COMPLETED

Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

Patrick Hensley

NCT04556617 TERMINATED

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Opna Bio LLC

NCT03654638 COMPLETED

Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer

Ohio State University Comprehensive Cancer Center

NCT04383210 TERMINATED

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Elevation Oncology

NCT03888612 COMPLETED

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

Arvinas Inc.

NCT03093428 COMPLETED

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

Dana-Farber Cancer Institute

NCT05137067 COMPLETED

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

Optimal Health Research

NCT03655886 COMPLETED

Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation As a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial

University Hospital, Ghent

NCT04382898 TERMINATED

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

BioNTech SE

NCT02649790 COMPLETED

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Karyopharm Therapeutics Inc

NCT04298983 TERMINATED

Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer

University of Alabama at Birmingham

NCT06257758 TERMINATED

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Valerio Therapeutics

NCT04832958 COMPLETED

Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients

IRCCS San Raffaele

NCT06643494 SUSPENDED

Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical

Optimal Health Research

NCT04032704 TERMINATED

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Seagen Inc.

NCT05075577 TERMINATED

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

ESSA Pharmaceuticals

NCT01309672 COMPLETED

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

SWOG Cancer Research Network

NCT05501548 TERMINATED

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01254864 COMPLETED

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

M.D. Anderson Cancer Center

NCT04869488 COMPLETED

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

NCT03643107 COMPLETED

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Allarity Therapeutics

NCT04487847 COMPLETED

18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

Radboud University Medical Center

NCT03518606 COMPLETED

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

UNICANCER

NCT06398470 COMPLETED

Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy

University College, London

NCT04775602 COMPLETED

Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer.

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

NCT03454750 COMPLETED

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

NCT02643667 COMPLETED

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Washington University School of Medicine

NCT04951492 TERMINATED

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

University of Washington

NCT05146973 COMPLETED

External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)

Telix Pharmaceuticals (Innovations) Pty Limited

NCT01784913 COMPLETED

A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

Ultimovacs ASA

NCT05917470 TERMINATED

A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Oncternal Therapeutics, Inc

NCT03002220 COMPLETED

Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status

MedSIR

NCT02362464 COMPLETED

Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139

National Cancer Institute (NCI)

NCT02218606 COMPLETED

Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT01650194 COMPLETED

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Astellas Pharma Global Development, Inc.

NCT02799745 COMPLETED

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Astellas Pharma Global Development, Inc.

NCT01534052 COMPLETED

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

Astellas Pharma Inc

NCT04992026 COMPLETED

The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT03707184 COMPLETED

Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

University of Utah

NCT02787005 COMPLETED

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

Merck Sharp & Dohme LLC

NCT02124668 COMPLETED

A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Astellas Pharma Europe B.V.

NCT01284920 COMPLETED

A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Astellas Pharma Inc

NCT03248570 COMPLETED

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

University of California, San Francisco

NCT02213107 COMPLETED

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

University of Rochester

NCT03414034 COMPLETED

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Cardiff Oncology

NCT06218667 WITHDRAWN

A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT06472531 COMPLETED

A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

Yunhe Pharmaceutical (Tianjin) Co., Ltd

NCT03413995 COMPLETED

Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05655715 COMPLETED

Checkpoint Inhibitors and SBRT for MCRPC

Herlev and Gentofte Hospital

NCT04716725 TERMINATED

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Thomas Hope

NCT03204812 COMPLETED

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

M.D. Anderson Cancer Center

NCT04060394 COMPLETED

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Laekna Limited

NCT03207867 TERMINATED

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Novartis Pharmaceuticals

NCT01774071 COMPLETED

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT03177187 TERMINATED

Combination Study of AZD5069 and Enzalutamide.

Institute of Cancer Research, United Kingdom

NCT04207255 COMPLETED

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Medical University of South Carolina

NCT06329830 WITHDRAWN

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

Baptist Health South Florida

NCT04733768 COMPLETED

18F-PSMA-1007 PET/CT Imaging in Patients with Biochemically Recurrent or High-risk Prostate Cancer

University of Alberta

NCT05700669 COMPLETED

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

Valerio Therapeutics

NCT02099864 COMPLETED

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

OHSU Knight Cancer Institute

NCT02825628 COMPLETED

Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

DexTech Medical AB

NCT03473925 COMPLETED

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Merck Sharp & Dohme LLC

NCT02431676 COMPLETED

Survivorship Promotion In Reducing IGF-1 Trial

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06065059 TERMINATED

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Tango Therapeutics, Inc.

NCT01685268 COMPLETED

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Astex Pharmaceuticals, Inc.

NCT03336983 COMPLETED

Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

NCT04159896 TERMINATED

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Barbara Ann Karmanos Cancer Institute

NCT03770455 TERMINATED

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Jodi Layton, MD

NCT04346225 SUSPENDED

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

Ivan de Kouchkovsky, MD

NCT04408924 COMPLETED

Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

Eli Lilly and Company

NCT03690141 TERMINATED

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

Effector Therapeutics

NCT04957290 TERMINATED

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Noxopharm Limited

NCT05553639 TERMINATED

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Hookipa Biotech GmbH

NCT05141760 COMPLETED

18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients

University of Alberta

NCT01194271 COMPLETED

Neoadjuvant Ipilimumab in Prostate Cancer

M.D. Anderson Cancer Center

NCT02933255 COMPLETED

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

National Cancer Institute (NCI)

NCT05679193 COMPLETED

Perioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence

Oslo University Hospital

NCT03035357 WITHDRAWN

Neoadjuvant Listeria or Daratumumab in Prostate Cancer

M.D. Anderson Cancer Center

NCT03572387 COMPLETED

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Icahn School of Medicine at Mount Sinai

NCT04742959 COMPLETED

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

TransThera Sciences (Nanjing), Inc.

NCT04458311 TERMINATED

Abiraterone Acetate in Combination With Tildrakizumab

Institute of Cancer Research, United Kingdom

NCT01393119 TERMINATED

Phase II, Dose Finding Study of GTx-758

GTx

NCT04028388 COMPLETED

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Modra Pharmaceuticals

NCT04089553 COMPLETED

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

AstraZeneca

NCT03810105 TERMINATED

A Study of Olaparib and Durvalumab in Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT03148795 COMPLETED

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Pfizer

NCT05445882 WITHDRAWN

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

National Cancer Institute (NCI)

NCT02325557 COMPLETED

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Advaxis, Inc.

NCT04243941 WITHDRAWN

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

UNC Lineberger Comprehensive Cancer Center

NCT03311555 COMPLETED

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

Andrew J. Armstrong, MD

NCT05574712 WITHDRAWN

A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01759771 COMPLETED

Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial

VA Office of Research and Development

NCT05361915 SUSPENDED

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

Sorrento Therapeutics, Inc.

NCT03533946 TERMINATED

Rucaparib in Nonmetastatic prOstAte With BRCAness

University of Utah

NCT02933801 TERMINATED

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Swiss Cancer Institute

NCT05034562 WITHDRAWN

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

M.D. Anderson Cancer Center

NCT02280356 COMPLETED

Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT03934840 COMPLETED

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Masonic Cancer Center, University of Minnesota

NCT03554317 COMPLETED

COMbination of Bipolar Androgen Therapy and Nivolumab

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04727736 TERMINATED

18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer

Ashok Muthukrishnan

NCT03577028 TERMINATED

Study of HPN424 in Patients With Advanced Prostate Cancer

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT03899467 COMPLETED

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Suzhou Kintor Pharmaceutical Inc,

NCT02903160 COMPLETED

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Icahn School of Medicine at Mount Sinai

NCT03651271 COMPLETED

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Parker Institute for Cancer Immunotherapy

NCT00946881 COMPLETED

Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

Steba Biotech S.A.

NCT03878823 COMPLETED

Safety and Pharmacokinetics of ODM-209

Orion Corporation, Orion Pharma

NCT04264208 TERMINATED

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

Andrei Iagaru

NCT02543255 COMPLETED

Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)

University Health Network, Toronto

NCT03698370 COMPLETED

Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer

Andrei Iagaru

NCT03949517 COMPLETED

68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

Andrei Iagaru

NCT01996696 TERMINATED

Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate

AHS Cancer Control Alberta

NCT03809078 COMPLETED

68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Andrei Iagaru

NCT01704274 COMPLETED

GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy

Dr. D. Robert Siemens

NCT03837353 TERMINATED

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

NYU Langone Health

NCT03113617 COMPLETED

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Andrei Iagaru

NCT03513211 COMPLETED

Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer

St Vincent's Hospital, Sydney

NCT01972217 COMPLETED

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

AstraZeneca

NCT04737109 TERMINATED

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer

David VanderWeele

NCT05405439 TERMINATED

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT03396874 COMPLETED

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

University of Michigan

NCT03649841 TERMINATED

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

University of Washington

NCT01956058 COMPLETED

Brachytherapy for Recurrent Prostate Cancer

Centre Georges Francois Leclerc

NCT03830164 COMPLETED

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

M.D. Anderson Cancer Center

NCT01234025 COMPLETED

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Ionis Pharmaceuticals, Inc.

NCT01420861 TERMINATED

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

GTx

NCT00736645 COMPLETED

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Roswell Park Cancer Institute

NCT01377389 TERMINATED

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

M.D. Anderson Cancer Center

NCT03999515 TERMINATED

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

University of Washington

NCT03752099 TERMINATED

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Veru Inc.

NCT01867333 COMPLETED

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

National Cancer Institute (NCI)

NCT05613842 COMPLETED

Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)

St Vincent's Hospital, Sydney

NCT01607879 COMPLETED

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

Medical College of Wisconsin

NCT05516329 COMPLETED

Study of 18F-Thretide PET/CT in Patients With Prostate Cancer

First Affiliated Hospital of Fujian Medical University

NCT01485861 COMPLETED

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Genentech, Inc.

NCT01093183 TERMINATED

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

University of Nebraska

NCT01558427 COMPLETED

Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer

University Hospital, Ghent

NCT04614363 COMPLETED

68 Ga-PSMA for High Risk Prostate Cancer

The Methodist Hospital Research Institute

NCT01331083 COMPLETED

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

NCIC Clinical Trials Group

NCT05489991 TERMINATED

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Tceleron Therapeutics, Inc.

NCT00786682 TERMINATED

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

University of Medicine and Dentistry of New Jersey

NCT04495179 COMPLETED

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

AstraZeneca

NCT01075308 COMPLETED

SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer

NCIC Clinical Trials Group

NCT01619813 COMPLETED

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Canadian Cancer Trials Group

NCT04936334 COMPLETED

The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer

Clinton Bahler

NCT03602079 COMPLETED

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

NCT02499835 COMPLETED

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

University of Wisconsin, Madison

NCT03658447 COMPLETED

PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)

Peter MacCallum Cancer Centre, Australia

NCT04424641 TERMINATED

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Genmab

NCT02326805 COMPLETED

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

National Cancer Institute (NCI)

NCT03456804 COMPLETED

ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

Barbara Ann Karmanos Cancer Institute

NCT05549778 COMPLETED

Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC

Jiangnan University

NCT04781374 WITHDRAWN

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Beth Israel Deaconess Medical Center

NCT03735680 COMPLETED

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

OncoNano Medicine, Inc.

NCT02640534 TERMINATED

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

Swiss Cancer Institute

NCT04995978 WITHDRAWN

Insulin Resistance and Androgen Deprivation Therapy

St. Louis University

NCT01326312 TERMINATED

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

GTx

NCT04676607 COMPLETED

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NCT02952534 COMPLETED

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

pharmaand GmbH

NCT02516670 TERMINATED

Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05582031 WITHDRAWN

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Translational Research in Oncology

NCT00866554 COMPLETED

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

CHU de Quebec-Universite Laval

NCT00771017 WITHDRAWN

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

Eastern Cooperative Oncology Group

NCT04843319 TERMINATED

To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer

Veru Inc.

NCT04483414 WITHDRAWN

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

Dana Mathews

NCT02058706 COMPLETED

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Barbara Ann Karmanos Cancer Institute

NCT03429244 COMPLETED

PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer

Indiana University

NCT03437941 TERMINATED

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Corcept Therapeutics

NCT02028988 COMPLETED

Enzalutamide + External Beam Rt For Prostate

Dana-Farber Cancer Institute

NCT03406858 COMPLETED

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Barbara Ann Karmanos Cancer Institute

NCT02159950 COMPLETED

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Roswell Park Cancer Institute

NCT01751438 COMPLETED

Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)

M.D. Anderson Cancer Center

NCT04085991 TERMINATED

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer

Sir Mortimer B. Davis - Jewish General Hospital

NCT05806853 COMPLETED

PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study

IRCCS San Raffaele

NCT02278055 COMPLETED

Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT03679260 COMPLETED

Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance

Cedars-Sinai Medical Center

NCT04423913 TERMINATED

Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial Chemoembolization With Doxorubicin in Prostate Cancer Patients Before Radical Prostatectomy

Centre Hospitalier Universitaire de Nīmes

NCT04179968 COMPLETED

The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer

Dana Mathews

NCT01709734 TERMINATED

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

LTN PHARMACEUTICALS, INC.

NCT03439033 TERMINATED

Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer

Weill Medical College of Cornell University

NCT01385059 COMPLETED

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

City of Hope Medical Center

NCT05705700 WITHDRAWN

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Masonic Cancer Center, University of Minnesota

NCT03043807 COMPLETED

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02721979 TERMINATED

Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

University of Washington

NCT02420652 TERMINATED

Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy

Rutgers, The State University of New Jersey

NCT01074138 COMPLETED

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

Athenex, Inc.

NCT01903408 COMPLETED

Radiotherapy of the Prostate and the Pelvic Lymph Nodes After Neoadjuvant Antihormonal Treatment

Heidelberg University

NCT02146833 TERMINATED

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

Karyopharm Therapeutics Inc

NCT03982173 WITHDRAWN

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors

Gustave Roussy, Cancer Campus, Grand Paris

NCT02311049 COMPLETED

Hypofractionated Radiotherapy for Prostate Cancer

University Hospital, Ghent

NCT01921803 COMPLETED

Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer

University Hospital, Ghent

NCT02217709 COMPLETED

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

University of Southern California

NCT02643303 COMPLETED

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

NCT02680587 COMPLETED

Stereotactic Body Radiation for Prostate Oligometastases

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02598895 COMPLETED

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

University of Washington

NCT02649439 COMPLETED

Prostvac in Patients With Biochemically Recurrent Prostate Cancer

National Cancer Institute (NCI)

NCT03434158 COMPLETED

Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)

Spanish Oncology Genito-Urinary Group

NCT01942837 COMPLETED

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

NCT04928820 TERMINATED

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

Jonsson Comprehensive Cancer Center

NCT02176161 COMPLETED

Metformin Prostate Cancer Adjuvant Trial

NYU Langone Health

NCT01717053 COMPLETED

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

Duke University

NCT03709550 WITHDRAWN

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

NCT02346526 COMPLETED

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Massachusetts General Hospital

NCT02766478 TERMINATED

Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer

Emory University

NCT04685811 COMPLETED

Evaluation of PSMA Antagonist Produced by Two Different Methods

Weill Medical College of Cornell University

NCT02789878 COMPLETED

Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer

Instituto do Cancer do Estado de São Paulo

NCT02203513 TERMINATED

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

National Cancer Institute (NCI)

NCT02494921 COMPLETED

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Rahul Aggarwal

NCT03279250 COMPLETED

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

M.D. Anderson Cancer Center

NCT05191017 WITHDRAWN

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Nuvation Bio Inc.

NCT02716974 COMPLETED

A Study of Definitive Therapy to Treat Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04424654 COMPLETED

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy

Hospital Sirio-Libanes

NCT02012296 COMPLETED

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

University of Chicago

NCT03531827 TERMINATED

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

National Cancer Institute (NCI)

NCT02582749 TERMINATED

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Ajjai Alva, MD

NCT01681433 TERMINATED

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Costantine Albany

NCT03964337 TERMINATED

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

Duke University

NCT02090114 COMPLETED

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02770391 COMPLETED

Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer

Case Comprehensive Cancer Center

NCT04090775 COMPLETED

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

Rampart Health, L.L.C.

NCT00726596 COMPLETED

Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

Rutgers, The State University of New Jersey

NCT01434290 COMPLETED

Radiation Therapy in Treating Patients With Prostate Cancer

Radiation Therapy Oncology Group

NCT03365791 COMPLETED

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Novartis Pharmaceuticals

NCT03373006 COMPLETED

A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer

HALO Diagnostics

NCT01780220 COMPLETED

Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery

UNICANCER

NCT00964002 COMPLETED

Efavirenz in Treating Patients With Metastatic Prostate Cancer

Institut Bergonié

NCT03367819 TERMINATED

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Sanofi

NCT01818986 COMPLETED

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

University of Texas Southwestern Medical Center

NCT02121639 COMPLETED

Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy

University Hospital Southampton NHS Foundation Trust

NCT04331717 WITHDRAWN

Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02913131 TERMINATED

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

Rahul Aggarwal

NCT02268175 COMPLETED

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

Dana-Farber Cancer Institute

NCT02945813 TERMINATED

SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy

Swiss Cancer Institute

NCT02814968 COMPLETED

PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide

The European Uro-Oncology Group

NCT02815033 COMPLETED

Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

The European Uro-Oncology Group

NCT04221828 TERMINATED

Trial of NanoPac Focal Therapy for Prostate Cancer

NanOlogy, LLC

NCT02353832 COMPLETED

Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer

University of Texas Southwestern Medical Center

NCT01630590 COMPLETED

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

M.D. Anderson Cancer Center

NCT02362451 TERMINATED

Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer

National Cancer Institute (NCI)

NCT00828308 COMPLETED

Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer

Brown University

NCT01650350 TERMINATED

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Brown University

NCT01650285 TERMINATED

Cabazitaxel and Radiation For Patients With Prostate Cancer

Brown University

NCT04862091 COMPLETED

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

NCT03441464 TERMINATED

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

Lumicell, Inc.

NCT03101046 COMPLETED

Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic

UNICANCER

NCT02601014 COMPLETED

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01377753 COMPLETED

MR Image Guided Therapy in Prostate Cancer

National Cancer Institute (NCI)

NCT02849990 COMPLETED

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

University of Washington

NCT03689582 TERMINATED

Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

University of Michigan Rogel Cancer Center

NCT02001623 COMPLETED

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

NCT03646162 COMPLETED

Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

Veru Inc.

NCT02711956 COMPLETED

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Zenith Epigenetics

NCT02648919 TERMINATED

Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer

University of Hawaii

NCT02737332 COMPLETED

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

Sun Pharmaceutical Industries Limited

NCT01751451 COMPLETED

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

Memorial Sloan Kettering Cancer Center

NCT02962284 COMPLETED

One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™

Sun Pharmaceutical Industries Limited

NCT03712930 TERMINATED

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

BeiGene

NCT04555343 COMPLETED

Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention

Fraser Health

NCT03245736 COMPLETED

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Seagen Inc.

NCT03886493 TERMINATED

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04052204 TERMINATED

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Pfizer

NCT01252693 COMPLETED

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Spectrum Pharmaceuticals, Inc

NCT02565901 TERMINATED

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

University of Washington

NCT04050215 COMPLETED

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

Jonsson Comprehensive Cancer Center

NCT01105130 COMPLETED

L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

Wake Forest University Health Sciences

NCT02499497 COMPLETED

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Dana-Farber Cancer Institute

NCT01535040 COMPLETED

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

Wake Forest University Health Sciences

NCT04020094 WITHDRAWN

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer

University of Utah

NCT03062254 COMPLETED

Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy

Sir Mortimer B. Davis - Jewish General Hospital

NCT02346578 COMPLETED

Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Taro Iguchi, MD, PHD

NCT03545165 TERMINATED

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Weill Medical College of Cornell University

NCT01804465 COMPLETED

Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer

University of California, San Francisco

NCT01631552 COMPLETED

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

NCT02985021 TERMINATED

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Seattle Institute for Biomedical and Clinical Research

NCT01505868 COMPLETED

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

M.D. Anderson Cancer Center

NCT02463799 COMPLETED

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02867020 COMPLETED

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

Latin American Cooperative Oncology Group

NCT00667862 COMPLETED

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Novartis Pharmaceuticals

NCT03361969 COMPLETED

Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.

Pantarhei Oncology B.V.

NCT01706458 COMPLETED

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

University of Wisconsin, Madison

NCT01254513 COMPLETED

Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients

UNICANCER

NCT02229734 COMPLETED

Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT02559115 COMPLETED

68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT01540071 COMPLETED

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Io Therapeutics

NCT01503229 COMPLETED

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Washington

NCT02407054 COMPLETED

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Eli Lilly and Company

NCT01802307 WITHDRAWN

Focal Therapy for Prostate Cancer

University of Maryland, Baltimore

NCT02805894 TERMINATED

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

Nanobiotix

NCT01868386 COMPLETED

Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate

Timothy Showalter, MD

NCT02987829 COMPLETED

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Tracon Pharmaceuticals Inc.

NCT02497638 WITHDRAWN

LIpitor and biGuanide to Androgen Delay Trial

University Health Network, Toronto

NCT02046837 COMPLETED

An Exercise Trial and Economic Analysis in Men With Prostate Cancer

University Health Network, Toronto

NCT02685267 TERMINATED

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

Prostate Cancer Clinical Trials Consortium

NCT02552121 COMPLETED

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Seagen Inc.

NCT00737893 COMPLETED

Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy

Johns Hopkins University

NCT01317199 COMPLETED

Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02142608 COMPLETED

A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

Bracco Diagnostics, Inc

NCT01468532 COMPLETED

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Barbara Ann Karmanos Cancer Institute

NCT01615120 COMPLETED

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

GTx

NCT03042312 TERMINATED

Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy

Endocyte

NCT01748500 COMPLETED

Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer

University Health Network, Toronto

NCT03572478 TERMINATED

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

University of Chicago

NCT03179410 COMPLETED

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

Andrew J. Armstrong, MD

NCT03263780 COMPLETED

High Resolution PET-MRI Before Prostate Cancer HIFU

Timothy J. Daskivich

NCT01741116 COMPLETED

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

Korean Cancer Study Group

NCT02628041 COMPLETED

HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate Cancer

CHU de Quebec-Universite Laval

NCT03261336 TERMINATED

Oral Calcitriol With Ketoconazole in CRPC

Donald Trump, MD

NCT03741712 TERMINATED

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Jiangsu HengRui Medicine Co., Ltd.

NCT03514836 TERMINATED

A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

SOTIO a.s.

NCT02844582 TERMINATED

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

NCT01341652 COMPLETED

Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

University of Wisconsin, Madison

NCT04585932 WITHDRAWN

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

M.D. Anderson Cancer Center

NCT01695473 TERMINATED

Neoadjuvant BKM120 in High-risk Prostate Cancer

Won Kim

NCT01882985 COMPLETED

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

University of California, Irvine

NCT03418324 COMPLETED

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Cedars-Sinai Medical Center

NCT02611882 COMPLETED

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

Thomas Hope

NCT03348527 COMPLETED

A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer

Lidds AB

NCT00757757 TERMINATED

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Novartis Pharmaceuticals

NCT01940276 COMPLETED

Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer

Duke University

NCT02607228 TERMINATED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Gilead Sciences

NCT01051570 COMPLETED

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Barbara Ann Karmanos Cancer Institute

NCT02397408 COMPLETED

11C- and 18F-Choline PET/MR Imaging for Prostate Cancer

University of California, San Francisco

NCT03490032 COMPLETED

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

Advanced Accelerator Applications

NCT02036060 COMPLETED

Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.

Spanish Oncology Genito-Urinary Group

NCT01576172 COMPLETED

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

National Cancer Institute (NCI)

NCT02286921 COMPLETED

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00970203 COMPLETED

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

Roswell Park Cancer Institute

NCT02199197 COMPLETED

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

University of Utah

NCT03724253 TERMINATED

[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

Advanced Accelerator Applications

NCT01928485 TERMINATED

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

Sanjay Gupta PhD

NCT01194960 TERMINATED

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Oxford BioMedica

NCT02709889 TERMINATED

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

NCT03675451 COMPLETED

PSMA Imaging of Localized Prostate Cancer

Weill Medical College of Cornell University

NCT01498978 COMPLETED

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

OHSU Knight Cancer Institute

NCT02064582 COMPLETED

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

University of Texas Southwestern Medical Center

NCT03570476 TERMINATED

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

University of Washington

NCT01875250 COMPLETED

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

National Cancer Institute (NCI)

NCT02059213 COMPLETED

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

University of Michigan Rogel Cancer Center

NCT01931046 COMPLETED

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

Momotaro-Gene Inc.

NCT01807065 COMPLETED

Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

City of Hope Medical Center

NCT01079793 WITHDRAWN

Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery

University of Texas Southwestern Medical Center

NCT01637402 COMPLETED

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

Terence Friedlander, MD

NCT02125357 COMPLETED

Sequencing Abiraterone and Enzalutamide in mCRPC

British Columbia Cancer Agency

NCT01859689 WITHDRAWN

Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer

Jonsson Comprehensive Cancer Center

NCT03362359 COMPLETED

Ga-68-PSMA-11 in High-risk Prostate Cancer

German Cancer Research Center

NCT02168062 TERMINATED

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

University of California, San Francisco

NCT03493997 COMPLETED

Multicentre International STudy for the Prevention With Ialuril® of Radio-induced Cystitis (MISTIC)

Study Group for Urogenital Diseases, Italy

NCT02293707 COMPLETED

A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer

Laboratoires Leurquin Mediolanum

NCT04272645 WITHDRAWN

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

University of Michigan Rogel Cancer Center

NCT01867424 COMPLETED

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

National Cancer Institute (NCI)

NCT01036594 COMPLETED

Ketoconazole and Dexamethasone in Prostate Cancer

University of California, San Francisco

NCT03827473 TERMINATED

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

University of Utah

NCT03617588 COMPLETED

68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer

Theragnostics Ltd

NCT03604757 COMPLETED

68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks

University Hospital, Bordeaux

NCT03199872 COMPLETED

RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

RhoVac APS

NCT02384382 COMPLETED

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Pfizer

NCT03093272 TERMINATED

A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

Dana-Farber Cancer Institute

NCT01560923 COMPLETED

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

Masonic Cancer Center, University of Minnesota

NCT01599793 COMPLETED

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

University of Chicago

NCT02077634 COMPLETED

Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

Universität des Saarlandes

NCT03763851 TERMINATED

Cannabis Oil and Radiation Therapy for the Management of Pain

Tetra Bio-Pharma

NCT01790126 COMPLETED

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Aragon Pharmaceuticals, Inc.

NCT03264456 COMPLETED

Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI

University of Alabama at Birmingham

NCT01499043 TERMINATED

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Daiichi Sankyo

NCT02811809 WITHDRAWN

Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer

The University of Texas Health Science Center, Houston

NCT02349022 COMPLETED

Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy

ImaginAb, Inc.

NCT01923727 COMPLETED

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer

ImaginAb, Inc.

NCT02512458 COMPLETED

Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer

Hellenic Cooperative Oncology Group

NCT02095145 COMPLETED

Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance

National Cancer Institute (NCI)

NCT01787331 COMPLETED

Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer

University of California, San Francisco

NCT01446991 COMPLETED

Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

British Columbia Cancer Agency

NCT02311764 TERMINATED

Carboplatin in Castration-resistant Prostate Cancer

Aurelius Omlin

NCT01065441 COMPLETED

Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer

Michael Har-Noy

NCT02429193 COMPLETED

Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA

University Health Network, Toronto

NCT02830880 COMPLETED

FACBC Prostate Therapy Response

Emory University

NCT00937768 TERMINATED

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Mayo Clinic

NCT02344017 COMPLETED

Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer

Orion Corporation, Orion Pharma

NCT00450749 COMPLETED

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

National Cancer Institute (NCI)

NCT01816048 TERMINATED

NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis

University of Wisconsin, Madison

NCT01946165 COMPLETED

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

M.D. Anderson Cancer Center

NCT02726113 COMPLETED

Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy

Medical University of South Carolina

NCT01732549 TERMINATED

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Ipsen

NCT01533753 TERMINATED

Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

University of Wisconsin, Madison

NCT00849121 COMPLETED

Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer

University of Wisconsin, Madison

NCT02091531 COMPLETED

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Memorial Sloan Kettering Cancer Center

NCT01119118 TERMINATED

ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer

University of Wisconsin, Madison

NCT03365297 COMPLETED

Therapeutics in Active Prostate Cancer Surveillance

CCTU- Cancer Theme

NCT02758132 TERMINATED

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

University of Hawaii

NCT01562522 TERMINATED

Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.

Ipsen

NCT02538432 WITHDRAWN

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

University of Maryland, Baltimore

NCT02964988 TERMINATED

uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Rigshospitalet, Denmark

NCT01146340 COMPLETED

Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer

Sunnybrook Health Sciences Centre

NCT01253642 TERMINATED

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

OHSU Knight Cancer Institute

NCT01585246 COMPLETED

Saw Palmetto: Symptom Management for Men During Radiation Therapy

Michigan State University

NCT02288936 COMPLETED

Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer

Spanish Oncology Genito-Urinary Group

NCT01204710 COMPLETED

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

Eli Lilly and Company

NCT01987999 COMPLETED

Eradication of Prostate Cancer Using F-989

Optimal Health Research

NCT01059643 COMPLETED

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Eli Lilly and Company

NCT01374087 TERMINATED

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Ipsen

NCT00831792 COMPLETED

TKI258 in Castrate Resistant Prostate Cancer

M.D. Anderson Cancer Center

NCT02710422 TERMINATED

Miami Membrane for Potency (MMEP) Trial

University of Miami

NCT01126879 TERMINATED

Genistein in Treating Patients With Prostate Cancer

Northwestern University

NCT02141490 COMPLETED

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

National Cancer Institute (NCI)

NCT02279862 COMPLETED

Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

Bristol-Myers Squibb

NCT01083368 COMPLETED

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Case Comprehensive Cancer Center

NCT03384199 COMPLETED

Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer

Kasr El Aini Hospital

NCT01243385 COMPLETED

Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

Swiss Cancer Institute

NCT00976755 COMPLETED

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Swiss Cancer Institute

NCT00714753 COMPLETED

Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer

Mayo Clinic

NCT01036321 COMPLETED

Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness

H. Lee Moffitt Cancer Center and Research Institute

NCT01084655 COMPLETED

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Millennium Pharmaceuticals, Inc.

NCT00774436 COMPLETED

Study of Focal Cryoablation in Low-Risk Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT00669162 COMPLETED

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

University of Kansas Medical Center

NCT02796898 COMPLETED

Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer

Tyme, Inc

NCT01881867 COMPLETED

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Fred Hutchinson Cancer Center

NCT01867710 COMPLETED

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Janssen Pharmaceutica N.V., Belgium

NCT01543776 COMPLETED

Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer

University of Chicago

NCT02057939 COMPLETED

Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)

Duke University

NCT02379390 TERMINATED

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

Sanofi

NCT01026623 COMPLETED

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

NCT03543670 COMPLETED

Evaluation of Oncoxin-Viusid® in Prostate Cancer

Catalysis SL

NCT00728663 COMPLETED

Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer

Swiss Cancer Institute

NCT03573011 COMPLETED

PSMA PET/CT for Prostate Cancer

University Hospital, Ghent

NCT00528866 COMPLETED

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Radiation Therapy Oncology Group

NCT02256111 COMPLETED

EXTEND Exercise Trial

Duke University

NCT03081481 COMPLETED

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Sophiris Bio Corp

NCT00642018 COMPLETED

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

Eli Lilly and Company

NCT01696877 COMPLETED

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01487863 COMPLETED

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Dendreon

NCT01994590 TERMINATED

Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

M.D. Anderson Cancer Center

NCT01685983 COMPLETED

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Janssen Research & Development, LLC

NCT01304485 COMPLETED

PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma

Phoenix Molecular Imaging

NCT01530269 COMPLETED

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Phoenix Molecular Imaging

NCT01677897 COMPLETED

Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients

Kantonsspital Graubünden

NCT01553188 COMPLETED

AMG 386 and Abiraterone for Advanced Prostate Cancer

National Cancer Institute (NCI)

NCT01163084 TERMINATED

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

National Cancer Institute (NCI)

NCT02507427 COMPLETED

Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study)

Seoul National University Hospital

NCT01120470 COMPLETED

OGX-427 in Castration Resistant Prostate Cancer Patients

British Columbia Cancer Agency

NCT03001895 COMPLETED

Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer

Sir Mortimer B. Davis - Jewish General Hospital

NCT01257425 COMPLETED

Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg

Ipsen

NCT02459912 TERMINATED

Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer

NYU Langone Health

NCT02361086 COMPLETED

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Innocrin Pharmaceutical

NCT02445976 COMPLETED

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Innocrin Pharmaceutical

NCT02012920 COMPLETED

A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Innocrin Pharmaceutical

NCT01664923 COMPLETED

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Pfizer

NCT02409212 COMPLETED

Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer

Sheffield Teaching Hospitals NHS Foundation Trust

NCT03147196 WITHDRAWN

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Mayo Clinic

NCT01174368 COMPLETED

Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T

The Rogosin Institute

NCT01808222 COMPLETED

FACBC for Recurrent Prostate Cancer

David M. Schuster, MD

NCT02853110 COMPLETED

Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer

UMC Utrecht

NCT02047253 COMPLETED

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

University of Alabama at Birmingham

NCT01148069 COMPLETED

Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers

Rennes University Hospital

NCT00924807 TERMINATED

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

Beth Israel Medical Center

NCT01703065 TERMINATED

Cabozantinib in Men With Castration-Resistant Prostate Cancer

University of Washington

NCT02494713 TERMINATED

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

The University of Texas Health Science Center, Houston

NCT02107430 COMPLETED

Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer

SOTIO a.s.

NCT01981122 COMPLETED

A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

Dendreon

NCT01091103 COMPLETED

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Pfizer

NCT01547299 COMPLETED

Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Pfizer

NCT01354951 TERMINATED

Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT01620710 COMPLETED

Safety Study of a Shorter (Hypofractionated) Radiotherapy for the Prostate Bed With or Without the Pelvic Lymph Nodes

Heidelberg University

NCT02153918 COMPLETED

Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy

National Cancer Institute (NCI)

NCT00942578 COMPLETED

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

National Cancer Institute (NCI)

NCT00634647 COMPLETED

Satraplatin and Prednisone to Treat Prostate Cancer

National Cancer Institute (NCI)

NCT01302041 COMPLETED

A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy

Astellas Pharma Inc

NCT00670046 TERMINATED

Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01270880 COMPLETED

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Barbara Ann Karmanos Cancer Institute

NCT01519414 COMPLETED

Tivantinib in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

NCT00953576 TERMINATED

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

Dana-Farber Cancer Institute

NCT01496157 COMPLETED

Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01815515 COMPLETED

Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01439542 TERMINATED

FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

NCT01260688 COMPLETED

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

National Cancer Institute (NCI)

NCT02095717 TERMINATED

Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)

Centre Jean Perrin

NCT03343977 WITHDRAWN

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Peng Wang, MD PhD

NCT01335204 TERMINATED

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Medical University of South Carolina

NCT00634582 TERMINATED

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Wake Forest University Health Sciences

NCT01054079 COMPLETED

Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Wake Forest University Health Sciences

NCT02252978 WITHDRAWN

Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy

Wake Forest University Health Sciences

NCT02215161 TERMINATED

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

University of California, San Francisco

NCT01220973 COMPLETED

Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

Rutgers, The State University of New Jersey

NCT01521949 COMPLETED

Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA

University of Colorado, Denver

NCT01845792 TERMINATED

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

University of Colorado, Denver

NCT01620593 COMPLETED

Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer

The University of Texas Health Science Center at San Antonio

NCT01090765 COMPLETED

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

National Cancer Institute (NCI)

NCT02083185 COMPLETED

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

Millennium Pharmaceuticals, Inc.

NCT02130700 COMPLETED

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

Innocrin Pharmaceutical

NCT01717898 TERMINATED

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

Charles Ryan

NCT01666314 COMPLETED

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Millennium Pharmaceuticals, Inc.

NCT00831467 COMPLETED

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

CureVac

NCT00888654 COMPLETED

Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy

Barbara Ann Karmanos Cancer Institute

NCT01393730 COMPLETED

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Mary-Ellen Taplin, MD

NCT00860158 TERMINATED

Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

Noah Hahn, M.D.

NCT01188408 WITHDRAWN

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

INSYS Therapeutics Inc

NCT01496131 COMPLETED

Tecemotide (L-BLP25) in Prostate Cancer

EMD Serono

NCT02796807 COMPLETED

Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer

Sir Mortimer B. Davis - Jewish General Hospital

NCT01120236 COMPLETED

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

National Cancer Institute (NCI)

NCT00744549 COMPLETED

Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance

University Health Network, Toronto

NCT01289067 COMPLETED

Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca

William K. Oh

NCT00638378 TERMINATED

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Incyte Corporation

NCT00878436 COMPLETED

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

NYU Langone Health

NCT02097303 COMPLETED

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

Carolina Research Professionals, LLC

NCT00983710 COMPLETED

Prostate Cancer Symptom Management for Low Literacy Men

Baylor College of Medicine

NCT01799278 COMPLETED

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Weill Medical College of Cornell University

NCT02966587 WITHDRAWN

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Washington

NCT00814788 COMPLETED

Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

University of California, Davis

NCT01433913 COMPLETED

Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

National Cancer Institute (NCI)

NCT01199146 COMPLETED

Abiraterone Post Ketoconazole for Prostate Cancer

University of California, San Francisco

NCT00769990 WITHDRAWN

Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases

Masonic Cancer Center, University of Minnesota

NCT01428219 TERMINATED

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

University of Michigan Rogel Cancer Center

NCT00630344 COMPLETED

RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

Dana-Farber Cancer Institute

NCT01200810 TERMINATED

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

National Cancer Institute (NCI)

NCT01718353 COMPLETED

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Sanofi

NCT02793219 WITHDRAWN

Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer

The University of Texas Health Science Center, Houston

NCT02793765 WITHDRAWN

Docetaxel Followed by Provenge in Metastatic Prostate Cancer

The University of Texas Health Science Center, Houston

NCT00844792 COMPLETED

Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer

University Health Network, Toronto

NCT01992042 COMPLETED

Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer

University Health Network, Toronto

NCT02233608 COMPLETED

Advanced Pelvic Floor Training Program for Prostate Cancer Surgery

University of Guelph-Humber

NCT01288534 COMPLETED

Hypofractionated Stereotactic Body Radiation Therapy (SBRT)

University of Michigan Rogel Cancer Center

NCT01756638 COMPLETED

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Janssen Research & Development, LLC

NCT00887458 COMPLETED

A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

Johns Hopkins University

NCT00953225 COMPLETED

Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer

VA Office of Research and Development

NCT03297385 COMPLETED

Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation

The Netherlands Cancer Institute

NCT01834651 COMPLETED

A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

Edwin Posadas, MD

NCT01145508 TERMINATED

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

National Cancer Institute (NCI)

NCT01866423 TERMINATED

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Southern California

NCT02036684 COMPLETED

Prehabilitation for Prostate Cancer Surgery

University of Guelph-Humber

NCT00928252 COMPLETED

Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Queen's Medical Center

NCT00551525 COMPLETED

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Radiation Therapy Oncology Group

NCT00924313 COMPLETED

Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer

National Cancer Institute (NCI)

NCT01240629 COMPLETED

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Southern California

NCT03211052 TERMINATED

A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone

Centre of Experimental Medicine

NCT01518283 COMPLETED

Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Spanish Oncology Genito-Urinary Group

NCT01558492 TERMINATED

Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Weill Medical College of Cornell University

NCT01023061 COMPLETED

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

University of Washington

NCT01338012 TERMINATED

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer

Dendreon

NCT01431391 COMPLETED

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

Dendreon

NCT00658697 COMPLETED

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

Dana-Farber Cancer Institute

NCT02107404 COMPLETED

Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer

SOTIO a.s.

NCT02107391 COMPLETED

Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

SOTIO a.s.

NCT02137746 COMPLETED

Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer

SOTIO a.s.

NCT02105675 COMPLETED

Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

SOTIO a.s.

NCT00715078 COMPLETED

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

Dendreon

NCT00901342 COMPLETED

Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer

Dendreon

NCT01385293 TERMINATED

BKM120 in Metastatic Castration-resistant Prostate Cancer

Andrew J. Armstrong, MD

NCT01215032 TERMINATED

Metformin in Castration-Resistant Prostate Cancer

Massachusetts General Hospital

NCT01735396 TERMINATED

Abiraterone Acetate Trial in African American Prostate Cancer Patients

Icahn School of Medicine at Mount Sinai

NCT02022371 COMPLETED

Prostate Cancer Genomic Heterogeneity

University College London Hospitals

NCT01828476 TERMINATED

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Rutgers, The State University of New Jersey

NCT01228084 COMPLETED

Sulforaphane in Treating Patients With Recurrent Prostate Cancer

OHSU Knight Cancer Institute

NCT02212197 COMPLETED

Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer

Camurus AB

NCT00669656 COMPLETED

Herbal Therapy for Treatment of Recurrent Prostate Cancer

University of Southern California

NCT02135445 COMPLETED

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

Millennium Pharmaceuticals, Inc.

NCT00574769 COMPLETED

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

University of Southern California

NCT01450683 TERMINATED

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Stanford University

NCT00895310 COMPLETED

Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy

University of California, Davis

NCT01317641 COMPLETED

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Orion Corporation, Orion Pharma

NCT00769795 COMPLETED

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

University of Washington

NCT02656615 TERMINATED

Abiraterone-Rechallenge Study for CRPC Patients

Aurelius Omlin

NCT01695044 COMPLETED

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Progenics Pharmaceuticals, Inc.

NCT02020135 COMPLETED

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Progenics Pharmaceuticals, Inc.

NCT02483884 TERMINATED

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Life Molecular Imaging SA

NCT01620515 COMPLETED

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Nymox Corporation

NCT01087580 WITHDRAWN

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

Northwestern University

NCT01429064 COMPLETED

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Orion Corporation, Orion Pharma

NCT01817738 TERMINATED

Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer

CureVac

NCT01667536 COMPLETED

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Molecular Insight Pharmaceuticals, Inc.

NCT00879619 TERMINATED

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

John P. Fruehauf

NCT02928432 COMPLETED

SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone

Centro Nacional de Investigaciones Oncologicas CARLOS III

NCT01913197 TERMINATED

Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy

St. Luke's-Roosevelt Hospital Center

NCT01106352 COMPLETED

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Bayer

NCT00686036 TERMINATED

Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy

Genzyme, a Sanofi Company

NCT00661492 COMPLETED

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

US Oncology Research

NCT00598858 WITHDRAWN

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate

John P. Fruehauf

NCT00659438 COMPLETED

Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer

Genzyme, a Sanofi Company

NCT01750398 COMPLETED

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02645591 WITHDRAWN

Randomized AmnioFix Study During Radical Prostatectomy

M.D. Anderson Cancer Center

NCT00946309 COMPLETED

Effects of Sulforaphane on Normal Prostate Tissue

Fred Hutchinson Cancer Center

NCT00776594 COMPLETED

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Dana-Farber Cancer Institute

NCT01558219 COMPLETED

Second-line Chemotherapy in Castration Resistant Prostate Cancer

Tampere University Hospital

NCT02656563 WITHDRAWN

Radium 223 Following Intermittent ADT

Canadian Urology Research Consortium

NCT00852007 COMPLETED

A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1

Hamilton Health Sciences Corporation

NCT01325311 COMPLETED

Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer

National Cancer Institute (NCI)

NCT01511536 COMPLETED

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Sanofi

NCT02499848 COMPLETED

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Sophiris Bio Corp

NCT02678520 WITHDRAWN

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

University of Kansas Medical Center

NCT02378870 TERMINATED

A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC

DexTech Medical AB

NCT01658527 WITHDRAWN

TAK-700 in Castration Resistant Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC

NCT01549951 COMPLETED

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

Millennium Pharmaceuticals, Inc.

NCT00985738 TERMINATED

Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer

University of Colorado, Denver

NCT02423889 COMPLETED

Stereotactic Volumetric Radiotherapy in Prostate Cancer

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

NCT00707356 COMPLETED

Study of WST11 in Patients With Localized Prostate Cancer

Steba Biotech S.A.

NCT01812746 COMPLETED

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

BIND Therapeutics

NCT01046916 COMPLETED

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Millennium Pharmaceuticals, Inc.

NCT02341404 COMPLETED

A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer

Lidds AB

NCT02035124 WITHDRAWN

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

SCRI Development Innovations, LLC

NCT00734851 TERMINATED

Multimodality Phase II Study in Prostate Cancer

Duke University

NCT01674270 COMPLETED

Degarelix Neo-Adjuvant Radical Prostatectomy Trial

University Health Network, Toronto

NCT01360840 COMPLETED

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

EMD Serono

NCT01477749 COMPLETED

Sipuleucel-T Manufacturing Demonstration Study

Dendreon

NCT00932672 TERMINATED

Atkins Diet and Prostate Cancer Clinical Trial

Duke University

NCT00741039 COMPLETED

Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older

Memorial Sloan Kettering Cancer Center

NCT00928174 COMPLETED

Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer

Queen's Medical Center

NCT01898065 COMPLETED

Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer

Institut Cancerologie de l'Ouest

NCT01795703 COMPLETED

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Janssen Research & Development, LLC

NCT01541007 COMPLETED

A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer

Jeffrey Yachnin M.D., PhD.

NCT00853697 COMPLETED

Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT02042885 TERMINATED

A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

Otsuka Novel Products GmbH

NCT01530984 WITHDRAWN

Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Lawrence Fong

NCT00777959 COMPLETED

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Merck Sharp & Dohme LLC

NCT00936975 COMPLETED

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

National Cancer Institute (NCI)

NCT01705652 TERMINATED

Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients

The University of Texas Health Science Center at San Antonio

NCT02424513 WITHDRAWN

A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer

ImaginAb, Inc.

NCT00743379 COMPLETED

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Threshold Pharmaceuticals

NCT00715104 COMPLETED

Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer

Dendreon

NCT00975429 COMPLETED

Study Using WST11 in Patients With Localized Prostate Cancer

Steba Biotech S.A.

NCT02425163 COMPLETED

Shear Wave Elastography of Prostate Cancer

University of Magdeburg

NCT02420587 WITHDRAWN

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

M.D. Anderson Cancer Center

NCT01267266 TERMINATED

Saracatinib in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

NCT01533246 COMPLETED

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

National Cancer Institute (NCI)

NCT00694291 WITHDRAWN

Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer

Fox Chase Cancer Center

NCT01565512 WITHDRAWN

Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort

Columbia University

NCT02159690 WITHDRAWN

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

Kenneth Pienta, MD

NCT00913263 COMPLETED

An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate

Lidds AB

NCT00666666 COMPLETED

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

National Cancer Institute (NCI)

NCT01469338 TERMINATED

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

University of Southern California

NCT01595087 COMPLETED

A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

DexTech Medical AB

NCT01531205 TERMINATED

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

H. Lee Moffitt Cancer Center and Research Institute

NCT00753220 TERMINATED

Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

Bostwick Laboratories

NCT00918385 TERMINATED

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Duke University

NCT00751205 COMPLETED

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

NCT01009736 COMPLETED

Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy

Ohio State University Comprehensive Cancer Center

NCT00683475 COMPLETED

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Eli Lilly and Company

NCT01020305 TERMINATED

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Sandy Srinivas

NCT01704027 TERMINATED

Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer

Centre Georges Francois Leclerc

NCT01424930 COMPLETED

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Janssen-Ortho Inc., Canada

NCT02054793 WITHDRAWN

Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)

Emmanuel Antonarakis, MD

NCT00919035 COMPLETED

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Oncology Specialists, S.C.

NCT01088529 COMPLETED

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Cougar Biotechnology, Inc.

NCT01483586 TERMINATED

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

KangLaiTe USA

NCT00678015 TERMINATED

Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer

University of California, San Francisco

NCT00654186 COMPLETED

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

Oncology Specialists, S.C.

NCT01352208 TERMINATED

Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients

Astellas Pharma Inc

NCT00859729 COMPLETED

Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer

Uppsala University

NCT00770848 COMPLETED

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Amgen

NCT00887640 TERMINATED

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

Duke University

NCT01734681 WITHDRAWN

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

GenSpera, Inc.

NCT01176513 TERMINATED

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

GE Healthcare

NCT01409473 WITHDRAWN

Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer

Rocky Mountain Cancer Centers

NCT01000948 TERMINATED

A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer

Aarhus University Hospital

NCT01491971 COMPLETED

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Ferring Pharmaceuticals

NCT01487720 COMPLETED

GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

Asan Medical Center

NCT00945477 TERMINATED

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

Illinois CancerCare, P.C.

NCT00814892 TERMINATED

Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer

Mayo Clinic

NCT01750866 WITHDRAWN

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Case Comprehensive Cancer Center

NCT01481233 WITHDRAWN

Oral Colchicine in Men With Castrate Resistant Prostate Cancer

Milton S. Hershey Medical Center

NCT00685633 WITHDRAWN

Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer

Eastern Cooperative Oncology Group

NCT00992186 COMPLETED

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer

Centocor Research & Development, Inc.

NCT00558272 COMPLETED

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

AstraZeneca

NCT01733836 WITHDRAWN

Prostate Cancer Active Surveillance Metformin Trial

University Health Network, Toronto

NCT00924469 COMPLETED

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

Janssen Research & Development, LLC

NCT01012141 COMPLETED

Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer

Centre Jean Perrin

NCT01478308 WITHDRAWN

Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer

New Mexico Cancer Research Alliance

NCT00757692 COMPLETED

Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.

British Columbia Cancer Agency

NCT00738673 COMPLETED

Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

Ferring Pharmaceuticals

NCT00714376 TERMINATED

Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients

CHU de Quebec-Universite Laval

NCT01663415 WITHDRAWN

A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Global Development, Inc.

NCT00881725 TERMINATED

A Study of Pre-operative Metformin in Prostate Cancer

University Health Network, Toronto

NCT00906243 TERMINATED

RNActive®-Derived Therapeutic Vaccine

University of Florida

NCT01132599 WITHDRAWN

Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer

Cancer Research UK

NCT00736164 WITHDRAWN

Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer

Roswell Park Cancer Institute

NCT01132404 TERMINATED

Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448

Millennium Pharmaceuticals, Inc.

NCT01215799 COMPLETED

Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer

CytRx

NCT01153113 WITHDRAWN

Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines

University of Florida

NCT01039038 TERMINATED

Feasibility Study of a Dose Increase by a Boost of Curietherapy in Pulse Dose Rate (PDR) Associated With the Extern Radiotherapy in Prostate Cancer

Centre Francois Baclesse

NCT00716794 COMPLETED

A Phase I/II Study of HE3235 in Patients With Prostate Cancer

Harbor Therapeutics

NCT00577356 TERMINATED

Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer

Benaroya Research Institute

NCT00686088 COMPLETED

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

Sophiris Bio Corp

NCT00636740 COMPLETED

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

Merrion Pharmaceuticals, LLC

NCT04565496 WITHDRAWN

Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients

IRCCS San Raffaele

NCT05708950 COMPLETED

A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Kineta Inc.

NCT06673329 RECRUITING

Brodalumab in the Treatment of Immune-Related Adverse Events

Brian Henick, MD

NCT07583160 ENROLLING BY INVITATION

YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer

Changhai Hospital

NCT06982222 NOT YET RECRUITING

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

NCT06465069 RECRUITING

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Eli Lilly and Company

NCT06879041 RECRUITING

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

AstraZeneca

NCT07581184 RECRUITING

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

Aktis Oncology, Inc.

NCT04846478 ACTIVE NOT RECRUITING

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Dana-Farber Cancer Institute

NCT06379217 ACTIVE NOT RECRUITING

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Novartis Pharmaceuticals

NCT04486755 ACTIVE NOT RECRUITING

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

University of Maryland, Baltimore

NCT06257264 ACTIVE NOT RECRUITING

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeiGene

NCT04662580 ACTIVE NOT RECRUITING

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

Janssen Research & Development, LLC

NCT04221542 RECRUITING

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Amgen

NCT02123758 ACTIVE NOT RECRUITING

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.

NCT06826768 RECRUITING

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

M.D. Anderson Cancer Center

NCT05818683 RECRUITING

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

NCT07570979 RECRUITING

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Novartis Pharmaceuticals

NCT03460977 RECRUITING

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

NCT07006727 RECRUITING

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Novartis Pharmaceuticals

NCT07140900 RECRUITING

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Amgen

NCT06217822 RECRUITING

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Bayer

NCT05283330 RECRUITING

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Orano Med Theranostics, SAS

NCT07488923 NOT YET RECRUITING

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Moonlight Bio, Inc

NCT07174063 RECRUITING

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Novartis Pharmaceuticals

NCT06895811 ACTIVE NOT RECRUITING

Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC

Shanghai Changzheng Hospital

NCT07177937 RECRUITING

A Study of DXC014 in Patients With Advanced Solid Tumors.

Hangzhou DAC Biotechnology Co., Ltd.

NCT04388852 ACTIVE NOT RECRUITING

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

M.D. Anderson Cancer Center

NCT06926283 RECRUITING

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

Hangzhou DAC Biotechnology Co., Ltd.

NCT06305598 RECRUITING

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

NCT07545811 RECRUITING

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Janux Therapeutics

NCT07543055 NOT YET RECRUITING

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

Regeneron Pharmaceuticals

NCT06966024 RECRUITING

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Deciphera Pharmaceuticals, LLC

NCT07540572 RECRUITING

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

IDEAYA Biosciences

NCT05997615 RECRUITING

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Vir Biotechnology, Inc.

NCT07219147 RECRUITING

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

City of Hope Medical Center

NCT05800665 RECRUITING

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Genentech, Inc.

NCT07537010 RECRUITING

3D1015 Injection for Patients With mCRPC

Chunjing Yu

NCT06052306 ACTIVE NOT RECRUITING

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Bayer

NCT06545942 ACTIVE NOT RECRUITING

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

MOMA Therapeutics

NCT07236112 ACTIVE NOT RECRUITING

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

C Ray Therapeutics

NCT06044857 RECRUITING

PSMA PET Response Guided SabR in High Risk Pca

University of Texas Southwestern Medical Center

NCT01480154 ACTIVE NOT RECRUITING

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

NCT06582017 RECRUITING

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Nammi Therapeutics Inc

NCT06238479 ACTIVE NOT RECRUITING

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Eli Lilly and Company

NCT06801236 RECRUITING

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Acerand Therapeutics (Hong Kong) Limited

NCT06303713 ACTIVE NOT RECRUITING

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Dana-Farber Cancer Institute

NCT07517198 RECRUITING

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

NCT06318273 ACTIVE NOT RECRUITING

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

AbbVie

NCT05079698 ACTIVE NOT RECRUITING

A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT07514065 RECRUITING

TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy

Tasly Pharmaceutical Group Co., Ltd

NCT07214961 ACTIVE NOT RECRUITING

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

ARTBIO Inc.

NCT04147806 ACTIVE NOT RECRUITING

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

Albert Einstein College of Medicine

NCT06451497 RECRUITING

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

NCT07054346 RECRUITING

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

Thomas Hope

NCT04886986 RECRUITING

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

Weill Medical College of Cornell University

NCT06193486 RECRUITING

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

H. Lee Moffitt Cancer Center and Research Institute

NCT07503808 RECRUITING

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

IDEAYA Biosciences

NCT05398302 RECRUITING

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

Jonsson Comprehensive Cancer Center

NCT03860272 ACTIVE NOT RECRUITING

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

NCT07495293 NOT YET RECRUITING

Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer

Yonsei University

NCT04167969 RECRUITING

The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT07493512 RECRUITING

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

Amgen

NCT07103018 RECRUITING

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

K36 Therapeutics, Inc.

NCT04514484 ACTIVE NOT RECRUITING

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

National Cancer Institute (NCI)

NCT07145177 RECRUITING

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

University of California, San Francisco

NCT06705686 RECRUITING

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

TechnoGenesys, Inc.

NCT05245006 ACTIVE NOT RECRUITING

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Robert Flavell, MD, PhD

NCT05176483 RECRUITING

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis

NCT07468396 NOT YET RECRUITING

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

Gan & Lee Pharmaceuticals.

NCT07090148 RECRUITING

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

University of Wisconsin, Madison

NCT06369246 RECRUITING

PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.

M.D. Anderson Cancer Center

NCT06130995 RECRUITING

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

University of Oklahoma

NCT05806814 ACTIVE NOT RECRUITING

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

University of Oklahoma

NCT06910657 RECRUITING

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

NCT04109729 ACTIVE NOT RECRUITING

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

University of Utah

NCT04943536 ACTIVE NOT RECRUITING

Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer

Alessa Therapeutics Inc.

NCT06257693 RECRUITING

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Alessa Therapeutics Inc.

NCT07189403 RECRUITING

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

Daiichi Sankyo

NCT05938270 RECRUITING

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

AstraZeneca

NCT02353819 ACTIVE NOT RECRUITING

Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer

University of Texas Southwestern Medical Center

NCT03089203 ACTIVE NOT RECRUITING

CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

University of Pennsylvania

NCT07423117 NOT YET RECRUITING

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

IntoCell, Inc

NCT06450106 RECRUITING

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

SURGE Therapeutics

NCT07339267 RECRUITING

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

Astellas Pharma Global Development, Inc.

NCT06778863 RECRUITING

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Clasp Therapeutics, Inc.

NCT06440005 RECRUITING

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Angiex, Inc.

NCT05787587 ACTIVE NOT RECRUITING

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

IDEAYA Biosciences

NCT07080242 RECRUITING

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

SystImmune Inc.

NCT06631521 RECRUITING

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

AdventHealth

NCT07244341 RECRUITING

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Daiichi Sankyo

NCT04729114 RECRUITING

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Astellas Pharma Global Development, Inc.

NCT06067841 RECRUITING

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

NCT05983432 RECRUITING

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

SystImmune Inc.

NCT06492122 RECRUITING

Study With [225Ac]Ac-FL-020 in mCRPC Participants

Full-Life Technologies GmbH

NCT05864196 RECRUITING

Two Fraction Prostate SBRT With DIL SIB

NYU Langone Health

NCT06636123 RECRUITING

GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

Virginia Commonwealth University

NCT06555796 ACTIVE NOT RECRUITING

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Amgen

NCT07358806 RECRUITING

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Oscotec Inc.

NCT05519449 RECRUITING

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Janux Therapeutics

NCT01140373 ACTIVE NOT RECRUITING

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

Memorial Sloan Kettering Cancer Center

NCT06830850 RECRUITING

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Atridia Pty Ltd.

NCT06044025 RECRUITING

A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

University of Arkansas

NCT07344311 RECRUITING

A Phase I Trial of A-CAR032 in Participants With mCRPC

Shanghai AbelZeta Ltd.

NCT07181473 RECRUITING

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

Phrontline Biopharma

NCT05010200 ACTIVE NOT RECRUITING

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Ashutosh Kumar Tewari

NCT06999187 RECRUITING

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Dren Bio

NCT07316686 NOT YET RECRUITING

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

Instituto do Cancer do Estado de São Paulo

NCT06531499 RECRUITING

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

Novartis Pharmaceuticals

NCT06046040 RECRUITING

TmPSMA-02 in mCRPC

University of Pennsylvania

NCT06229366 ACTIVE NOT RECRUITING

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Eli Lilly and Company

NCT06105918 ACTIVE NOT RECRUITING

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

Emory University

NCT07271017 RECRUITING

Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe

Johns Hopkins University

NCT07115446 RECRUITING

Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

Hansoh BioMedical R&D Company

NCT06613100 RECRUITING

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Amgen

NCT03983954 ACTIVE NOT RECRUITING

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

NCT01923506 ACTIVE NOT RECRUITING

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

City of Hope Medical Center

NCT02023463 ACTIVE NOT RECRUITING

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Thomas Jefferson University

NCT07244393 NOT YET RECRUITING

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Cellbion Co., Ltd.

NCT05805371 RECRUITING

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

City of Hope Medical Center

NCT03582475 ACTIVE NOT RECRUITING

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Jonsson Comprehensive Cancer Center

NCT06062745 RECRUITING

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Brigham and Women's Hospital

NCT06784193 RECRUITING

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Olema Pharmaceuticals, Inc.

NCT04887935 RECRUITING

Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

Washington University School of Medicine

NCT03269422 ACTIVE NOT RECRUITING

Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

Memorial Sloan Kettering Cancer Center

NCT01655836 ACTIVE NOT RECRUITING

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT06943495 RECRUITING

Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

Jean-Mathieu Beauregard

NCT05107674 RECRUITING

A Study of NX-1607 in Adults With Advanced Malignancies

Nurix Therapeutics, Inc.

NCT07100847 RECRUITING

Periprostatic Neurolysis in Prostate Cancer

University of Texas Southwestern Medical Center

NCT06703437 ACTIVE NOT RECRUITING

Long Acting Neuraxial Peri-prostatic Block in Cancer

Icahn School of Medicine at Mount Sinai

NCT07149831 RECRUITING

A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults

Sinotau Pharmaceutical Group

NCT07135102 RECRUITING

A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer

Xiaorong Sun

NCT06168487 RECRUITING

Telmisartan in Prostate Cancer

Tyler J Curiel

NCT03170960 ACTIVE NOT RECRUITING

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Exelixis

NCT05413421 RECRUITING

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

ORIC Pharmaceuticals

NCT06441994 RECRUITING

Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer

Osaka University

NCT07090369 NOT YET RECRUITING

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Peter MacCallum Cancer Centre, Australia

NCT06666270 RECRUITING

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd

NCT06942104 RECRUITING

Imaging of Solid Tumors Using 18F-TRX

Rahul Aggarwal

NCT03873805 ACTIVE NOT RECRUITING

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

City of Hope Medical Center

NCT06769425 RECRUITING

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

NCT07007910 RECRUITING

Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer

Haisco Pharmaceutical Group Co., Ltd.

NCT03874884 ACTIVE NOT RECRUITING

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Peter MacCallum Cancer Centre, Australia

NCT04186585 RECRUITING

Recommended Dose Estimation of BP-C2

Meddoc

NCT05077098 ACTIVE NOT RECRUITING

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

Mark Stein

NCT04706962 ACTIVE NOT RECRUITING

TH1902 in Patients With Advanced Solid Tumors

Theratechnologies

NCT06866795 NOT YET RECRUITING

Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Geode Therapeutics Inc.

NCT06783829 RECRUITING

A Study of SHR-4394 Injection in Subjects With Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

NCT05942001 RECRUITING

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Jiangsu HengRui Medicine Co., Ltd.

NCT05917860 ACTIVE NOT RECRUITING

Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer

Turku University Hospital

NCT05104515 RECRUITING

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

Oxford Vacmedix UK Ltd.

NCT05488548 RECRUITING

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Epigenetix, Inc.

NCT05479578 ACTIVE NOT RECRUITING

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Rashmi Verma, MD

NCT06736054 RECRUITING

A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer

Hoag Memorial Hospital Presbyterian

NCT03845166 ACTIVE NOT RECRUITING

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Exelixis

NCT05656573 RECRUITING

CART-PSMA Cells for Advanced Prostate Cancer

Nova Therapeutics LLC

NCT06683066 RECRUITING

Study on Human Bioequivalence of Triprerelin Acetate for Injection

The Affiliated Hospital of Qingdao University

NCT05215574 ACTIVE NOT RECRUITING

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

NCT06614751 NOT YET RECRUITING

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Danatlas Pharmaceuticals Co., Ltd

NCT06343038 RECRUITING

Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study

University Hospital, Basel, Switzerland

NCT05646550 RECRUITING

Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer

University Hospital Tuebingen

NCT06193993 ACTIVE NOT RECRUITING

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

National University Hospital, Singapore

NCT06099990 NOT YET RECRUITING

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Jiangsu HengRui Medicine Co., Ltd.

NCT07600554 RECRUITING

A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer

Philogen S.p.A.

NCT04399876 ENROLLING BY INVITATION

Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

Brigham and Women's Hospital

NCT07621692 RECRUITING

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

National Taiwan University Hospital

NCT07641049 RECRUITING

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Beijing Biotech

NCT07636707 NOT YET RECRUITING

QLF4113 in Participants With Metastatic Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

NCT07657806 NOT YET RECRUITING

DEC003M in Prostate Cancer

Hangzhou DAC Biotechnology Co., Ltd.

NCT07661641 RECRUITING

A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors

Alpha-9 Oncology USA Inc.

NCT07660211 RECRUITING

Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC）

VitsGen Therapeutics Inc.

NCT02206334 COMPLETED

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer

NRG Oncology

NCT05375539 COMPLETED

AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients

Milton S. Hershey Medical Center

NCT03123978 COMPLETED

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

University of California, Davis

NCT03218826 COMPLETED

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

NCT05177042 COMPLETED

Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer

Arvinas Androgen Receptor, Inc.

NCT06104449 COMPLETED

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Merck Sharp & Dohme LLC

NCT02913196 COMPLETED

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

Weill Medical College of Cornell University

NCT04853498 TERMINATED

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT03674814 COMPLETED

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

University of Chicago

NCT06136598 COMPLETED

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Merck Sharp & Dohme LLC

NCT06287463 TERMINATED

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Deciphera Pharmaceuticals, LLC

NCT05617885 COMPLETED

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Praful Ravi, MB BCHir, MRCP

NCT02744287 TERMINATED

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Regeneron Pharmaceuticals

NCT03388619 COMPLETED

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

National Cancer Institute (NCI)

NCT02776436 COMPLETED

Reducing Dexamethasone Around Docetaxel Infusion

Leiden University Medical Center

NCT03995888 COMPLETED

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Blue Earth Diagnostics

NCT06840535 COMPLETED

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer

Philogen S.p.A.

NCT05162573 COMPLETED

EBRT + Lu-PSMA for N1M0 Prostate Cancer

The Netherlands Cancer Institute

NCT04477512 COMPLETED

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

NCT05037500 TERMINATED

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Roswell Park Cancer Institute

NCT05252390 TERMINATED

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Nuvation Bio Inc.

NCT05613894 SUSPENDED

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

University of Utah

NCT03792841 TERMINATED

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Amgen

NCT03253744 COMPLETED

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

National Cancer Institute (NCI)

NCT03737370 COMPLETED

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Tufts Medical Center

NCT05276492 TERMINATED

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

University of Chicago

NCT04521361 COMPLETED

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

Bayer

NCT04983862 COMPLETED

Fluorescent Imaging of Nerves With Illuminare-1 During Surgery

Memorial Sloan Kettering Cancer Center

NCT05733351 TERMINATED

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Emory University

NCT04702737 COMPLETED

A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

Amgen

NCT07014488 COMPLETED

A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

NCT05605522 TERMINATED

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

3B Pharmaceuticals GmbH

NCT04666129 COMPLETED

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

NCT05585034 COMPLETED

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Xencor, Inc.

NCT07101354 COMPLETED

Research on PSMA-Targeted Intraoperative Fluorescent Imaging Agents

Haitao Niu, MD

NCT05369000 TERMINATED

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Lava Therapeutics

NCT05544227 COMPLETED

Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

Williams Cancer Foundation

NCT03199586 COMPLETED

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals, Inc.

NCT04580485 COMPLETED

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Incyte Corporation

NCT04740034 TERMINATED

A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Amgen

NCT00911118 COMPLETED

Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT04927663 TERMINATED

11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression

Rahul Aggarwal

NCT01420250 COMPLETED

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT03300505 TERMINATED

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

University of Michigan Rogel Cancer Center

NCT03490838 TERMINATED

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

Advanced Accelerator Applications

NCT02603965 COMPLETED

Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT01341288 TERMINATED

Robotic Seed Implantation for Prostate Cancer Brachytherapy

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT02339168 COMPLETED

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

University of California, Davis

NCT03477864 WITHDRAWN

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT03076203 COMPLETED

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT06101927 COMPLETED

Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413

Tomsk National Research Medical Center of the Russian Academy of Sciences

NCT05940298 COMPLETED

Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8

Tomsk National Research Medical Center of the Russian Academy of Sciences

NCT04925284 COMPLETED

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Exelixis

NCT06094842 WITHDRAWN

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Fred Hutchinson Cancer Center

NCT06377683 COMPLETED

Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

The First Affiliated Hospital of Xiamen University

NCT06559007 COMPLETED

Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

Atridia Pty Ltd.

NCT05332340 COMPLETED

Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered

Biozeus Biopharmaceutical S.A.

NCT03761017 COMPLETED

MGD019 DART® Protein in Unresectable/Metastatic Cancer

MacroGenics

NCT04428203 COMPLETED

Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer

Zin W Myint

NCT01823562 COMPLETED

Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery

Ohio State University Comprehensive Cancer Center

NCT01792687 COMPLETED

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

Aragon Pharmaceuticals, Inc.

NCT04421222 TERMINATED

Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

ESSA Pharmaceuticals

NCT03073395 COMPLETED

Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

Five Eleven Pharma, Inc.

NCT03805594 COMPLETED

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

University of California, San Francisco

NCT04249947 TERMINATED

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Poseida Therapeutics, Inc.

NCT05241613 TERMINATED

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Accutar Biotechnology Inc

NCT01638533 COMPLETED

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

National Cancer Institute (NCI)

NCT04703920 COMPLETED

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

University of Michigan Rogel Cancer Center

NCT03549000 TERMINATED

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Novartis Pharmaceuticals

NCT04094519 COMPLETED

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

Astellas Pharma Global Development, Inc.

NCT02009449 COMPLETED

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Eli Lilly and Company

NCT03724747 COMPLETED

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Bayer

NCT04978675 COMPLETED

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

M.D. Anderson Cancer Center

NCT03776968 COMPLETED

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

Hinova Pharmaceuticals Inc.

NCT06566989 COMPLETED

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

Merck Sharp & Dohme LLC

NCT04291664 TERMINATED

PK and Dose Escalation and Expansion Study of DST-2970

DisperSol Technologies, LLC

NCT02555397 COMPLETED

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

Henry Ford Health System

NCT05156905 TERMINATED

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

University of California, San Diego

NCT04672460 COMPLETED

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Pfizer

NCT05679388 TERMINATED

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

University of Chicago

NCT03558711 COMPLETED

PSMA-PET/CT for Prostate Cancer

University Hospital, Ghent

NCT02566772 COMPLETED

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

Taiho Oncology, Inc.

NCT05084859 TERMINATED

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Biosplice Therapeutics, Inc.

NCT00848601 TERMINATED

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Astex Pharmaceuticals, Inc.

NCT04629781 TERMINATED

Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

Swiss Cancer Institute

NCT04701021 COMPLETED

TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy

Ultimovacs ASA

NCT04284761 COMPLETED

A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Alessa Therapeutics Inc.

NCT03276572 COMPLETED

Phase I Trial of 225Ac-J591 in Patients With mCRPC

Weill Medical College of Cornell University

NCT02184533 COMPLETED

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

Stanford University

NCT03629756 COMPLETED

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

NCT04726332 TERMINATED

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Exelixis

NCT03177460 COMPLETED

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

NCT05807126 WITHDRAWN

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

National Cancer Institute (NCI)

NCT04086966 COMPLETED

PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study

University of Alabama at Birmingham

NCT04633148 TERMINATED

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

AvenCell Europe GmbH

NCT03835533 COMPLETED

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Parker Institute for Cancer Immunotherapy

NCT04677855 TERMINATED

Study of PCUR-101 in Combination With ADT in Patients With mCRPC

Pellficure Pharmaceuticals, Inc

NCT05252364 COMPLETED

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Hinova Pharmaceuticals Aus Pty Ltd

NCT03822871 COMPLETED

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

Cancer Targeted Technology

NCT04586335 TERMINATED

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Haihe Biopharma Co., Ltd.

NCT03878524 TERMINATED

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

NCT02864784 WITHDRAWN

Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC

Amorphical Ltd.

NCT02995330 TERMINATED

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04786847 COMPLETED

177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study

Telix Pharmaceuticals (Innovations) Pty Limited

NCT06014853 COMPLETED

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

Bukwang Pharmaceutical

NCT03575819 COMPLETED

A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Fortis Therapeutics, Inc.

NCT05673109 TERMINATED

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Accutar Biotechnology Inc

NCT05124795 TERMINATED

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

Immunic AG

NCT04528199 TERMINATED

[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04803305 COMPLETED

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Pfizer

NCT04053062 SUSPENDED

LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Bioray Laboratories

NCT03454451 COMPLETED

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

NCT05425862 SUSPENDED

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Peter MacCallum Cancer Centre, Australia

NCT05159518 COMPLETED

A Study of PRT2527 in Participants With Advanced Solid Tumors

Prelude Therapeutics

NCT05868057 COMPLETED

A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets

Jiangsu HengRui Medicine Co., Ltd.

NCT03861403 TERMINATED

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Leap Therapeutics, Inc.

NCT04746638 COMPLETED

Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26

Tomsk National Research Medical Center of the Russian Academy of Sciences

NCT03784677 COMPLETED

A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

M.D. Anderson Cancer Center

NCT02578797 COMPLETED

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Aragon Pharmaceuticals, Inc.

NCT03619655 TERMINATED

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03840200 COMPLETED

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Hoffmann-La Roche

NCT03751436 COMPLETED

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

NCT04995042 COMPLETED

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

NCT05567770 WITHDRAWN

ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer

Weill Medical College of Cornell University

NCT04227275 TERMINATED

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Tceleron Therapeutics, Inc.

NCT04575766 TERMINATED

A Study of FT-7051 in Men With MCRPC

Novo Nordisk A/S

NCT03569280 COMPLETED

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Kangpu Biopharmaceuticals, Ltd.

NCT04768608 COMPLETED

PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer

Zhejiang University

NCT04541225 TERMINATED

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Nuvation Bio Inc.

NCT03927573 TERMINATED

Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker

AvenCell Europe GmbH

NCT03829436 COMPLETED

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Tempest Therapeutics

NCT04179396 COMPLETED

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

pharmaand GmbH

NCT02106507 COMPLETED

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Memorial Sloan Kettering Cancer Center

NCT05140512 COMPLETED

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Luye Pharma Group Ltd.

NCT04077021 TERMINATED

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Calibr, a division of Scripps Research

NCT03310541 COMPLETED

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Memorial Sloan Kettering Cancer Center

NCT04879589 WITHDRAWN

Phase 1 Study of ATRS-2002 in Healthy Male Adults

Syneos Health

NCT01191775 COMPLETED

A Study of PNT2258 in Patients With Advanced Solid Tumors

Sierra Oncology LLC - a GSK company

NCT00788307 TERMINATED

Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy

Mayo Clinic

NCT02552394 COMPLETED

J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts

Weill Medical College of Cornell University

NCT02844647 TERMINATED

Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer

Sunnybrook Health Sciences Centre

NCT02048150 COMPLETED

Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer

City of Hope Medical Center

NCT04676035 COMPLETED

The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Jiangsu HengRui Medicine Co., Ltd.

NCT02833883 COMPLETED

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT02572284 COMPLETED

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT04430842 COMPLETED

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

NCT04615845 TERMINATED

Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)

Pharmicell Co., Ltd.

NCT04509557 COMPLETED

[177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.

FutureChem

NCT01174199 TERMINATED

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Roswell Park Cancer Institute

NCT04470843 COMPLETED

Impact of Acetazolamide in Reducing Referred Postoperative Pain

Medical College of Wisconsin

NCT04279561 TERMINATED

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Jonsson Comprehensive Cancer Center

NCT03262103 COMPLETED

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Ashutosh Kumar Tewari

NCT04060342 TERMINATED

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

NCT03532217 COMPLETED

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Washington University School of Medicine

NCT04087174 COMPLETED

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

AstraZeneca

NCT04634344 TERMINATED

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Dizal Pharmaceuticals

NCT03041285 TERMINATED

Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer

Royal North Shore Hospital

NCT00779168 COMPLETED

White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy

City of Hope Medical Center

NCT01826838 WITHDRAWN

Study of Dasatinib, Androgen Deprivation Therapy and Radiation

Brown University

NCT02653248 COMPLETED

SBRT for Organ Confined Prostate Cancer

Northwell Health

NCT02250014 COMPLETED

The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer

University of Colorado, Denver

NCT01391143 COMPLETED

Safety Study of MGA271 in Refractory Cancer

MacroGenics

NCT02628535 TERMINATED

Safety Study of MGD009 in B7-H3-expressing Tumors

MacroGenics

NCT03412786 COMPLETED

Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases

Herlev Hospital

NCT02207504 COMPLETED

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

NCT03793543 COMPLETED

Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02767921 TERMINATED

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

University of Southern California

NCT03120832 COMPLETED

Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients

Sensei Biotherapeutics, Inc.

NCT04374240 COMPLETED

A Clinical Trial of AdNRGM Plus CB1954 in Prostate Cancer

University of Birmingham

NCT04574401 COMPLETED

A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy

Intuitive Surgical

NCT03136640 COMPLETED

ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer

Modra Pharmaceuticals

NCT01353625 COMPLETED

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Celgene

NCT02963051 TERMINATED

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Daniel George, MD

NCT02655822 COMPLETED

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Corvus Pharmaceuticals, Inc.

NCT04296578 WITHDRAWN

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

Stanford University

NCT01574937 COMPLETED

XL-184+Abiraterone in Post-Chemo CRPC

Dana-Farber Cancer Institute

NCT03829930 TERMINATED

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

George Washington University

NCT04889651 COMPLETED

A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers

Boryung Pharmaceutical Co., Ltd

NCT01912820 COMPLETED

Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery

Jonsson Comprehensive Cancer Center

NCT03024216 COMPLETED

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

University of Hawaii

NCT00916123 COMPLETED

Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Weill Medical College of Cornell University

NCT03478904 TERMINATED

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

National Cancer Institute (NCI)

NCT03205176 COMPLETED

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

AstraZeneca

NCT02125084 COMPLETED

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

SCRI Development Innovations, LLC

NCT02458716 COMPLETED

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Rutgers, The State University of New Jersey

NCT03507543 COMPLETED

The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

Impact Therapeutics, Inc.

NCT03508011 COMPLETED

A Study of IMP4297 in Patients With Advanced Solid Tumors

Impact Therapeutics, Inc.

NCT01784757 COMPLETED

Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer

Orion Corporation, Orion Pharma

NCT02411786 COMPLETED

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

University of Wisconsin, Madison

NCT02698176 TERMINATED

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Merck Sharp & Dohme LLC

NCT02179515 COMPLETED

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

National Cancer Institute (NCI)

NCT02259114 COMPLETED

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT02730975 COMPLETED

Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

NCT01646684 COMPLETED

Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer

Novartis Pharmaceuticals

NCT00663832 COMPLETED

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

Novartis Pharmaceuticals

NCT01338831 COMPLETED

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Novartis Pharmaceuticals

NCT01634061 COMPLETED

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Novartis Pharmaceuticals

NCT02883166 COMPLETED

Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake

Radboud University Medical Center

NCT03774056 COMPLETED

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

Hinova Pharmaceuticals Inc.

NCT03778047 COMPLETED

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

Hinova Pharmaceuticals Inc.

NCT03183544 COMPLETED

Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

NCT03110588 WITHDRAWN

Phase I Trial of PACE for Metastatic Prostate Cancer

University of Alabama at Birmingham

NCT02472275 COMPLETED

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Barbara Ann Karmanos Cancer Institute

NCT02693860 COMPLETED

Neoadjuvant J591 Treatment for Prostate Cancer

Weill Medical College of Cornell University

NCT03384316 COMPLETED

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

National Cancer Institute (NCI)

NCT00959959 COMPLETED

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

LTN PHARMACEUTICALS, INC.

NCT02092948 COMPLETED

Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer

Jonsson Comprehensive Cancer Center

NCT02911467 TERMINATED

Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer

Rahul Aggarwal

NCT02747342 COMPLETED

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

Atridia Pty Ltd.

NCT01884285 COMPLETED

AZD8186 First Time In Patient Ascending Dose Study

AstraZeneca

NCT02151760 COMPLETED

Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03497377 COMPLETED

Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02285101 COMPLETED

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

Bio-Cancer Treatment International Limited

NCT02036918 COMPLETED

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

Duke University

NCT03618355 COMPLETED

Trial of eRapa in Prostate Cancer Patients

Rapamycin Holdings, Inc. dba Emtora Biosciences

NCT02826772 COMPLETED

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Suzhou Kintor Pharmaceutical Inc,

NCT03137758 TERMINATED

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Pellficure Pharmaceuticals, Inc

NCT03043989 TERMINATED

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02390063 COMPLETED

Vaccination in Prostate Cancer (VANCE)

University of Oxford

NCT02991911 COMPLETED

A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer

MedImmune LLC

NCT03811652 COMPLETED

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

MedImmune LLC

NCT00924092 COMPLETED

An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

National Cancer Institute (NCI)

NCT02391480 COMPLETED

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

AbbVie

NCT02946008 COMPLETED

Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer

University of Michigan Rogel Cancer Center

NCT00702923 TERMINATED

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

University of Wisconsin, Madison

NCT01540526 COMPLETED

Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib

University of Wisconsin, Madison

NCT02423928 COMPLETED

Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer

Alden Cancer Therapy II

NCT02500901 TERMINATED

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Paul Mathew, MD

NCT01823978 COMPLETED

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Bellicum Pharmaceuticals

NCT00868595 COMPLETED

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Bellicum Pharmaceuticals

NCT02274623 COMPLETED

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

OPKO Health, Inc.

NCT02814669 COMPLETED

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Hoffmann-La Roche

NCT02324998 COMPLETED

Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy

Cambridge University Hospitals NHS Foundation Trust

NCT02262910 COMPLETED

Study of ES414 in Metastatic Castration-Resistant Prostate Cancer

Aptevo Therapeutics

NCT01028885 COMPLETED

MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

Abramson Cancer Center at Penn Medicine

NCT02064608 COMPLETED

Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer

Cambridge University Hospitals NHS Foundation Trust

NCT00636558 COMPLETED

Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)

Viralytics

NCT02182622 WITHDRAWN

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

Martin Gutierrez

NCT01565928 COMPLETED

Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

Pfizer

NCT03030885 COMPLETED

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Memorial Sloan Kettering Cancer Center

NCT00629057 COMPLETED

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer

Bavarian Nordic

NCT02111187 COMPLETED

A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT02202447 COMPLETED

Phase 1 of EC1169 In Patients With Recurrent MCRPC

Endocyte

NCT01741753 TERMINATED

BKM120+Abiraterone Acetate for Metastatic CRPC

Dana-Farber Cancer Institute

NCT02478125 TERMINATED

Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01417182 COMPLETED

Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00790374 COMPLETED

BN83495 in Prostate Cancer

Ipsen

NCT01286987 COMPLETED

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Pfizer

NCT01262664 TERMINATED

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

M.D. Anderson Cancer Center

NCT02655952 COMPLETED

Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients

WntResearch AB

NCT02141659 COMPLETED

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

Takeda

NCT01144897 COMPLETED

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

Daniel Vaena

NCT01497925 COMPLETED

Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer

Polaris Group

NCT01513733 COMPLETED

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

Andrew J. Armstrong, MD

NCT01303705 COMPLETED

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Providence Health & Services

NCT01548807 COMPLETED

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

Abramson Cancer Center at Penn Medicine

NCT02297386 COMPLETED

[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT03465345 WITHDRAWN

Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Medical University of South Carolina

NCT01983709 TERMINATED

Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01296139 COMPLETED

Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer

National Cancer Institute (NCI)

NCT00804245 COMPLETED

C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer

Wake Forest University Health Sciences

NCT01385228 COMPLETED

Pazopanib, Docetaxel, Prednisone Prostate

Daniel George, MD

NCT02284971 TERMINATED

Pilot Study of SBRT and CDX-1127 in Prostate Cancer

James Larner, MD

NCT02532114 COMPLETED

Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

University of Washington

NCT01400555 COMPLETED

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Cougar Biotechnology, Inc.

NCT02349139 TERMINATED

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Asana BioSciences

NCT02119858 COMPLETED

Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery

City of Hope Medical Center

NCT01460134 COMPLETED

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Celldex Therapeutics

NCT02014337 COMPLETED

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Corcept Therapeutics

NCT02514213 COMPLETED

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Inovio Pharmaceuticals

NCT00703638 COMPLETED

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

NCT01085422 COMPLETED

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

AbbVie (prior sponsor, Abbott)

NCT02705469 COMPLETED

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Zenith Epigenetics

NCT02487823 TERMINATED

Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer

Institut Paoli-Calmettes

NCT02916537 COMPLETED

A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

Cancer Targeted Technology

NCT02468284 COMPLETED

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer

Ferring Pharmaceuticals

NCT02654938 COMPLETED

Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer

Panacela Labs LLC

NCT01677845 TERMINATED

Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer

NYU Langone Health

NCT01832870 COMPLETED

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

Prostate Oncology Specialists, Inc.

NCT00958477 COMPLETED

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Merck KGaA, Darmstadt, Germany

NCT01594918 COMPLETED

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

Rahul Aggarwal

NCT03074032 COMPLETED

Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Avionco LLC

NCT02225093 COMPLETED

A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

Astellas Pharma Europe B.V.

NCT01911728 COMPLETED

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Astellas Pharma Europe B.V.

NCT02429804 TERMINATED

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Stanford University

NCT01642732 TERMINATED

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

University of Michigan Rogel Cancer Center

NCT00670553 COMPLETED

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Novartis Pharmaceuticals

NCT01913015 TERMINATED

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

OHSU Knight Cancer Institute

NCT00937417 WITHDRAWN

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

SWOG Cancer Research Network

NCT02567396 WITHDRAWN

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

NCT01155791 TERMINATED

Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

Sandy Srinivas

NCT02198859 COMPLETED

Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer

University of Kansas Medical Center

NCT01347788 COMPLETED

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Massachusetts General Hospital

NCT00933426 TERMINATED

Lenalidomide and Paclitaxel in Prostate Cancer

M.D. Anderson Cancer Center

NCT01522820 COMPLETED

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Roswell Park Cancer Institute

NCT01283373 COMPLETED

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Genentech, Inc.

NCT01359189 COMPLETED

Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00676286 COMPLETED

Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers

AHS Cancer Control Alberta

NCT00664196 SUSPENDED

Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

Roger Williams Medical Center

NCT01155258 COMPLETED

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

University of Southern California

NCT02093390 COMPLETED

A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects

Millennium Pharmaceuticals, Inc.

NCT00943956 COMPLETED

Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer

Institut du Cancer de Montpellier - Val d'Aurelle

NCT01219790 COMPLETED

ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma

Institut Cancerologie de l'Ouest

NCT00811265 COMPLETED

Safety Evaluation of ExAblate MRgFUS for Prostate Cancer

InSightec

NCT02020291 COMPLETED

Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer

WntResearch AB

NCT01162395 COMPLETED

Open Label Prostate Cancer Study

AstraZeneca

NCT02057237 COMPLETED

A Safety and Feasibility Study of Mitotane in Prostate Cancer

University Health Network, Toronto

NCT01261754 COMPLETED

A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers

Molecular Insight Pharmaceuticals, Inc.

NCT01615406 COMPLETED

A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer

Molecular Insight Pharmaceuticals, Inc.

NCT01654874 COMPLETED

99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

Molecular Insight Pharmaceuticals, Inc.

NCT01572701 COMPLETED

Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection

Molecular Insight Pharmaceuticals, Inc.

NCT02396368 WITHDRAWN

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00872157 COMPLETED

BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets

M.D. Anderson Cancer Center

NCT01229618 COMPLETED

Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer

University of California, San Francisco

NCT02437539 COMPLETED

Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography

Rigshospitalet, Denmark

NCT00753415 COMPLETED

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Merck Sharp & Dohme LLC

NCT01163448 WITHDRAWN

Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer

Memorial Sloan Kettering Cancer Center

NCT01790451 COMPLETED

Safety and Efficacy of Irreversible Electroporation in Ablation of Prostate Cancer in Humans

Clinical Research Office of the Endourological Society

NCT02055716 COMPLETED

Sulforadex in Healthy Human Males MAD

Evgen Pharma

NCT00631527 COMPLETED

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

M.D. Anderson Cancer Center

NCT01324583 COMPLETED

Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

Sanofi

NCT01610050 COMPLETED

A Phase I Study of LFA102 in Japanese Patients

Novartis Pharmaceuticals

NCT01320787 WITHDRAWN

18-F-Fluoroacetate as PET Imaging Agent

M.D. Anderson Cancer Center

NCT01902251 COMPLETED

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

Astellas Pharma Europe B.V.

NCT00748046 COMPLETED

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Bayer

NCT01692262 COMPLETED

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

AstraZeneca

NCT01422850 COMPLETED

Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

CytoVac A/S

NCT00808418 COMPLETED

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

Synta Pharmaceuticals Corp.

NCT02001571 COMPLETED

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

Cougar Biotechnology, Inc.

NCT01414296 COMPLETED

Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Progenics Pharmaceuticals, Inc.

NCT01414283 COMPLETED

Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Progenics Pharmaceuticals, Inc.

NCT01948362 COMPLETED

Sulforadex in Healthy Volunteers SAD

Evgen Pharma

NCT01197209 WITHDRAWN

Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer

Momotaro-Gene Inc.

NCT01911741 COMPLETED

A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects

Astellas Pharma Europe B.V.

NCT01351688 COMPLETED

An Open Label Prostate Cancer Study in Japanese Patients

AstraZeneca

NCT01522118 COMPLETED

MR-guided Focused Ultrasound Treatment of Prostate Cancer: Focal Therapy for Locally Non-Advanced Disease

University of Roma La Sapienza

NCT00882232 COMPLETED

Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer

Cancer Center of Irvine

NCT01337518 SUSPENDED

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Enzon Pharmaceuticals, Inc.

NCT00895115 COMPLETED

Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer

University of Medicine and Dentistry of New Jersey

NCT00891345 COMPLETED

Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

CytoVac A/S

NCT00989105 TERMINATED

Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer

Cancer Research UK

NCT00712829 COMPLETED

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

Molecular Insight Pharmaceuticals, Inc.

NCT00992745 COMPLETED

A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer

Molecular Insight Pharmaceuticals, Inc.

NCT00644488 COMPLETED

A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer

Bristol-Myers Squibb

NCT00909558 SUSPENDED

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

Envita Medical Center, Inc.

NCT04597125 ACTIVE NOT RECRUITING

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Bayer

NCT07569926 NOT YET RECRUITING

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

NCT06733350 RECRUITING

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Roswell Park Cancer Institute

NCT05753046 ENROLLING BY INVITATION

Laparoscopic TAP Block During Robotic Assisted Laparoscopic Radical Prostatectomy for Improvement in Postoperative Pain

Corewell Health East

NCT05457257 ACTIVE NOT RECRUITING

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

NCT04549207 ACTIVE NOT RECRUITING

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Ottawa Hospital Research Institute

NCT05348876 RECRUITING

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Bayer

NCT03016741 ACTIVE NOT RECRUITING

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Northwestern University

NCT07278362 NOT YET RECRUITING

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

University of Miami

NCT06627530 ACTIVE NOT RECRUITING

COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer

Brazilian Clinical Research Institute

NCT07252726 RECRUITING

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

Ottawa Hospital Research Institute

NCT06099093 RECRUITING

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Brigham and Women's Hospital

NCT06660862 NOT YET RECRUITING

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

University of Chicago

NCT05722925 ACTIVE NOT RECRUITING

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

OHSU Knight Cancer Institute

NCT06479187 ACTIVE NOT RECRUITING

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Brigham and Women's Hospital

NCT05919329 RECRUITING

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

OHSU Knight Cancer Institute

NCT06226129 RECRUITING

Gadopiclenol in Contrast Enhanced MRI of the Prostate

Columbia University

NCT06074510 ACTIVE NOT RECRUITING

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

Lantheus Medical Imaging

NCT06908694 RECRUITING

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Hamilton Health Sciences Corporation

NCT07001709 RECRUITING

Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)

Deventer Ziekenhuis

NCT05805436 RECRUITING

Preop Laxatives in Robotic Urologic Surgery

Chad R. Tracy

NCT05803941 RECRUITING

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Novartis Pharmaceuticals

NCT06706921 RECRUITING

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

VA Greater Los Angeles Healthcare System

NCT05629494 RECRUITING

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

Albany Medical College

NCT05957822 RECRUITING

Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery

Konkuk University Medical Center

NCT06001619 RECRUITING

Prostate Medication, Metabolism and Gut Microbiota

Turku University Hospital

NCT06604442 COMPLETED

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Blue Earth Diagnostics

NCT05700903 COMPLETED

Contributions to Hypertension With Androgen Deprivation Therapy

University of Colorado, Denver

NCT02651948 COMPLETED

Transperineal, MRI-guided, Prostate Biopsy

University Hospital, Strasbourg, France

NCT06860893 COMPLETED

Spinal Anesthesia for Robotic Assisted Laparoscopic Prostatectomy

University Hospital of North Norway

NCT01673984 TERMINATED

GP Extended Action Triptorelin

Ipsen

NCT03641560 COMPLETED

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Astellas Pharma Inc

NCT02405858 COMPLETED

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Janssen Pharmaceutical K.K.

NCT04134208 TERMINATED

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

M.D. Anderson Cancer Center

NCT05568537 WITHDRAWN

Prostate MRI and Pylarify PSMA PET/CT

Corewell Health East

NCT02918968 COMPLETED

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

Astellas Pharma Inc

NCT02116582 COMPLETED

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Europe B.V.

NCT01977651 COMPLETED

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

Astellas Pharma Global Development, Inc.

NCT03035032 COMPLETED

A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients

Astellas Pharma Singapore Pte. Ltd.

NCT01794793 COMPLETED

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

NCT00953277 COMPLETED

Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

Axogen Corporation

NCT05803096 COMPLETED

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

Beth Israel Deaconess Medical Center

NCT03824808 TERMINATED

Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

University of Missouri-Columbia

NCT01995513 COMPLETED

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

Pfizer

NCT03796195 TERMINATED

(SGB) in Men Treated for Prostate Cancer Improve Hot Flashes

Northwestern University

NCT03971110 TERMINATED

A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.

AstraZeneca

NCT02485691 COMPLETED

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

Sanofi

NCT03228108 COMPLETED

Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.

Radboud University Medical Center

NCT05304169 COMPLETED

Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.

Zodiac Produtos Farmaceuticos S.A.

NCT02726009 COMPLETED

A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer

Ferring Pharmaceuticals

NCT03849365 TERMINATED

Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer

Steba Biotech S.A.

NCT04776889 COMPLETED

The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

National Cancer Institute, Egypt

NCT01753297 COMPLETED

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.

Ipsen

NCT02721433 COMPLETED

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases

Ottawa Hospital Research Institute

NCT03006562 TERMINATED

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

Johns Hopkins University

NCT01661166 COMPLETED

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

Abramson Cancer Center at Penn Medicine

NCT02812186 COMPLETED

Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

Stony Brook University

NCT01512472 TERMINATED

Firmagon (Degarelix) Intermittent Therapy

Canadian Urology Research Consortium

NCT02818816 COMPLETED

Preoperative Brimonidine on IOP of Patients Undergoing RALP

University Health Network, Toronto

NCT02441517 TERMINATED

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Astellas Pharma Global Development, Inc.

NCT01296672 COMPLETED

3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer

The University of Texas Health Science Center at San Antonio

NCT01230905 COMPLETED

Study to Monitor the Effects of Androgen Suppression Treatment on the Heart

Ottawa Heart Institute Research Corporation

NCT01933022 TERMINATED

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease

Astellas Pharma Europe Ltd.

NCT02441894 COMPLETED

Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

Sanofi

NCT01571544 COMPLETED

The Use of Thermal Suits as Preventing Hypothermia During Surgery

Tampere University Hospital

NCT01649635 COMPLETED

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Sanofi

NCT02074137 COMPLETED

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Sanofi

NCT02773251 COMPLETED

The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery

Bucheon St. Mary's Hospital

NCT02102646 COMPLETED

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

Herlev Hospital

NCT01511874 COMPLETED

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

HanAll BioPharma Co., Ltd.

NCT02149628 COMPLETED

The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide

Yonsei University

NCT01950871 TERMINATED

Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning

Advanced Medical Diagnostics s.a.

NCT00805701 COMPLETED

Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation

Bay State Clinical Trials, Inc.

NCT01486563 COMPLETED

Hydroxyethyl Starch and Renal Function After Radical Prostatectomy

Regional Hospital Holstebro

NCT01161563 COMPLETED

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Watson Pharmaceuticals

NCT01547416 COMPLETED

The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function

Yonsei University

NCT00771966 COMPLETED

Radical Prostatectomy and Perioperative Fluid Therapy

Rigshospitalet, Denmark

Full Prostate Cancer Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Frequently asked

Common questions about the Prostate Cancer landscape

How many companies are developing Prostate Cancer treatments?: 12 companies have active or registered Prostate Cancer programs in TheraRadar's competitive landscape (159 classified trials). The most active are Novartis, Johnson & Johnson, and AstraZeneca.
What mechanisms of action are being developed for Prostate Cancer?: 23 distinct mechanisms of action appear across the Prostate Cancer pipeline, including KLK2 BiTE, AR antagonist, PSMA, AR-directed, and Undisclosed target.
What is the most crowded mechanism in Prostate Cancer?: KLK2 BiTE is the most contested mechanism in Prostate Cancer, with 7 programs mapped to it.
Are there upcoming Prostate Cancer clinical readouts or FDA decisions?: Near-term Prostate Cancer catalysts include HRS-1738 Injection (data readout, Aug '26); 64Cu-SAR-bisPSMA (data readout, Sep '26); Ifinatamab deruxtecan (FDA decision, Oct '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
Where does TheraRadar's Prostate Cancer landscape data come from?: Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
Is the Prostate Cancer heatmap free to use?: Yes — viewing and searching the Prostate Cancer heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.

How this is built — methodology & limits

These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.

Where the data comes from

Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.

In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.

We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.

How a trial is matched to a disease

Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:

Healthy-volunteer studies are set aside as non-disease trials.
Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.

A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.

How a drug is matched to its mechanism

Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:

Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.

New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.

Where AI is used — and where it isn’t

The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.

What the on-page markers mean

✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
🌱 First-in-indication — the only program competing on that mechanism within this disease.
🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).

Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.

How we score programs — “what’s about to move”

Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:

Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.

Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”

What each grid plots

Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).

What we don’t claim

First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
Sponsor names are as-filed and may lag current ownership.
Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.

Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only